17. Literaturverzeichnis – Malignes Melanom

Version 3.3 · Juni 2020 · AWMF 032-024OL
Leitlinienprogramm Onkologie · Deutsche Krebsgesellschaft · Deutsche Krebshilfe · AWMF

1. Kaatsch, Peter, Spix, Claudia, Katalinic, Alexander, Hentschel, Stefan, Luttmann, Sabine, Stegmaier, Christa, Krebs in Deutschland 2011/2012Robert-Koch-Institut, 2015., http://www.rki.de

2. Saarland, Krebsregister, Krebsregister SaarlandKrebsregister Saarland, 2012. 2012:, http://www.krebsregister.saarland.de/

3. Voss, Lutz- D., Atlas der Krebsinzidenz in der DDR 1961-1989Urban & Fischer, Mchn., 1999. p. 408.

4. Kaatsch, Peter, Spix, Claudia, Katalinic, Alexander, Hentschel, Stefan, Baras, Nadja, Barnes, Benjamin, et.al. Beiträge zur Gesundheitsberichterstattung des Bundes - Krebs in Deutschland 2007/2008Robert Koch-Institut, 2012. p. 136.

5. Breitbart, E. W., Waldmann, A., Nolte, S., Capellaro, M., Greinert, R., Volkmer, B., et.al. Systematic skin cancer screening in Northern Germany, J Am Acad Dermatol, 2012. 66(2): p. 201-11., http://www.ncbi.nlm.nih.gov/pubmed/22074699

6. Elwood, J. M., Screening for melanoma and options for its evaluation [see comment, Journal of medical screening, 1994. 1(1): p. 22-38.

7. Balch, C. M., Gershenwald, J. E., Soong, S. J., Thompson, J. F., Atkins, M. B., Byrd, D. R., et.al. Final version of 2009 AJCC melanoma staging and classification, J Clin Oncol, 2009. 27(36): p. 6199-206., http://www.ncbi.nlm.nih.gov/pubmed/19917835

8. Azzola, M. F., Shaw, H. M., Thompson, J. F., Soong, S. J., Scolyer, R. A., Watson, G. F., et.al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center, Cancer, 2003. 97(6): p. 1488-98., http://www.ncbi.nlm.nih.gov/pubmed/12627514

9. Gershenwald, Jeffrey E., Scolyer, Richard A., Hess, Kenneth R., Thompson, John F., Long, Georgina V., Ross, Merrick I., et.al. Melanoma of the SkinSpringer International Publishing, AJCC Cancer Staging Manual, 2016. p. 563-585., http://dx.doi.org/10.1007/978-3-319-40618-3_47

10. American Joint Committee on Cancer, Implementation of AJCC 8th Edition Cancer Staging System, 2017. 2017:

11. Benati, E., Ribero, S., Longo, C., Piana, S., Puig, S., Carrera, C., et.al. Clinical and dermoscopic clues to differentiate pigmented nail bands: an International Dermoscopy Society study, J Eur Acad Dermatol Venereol, 2017. 31(4): p. 732-736.

12. Blum, A., Simionescu, O., Argenziano, G., Braun, R., Cabo, H., Eichhorn, A., et.al. Dermoscopy of pigmented lesions of the mucosa and the mucocutaneous junction: results of a multicenter study by the International Dermoscopy Society (IDS), Arch Dermatol, 2011. 147(10): p. 1181-7.

13. Braun, R. P., Thomas, L., Dusza, S. W., Gaide, O., Menzies, S., Dalle, S., et.al. Dermoscopy of acral melanoma: a multicenter study on behalf of the international dermoscopy society, Dermatology, 2013. 227(4): p. 373-80.

14. Bowling, J., Argenziano, G., Azenha, A., Bandic, J., Bergman, R., Blum, A., et.al. Dermoscopy key points: recommendations from the international dermoscopy society, Dermatology, 2007. 214(1): p. 3-5., http://www.ncbi.nlm.nih.gov/pubmed/17191039

15. Malvehy, J., Puig, S., Argenziano, G., Marghoob, A. A., Soyer, H. P., International Dermoscopy Society Board, members, Dermoscopy report: proposal for standardization. Results of a consensus meeting of the International Dermoscopy Society, J Am Acad Dermatol, 2007. 57(1): p. 84-95.

16. Menzies, S. W., Crotty, K. A., Ingvar, C., McCarthy, W. H., An Atlas of Surface Microscopy of Pigmented Skin Lesions: DermoscopyMcgraw-Hill Professional, 2003. p. 186.

17. Menzies, S. W., Zalaudek, I., Why perform dermoscopy? The evidence for its role in the routine management of pigmented skin lesions, Arch Dermatol, 2006. 142(9): p. 1211-2., http://www.ncbi.nlm.nih.gov/pubmed/16983009

18. Bafounta, M. L., Beauchet, A., Aegerter, P., Saiag, P., Is dermoscopy (epiluminescence microscopy) useful for the diagnosis of melanoma? Results of a meta-analysis using techniques adapted to the evaluation of diagnostic tests, Archives of Dermatology, 2001. 137(10): p. 1343-1350.

19. Kittler, H., Weitzdorfer, R., Pehamberger, H., Wolff, K., Binder, M., Compliance with follow-up and prognosis among patients with thin melanomas, European Journal of Cancer, 2001. 37(12): p. 1504-1509.

20. Argenziano, G., Puig, S., Zalaudek, I., Sera, F., Corona, R., Alsina, M., et.al. Dermoscopy improves accuracy of primary care physicians to triage lesions suggestive of skin cancer, J Clin Oncol, 2006. 24(12): p. 1877-82., http://www.ncbi.nlm.nih.gov/pubmed/16622262

21. Benelli, C., Roscetti, E., Pozzo, V. D., Gasparini, G., Cavicchini, S., The dermoscopic versus the clinical diagnosis of melanoma, Eur J Dermatol, 1999. 9(6): p. 470-6., http://www.ncbi.nlm.nih.gov/pubmed/10491506

22. Bono, A., Bartoli, C., Cascinelli, N., Lualdi, M., Maurichi, A., Moglia, D., et.al. Melanoma detection. A prospective study comparing diagnosis with the naked eye, dermatoscopy and telespectrophotometry, Dermatology, 2002. 205(4): p. 362-6., http://www.ncbi.nlm.nih.gov/pubmed/12444332

23. Bono, A., Tolomio, E., Trincone, S., Bartoli, C., Tomatis, S., Carbone, A., et.al. Micro-melanoma detection: a clinical study on 206 consecutive cases of pigmented skin lesions with a diameter < or = 3 mm, Br J Dermatol, 2006. 155(3): p. 570-3., http://www.ncbi.nlm.nih.gov/pubmed/16911283

24. Carli, P., Mannone, F., De Giorgi, V., Nardini, P., Chiarugi, A., Giannotti, B., The problem of false-positive diagnosis in melanoma screening: the impact of dermoscopy, Melanoma Res, 2003. 13(2): p. 179-82., http://www.ncbi.nlm.nih.gov/pubmed/12690302

25. Carli, P., de Giorgi, V., Chiarugi, A., Nardini, P., Weinstock, M. A., Crocetti, E., et.al. Addition of dermoscopy to conventional naked-eye examination in melanoma screening: a randomized study, J Am Acad Dermatol, 2004. 50(5): p. 683-9., http://www.ncbi.nlm.nih.gov/pubmed/15097950

26. Carli, P., De Giorgi, V., Crocetti, E., Mannone, F., Massi, D., Chiarugi, A., et.al. Improvement of malignant/benign ratio in excised melanocytic lesions in the 'dermoscopy era': a retrospective study 1997-2001, Br J Dermatol, 2004. 150(4): p. 687-92., http://www.ncbi.nlm.nih.gov/pubmed/15099364

27. Cristofolini, M., Zumiani, G., Bauer, P., Cristofolini, P., Boi, S., Micciolo, R., Dermatoscopy: usefulness in the differential diagnosis of cutaneous pigmentary lesions, Melanoma Res, 1994. 4(6): p. 391-4., http://www.ncbi.nlm.nih.gov/pubmed/7703719

28. Dummer, W., Doehnel, K. A., Remy, W., [Videomicroscopy in differential diagnosis of skin tumors and secondary prevention of malignant melanoma], Hautarzt, 1993. 44(12): p. 772-6., http://www.ncbi.nlm.nih.gov/pubmed/8113040

29. Stanganelli, I., Serafini, M., Bucch, L., A cancer-registry-assisted evaluation of the accuracy of digital epiluminescence microscopy associated with clinical examination of pigmented skin lesions, Dermatology, 2000. 200(1): p. 11-6., http://www.ncbi.nlm.nih.gov/pubmed/10681607

30. Vestergaard, M. E., Macaskill, P., Holt, P. E., Menzies, S. W., Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting, Br J Dermatol, 2008. 159(3): p. 669-76., http://www.ncbi.nlm.nih.gov/pubmed/18616769

31. The Cancer Council Australia/Australian Cancer Network/Ministry of Health New Zealand, Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand, 2008., http://www.health.govt.nz/system/files/documents/publications/melanoma-guideline-nov08-v2.pdf

32. Australian Cancer Network Melanoma Guidelines Revision Working, Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand, 2008., https://www.health.govt.nz/system/files/documents/publications/melanoma-guideline-nov08-v2.pdf

33. Westerhoff, K., McCarthy, W. H., Menzies, S. W., Increase in the sensitivity for melanoma diagnosis by primary care physicians using skin surface microscopy, British Journal of Dermatology, 2000. 143(5): p. 1016-1020., , to, ISI>://WOS:000165397700018

34. Binder, M., Puespoeck-Schwarz, M., Steiner, A., Kittler, H., Muellner, M., Wolff, K., et.al. Epiluminescence microscopy of small pigmented skin lesions: short-term formal training improves the diagnostic performance of dermatologists, J Am Acad Dermatol, 1997. 36(2 Pt 1): p. 197-202., http://www.ncbi.nlm.nih.gov/pubmed/9039168

35. Menzies, S. W., Kreusch, J., Byth, K., Pizzichetta, M. A., Marghoob, A., Braun, R., et.al. Dermoscopic evaluation of amelanotic and hypomelanotic melanoma, Arch Dermatol, 2008. 144(9): p. 1120-7., http://www.ncbi.nlm.nih.gov/pubmed/18794455

36. Ronger, S., Touzet, S., Ligeron, C., Balme, B., Viallard, A. M., Barrut, D., et.al. Dermoscopic examination of nail pigmentation, Arch Dermatol, 2002. 138(10): p. 1327-33., http://www.ncbi.nlm.nih.gov/pubmed/12374538

37. Haenssle, H. A., Krueger, U., Vente, C., Thoms, K. M., Bertsch, H. P., Zutt, M., et.al. Results from an observational trial: digital epiluminescence microscopy follow-up of atypical nevi increases the sensitivity and the chance of success of conventional dermoscopy in detecting melanoma, J Invest Dermatol, 2006. 126(5): p. 980-5., http://www.ncbi.nlm.nih.gov/pubmed/16514414

38. Haenssle, H. A., Mograby, N., Ngassa, A., Buhl, T., Emmert, S., Schon, M. P., et.al. Association of Patient Risk Factors and Frequency of Nevus-Associated Cutaneous Melanomas, JAMA Dermatol, 2016. 152(3): p. 291-8.

39. Kittler, H., Guitera, P., Riedl, E., Avramidis, M., Teban, L., Fiebiger, M., et.al. Identification of clinically featureless incipient melanoma using sequential dermoscopy imaging, Arch Dermatol, 2006. 142(9): p. 1113-9., http://www.ncbi.nlm.nih.gov/pubmed/16982998

40. Robinson, J. K., Nickoloff, B. J., Digital epiluminescence microscopy monitoring of high-risk patients, Arch Dermatol, 2004. 140(1): p. 49-56., http://www.ncbi.nlm.nih.gov/pubmed/14732660

41. Menzies, S. W., Gutenev, A., Avramidis, M., Batrac, A., McCarthy, W. H., Short-term digital surface microscopic monitoring of atypical or changing melanocytic lesions, Arch Dermatol, 2001. 137(12): p. 1583-9., http://www.ncbi.nlm.nih.gov/pubmed/11735708

42. Menzies, S. W., Emery, J., Staples, M., Davies, S., McAvoy, B., Fletcher, J., et.al. Impact of dermoscopy and short-term sequential digital dermoscopy imaging for the management of pigmented lesions in primary care: a sequential intervention trial, Br J Dermatol, 2009. 161(6): p. 1270-7., http://www.ncbi.nlm.nih.gov/pubmed/19747359

43. Tiersten, A. D., Grin, C. M., Kopf, A. W., Gottlieb, G. J., Bart, R. S., Rigel, D. S., et.al. Prospective follow-up for malignant melanoma in patients with atypical-mole (dysplastic-nevus) syndrome, J Dermatol Surg Oncol, 1991. 17(1): p. 44-8., http://www.ncbi.nlm.nih.gov/pubmed/1991880

44. Wang, S. Q., Kopf, A. W., Koenig, K., Polsky, D., Nudel, K., Bart, R. S., Detection of melanomas in patients followed up with total cutaneous examinations, total cutaneous photography, and dermoscopy, J Am Acad Dermatol, 2004. 50(1): p. 15-20., http://www.ncbi.nlm.nih.gov/pubmed/14699359

45. MacKie, R. M., Early detection, screening and surveillance for malignant melanoma. A critique of current methods of reducing secondary mortality from malignant melanoma, Skin Cancer, 1993. 8(4): p. 269-274.

46. Feit, N. E., Dusza, S. W., Marghoob, A. A., Melanomas detected with the aid of total cutaneous photography, Br J Dermatol, 2004. 150(4): p. 706-14., http://www.ncbi.nlm.nih.gov/pubmed/15099367

47. Kelly, J. W., Yeatman, J. M., Regalia, G., Mason, G., Henham, A. P., A high incidence of melanoma found in patients with multiple dysplastic naevi by photographic surveillance, Medical Journal of Australia, 1997. 167(4): p. 191-194., , to, ISI>://WOS:A1997XR88800006

48. Goodson, A. G., Florell, S. R., Hyde, M., Bowen, G. M., Grossman, D., Comparative analysis of total body and dermatoscopic photographic monitoring of nevi in similar patient populations at risk for cutaneous melanoma, Dermatol Surg, 2010. 36(7): p. 1087-98., http://www.ncbi.nlm.nih.gov/pubmed/20653722

49. Stevenson, A. D., Mickan, S., Mallett, S., Ayya, M., Systematic review of diagnostic accuracy of reflectance confocal microscopy for melanoma diagnosis in patients with clinically equivocal skin lesions, Dermatol Pract Concept, 2013. 3(4): p. 19-27.

50. Xiong, Y. D., Ma, S., Li, X., Zhong, X., Duan, C., Chen, Q., A meta-analysis of reflectance confocal microscopy for the diagnosis of malignant skin tumours, J Eur Acad Dermatol Venereol, 2016. 30(8): p. 1295-302.

51. Rahman, A, Miller, S, Whittington, B, Tee, C, Mclellan, G, Cole, D, et.al. Systematic Review and Meta-Analysis of the Accuracy of Confocal Microscopy in the Diagnosis of Skin Cancer, J Cancer Res Therap Oncol, 2015. 1(1): p. 1-8.

52. Alarcon, I., Carrera, C., Palou, J., Alos, L., Malvehy, J., Puig, S., Impact of in vivo reflectance confocal microscopy on the number needed to treat melanoma in doubtful lesions, Br J Dermatol, 2014. 170(4): p. 802-8.

53. Pellacani, G., Pepe, P., Casari, A., Longo, C., Reflectance confocal microscopy as a second-level examination in skin oncology improves diagnostic accuracy and saves unnecessary excisions: a longitudinal prospective study, Br J Dermatol, 2014. 171(5): p. 1044-51.

54. Pellacani, G., Witkowski, A., Cesinaro, A. M., Losi, A., Colombo, G. L., Campagna, A., et.al. Cost-benefit of reflectance confocal microscopy in the diagnostic performance of melanoma, J Eur Acad Dermatol Venereol, 2016. 30(3): p. 413-9.

55. Malvehy, J., Hauschild, A., Curiel-Lewandrowski, C., Mohr, P., Hofmann-Wellenhof, R., Motley, R., et.al. Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety, Br J Dermatol, 2014. 171(5): p. 1099-107.

56. Seidenari, S., Arginelli, F., Dunsby, C., French, P. M., Konig, K., Magnoni, C., et.al. Multiphoton laser tomography and fluorescence lifetime imaging of melanoma: morphologic features and quantitative data for sensitive and specific non-invasive diagnostics, PLoS One, 2013. 8(7): p. e70682.

57. Balu, M., Kelly, K. M., Zachary, C. B., Harris, R. M., Krasieva, T. B., Konig, K., et.al. Distinguishing between benign and malignant melanocytic nevi by in vivo multiphoton microscopy, Cancer Res, 2014. 74(10): p. 2688-97.

58. Elbaum, M., Kopf, A. W., Rabinovitz, H. S., Langley, R. G., Kamino, H., Mihm, M. C., Jr., et.al. Automatic differentiation of melanoma from melanocytic nevi with multispectral digital dermoscopy: a feasibility study, J Am Acad Dermatol, 2001. 44(2): p. 207-18.

59. Monheit, G., Cognetta, A. B., Ferris, L., Rabinovitz, H., Gross, K., Martini, M., et.al. The performance of MelaFind: a prospective multicenter study, Arch Dermatol, 2011. 147(2): p. 188-94.

60. Hauschild, A., Chen, S. C., Weichenthal, M., Blum, A., King, H. C., Goldsmith, J., et.al. To excise or not: impact of MelaFind on German dermatologists' decisions to biopsy atypical lesions, J Dtsch Dermatol Ges, 2014. 12(7): p. 606-14.

61. Gambichler, T., Schmid-Wendtner, M. H., Plura, I., Kampilafkos, P., Stucker, M., Berking, C., et.al. A multicentre pilot study investigating high-definition optical coherence tomography in the differentiation of cutaneous melanoma and melanocytic naevi, J Eur Acad Dermatol Venereol, 2015. 29(3): p. 537-41.

62. Lim, L., Nichols, B., Migden, M. R., Rajaram, N., Reichenberg, J. S., Markey, M. K., et.al. Clinical study of noninvasive in vivo melanoma and nonmelanoma skin cancers using multimodal spectral diagnosis, J Biomed Opt, 2014. 19(11): p. 117003.

63. Philipsen, P. A., Knudsen, L., Gniadecka, M., Ravnbak, M. H., Wulf, H. C., Diagnosis of malignant melanoma and basal cell carcinoma by in vivo NIR-FT Raman spectroscopy is independent of skin pigmentation, Photochem Photobiol Sci, 2013. 12(5): p. 770-6.

64. Tronnier, M., Garbe, C., Brocker, E. B., Stadler, R., Steinkraus, V., Soyer, H. P., et.al. [Standards in histopathologic diagnosis of malignant melanomas. Recommendations of the Working Group of the Central Malignant Melanoma Registry of the German Dermatologic Society], Hautarzt, 1997. 48(10): p. 720-9., http://www.ncbi.nlm.nih.gov/pubmed/9441164

65. Tran, K. T., Wright, N. A., Cockerell, C. J., Biopsy of the pigmented lesion--when and how, J Am Acad Dermatol, 2008. 59(5): p. 852-71., http://www.ncbi.nlm.nih.gov/pubmed/18762353

66. Martin, R. C., 2nd, Scoggins, C. R., Ross, M. I., Reintgen, D. S., Noyes, R. D., Edwards, M. J., et.al. Is incisional biopsy of melanoma harmful?, Am J Surg, 2005. 190(6): p. 913-7., http://www.ncbi.nlm.nih.gov/pubmed/16307945

67. Ng, J. C., Swain, S., Dowling, J. P., Wolfe, R., Simpson, P., Kelly, J. W., The impact of partial biopsy on histopathologic diagnosis of cutaneous melanoma: experience of an Australian tertiary referral service, Arch Dermatol, 2010. 146(3): p. 234-9., http://www.ncbi.nlm.nih.gov/pubmed/20231492

68. Pflugfelder, A., Weide, B., Eigentler, T. K., Forschner, A., Leiter, U., Held, L., et.al. Incisional biopsy and melanoma prognosis: Facts and controversies, Clin Dermatol, 2010. 28(3): p. 316-8., http://www.ncbi.nlm.nih.gov/pubmed/20541685

69. Stell, V. H., Norton, H. J., Smith, K. S., Salo, J. C., White, R. L., Jr., Method of biopsy and incidence of positive margins in primary melanoma, Ann Surg Oncol, 2007. 14(2): p. 893-8., http://www.ncbi.nlm.nih.gov/pubmed/17119869

70. Hunger, R. E., Seyed Jafari, S. M., Angermeier, S., Shafighi, M., Excision of fascia in melanoma thicker than 2 mm: no evidence for improved clinical outcome, Br J Dermatol, 2014. 171(6): p. 1391-6.

71. Sladden, M. J., Balch, C., Barzilai, D. A., Berg, D., Freiman, A., Handiside, T., et.al. Surgical excision margins for primary cutaneous melanoma, Cochrane Database Syst Rev, 2009. p. CD004835., http://www.ncbi.nlm.nih.gov/pubmed/19821334

72. Wheatley, K., Wilson, J. S., Gaunt, P., Marsden, J. R., Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation, Cancer Treat Rev, 2016. 42: p. 73-81.

73. Veronesi, U., Cascinelli, N., Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma, Arch Surg, 1991. 126(4): p. 438-41., http://www.ncbi.nlm.nih.gov/pubmed/2009058

74. Lichte, V., Breuninger, H., Metzler, G., Haefner, H. M., Moehrle, M., Acral lentiginous melanoma: conventional histology vs. three-dimensional histology, Br J Dermatol, 2009. 160(3): p. 591-9., http://www.ncbi.nlm.nih.gov/pubmed/19067697

75. Loser, C., Rompel, R., Breuninger, H., Mohrle, M., Hafner, H. M., Kunte, C., et.al. Microscopically controlled surgery (MCS), J Dtsch Dermatol Ges, 2010. 8(11): p. 920-5., http://www.ncbi.nlm.nih.gov/pubmed/20337775

76. Moehrle, M., Metzger, S., Schippert, W., Garbe, C., Rassner, G., Breuninger, H., "Functional" surgery in subungual melanoma, Dermatol Surg, 2003. 29(4): p. 366-74., http://www.ncbi.nlm.nih.gov/pubmed/12656815

77. Mohrle, M., [Micrographic controlled surgery (3D-histology) in cutaneous melanoma], J Dtsch Dermatol Ges, 2003. 1(11): p. 869-75., http://www.ncbi.nlm.nih.gov/pubmed/16281577

78. Joyce, K. M., Joyce, C. W., Jones, D. M., Donnellan, P., Hussey, A. J., Regan, P. J., et.al. An assessment of histological margins and recurrence of melanoma in situ, Plast Reconstr Surg Glob Open, 2015. 3(2): p. e301.

79. Shojaku, H., et al., Response to intra-arterial cisplatin and concurrent radiotherapy in a patient with primary mucosal malignant melanoma of the nasal cavity, 2013., https://www.ncbi.nlm.nih.gov/pubmed/22180318

80. McLeod, M., Choudhary, S., Giannakakis, G., Nouri, K., Surgical treatments for lentigo maligna: a review, Dermatol Surg, 2011. 37(9): p. 1210-28., http://onlinelibrary.wiley.com/store/10.1111/j.1524-4725.2011.02042.x/asset/j.1524-4725.2011.02042.x.pdf?v=1&t=ien2uoc1&s=275c3f3169f4af7d165a510e0c5ff103be84699e

81. Mohrle, M., Schippert, W., Garbe, C., Rassner, G., Rocken, M., Breuninger, H., [Prognostic parameters and surgical strategies for facial melanomas], J Dtsch Dermatol Ges, 2003. 1(6): p. 457-63., http://www.ncbi.nlm.nih.gov/pubmed/16295139

82. Stevenson, O., Ahmed, I., Lentigo maligna : prognosis and treatment options, Am J Clin Dermatol, 2005. 6(3): p. 151-64., http://www.ncbi.nlm.nih.gov/pubmed/15943492

83. Dengel, L., Turza, K., Noland, M. M., Patterson, J. W., Slingluff, C. L., Jr., Skin mapping with punch biopsies for defining margins in melanoma: when you don't know how far to go, Ann Surg Oncol, 2008. 15(11): p. 3028-35., http://www.ncbi.nlm.nih.gov/pubmed/18787905

84. Brown, C. D., Zitelli, J. A., The prognosis and treatment of true local cutaneous recurrent malignant melanoma, Dermatol Surg, 1995. 21(4): p. 285-90., http://www.ncbi.nlm.nih.gov/pubmed/7728476

85. Cohen, L. M., McCall, M. W., Hodge, S. J., Freedman, J. D., Callen, J. P., Zax, R. H., Successful treatment of lentigo maligna and lentigo maligna melanoma with Mohs' micrographic surgery aided by rush permanent sections, Cancer, 1994. 73(12): p. 2964-2970.

86. Dawn, M. E., Dawn, A. G., Miller, S. J., Mohs surgery for the treatment of melanoma in situ: a review, Dermatol Surg, 2007. 33(4): p. 395-402., http://www.ncbi.nlm.nih.gov/pubmed/17430372

87. Dong, X. D., Tyler, D., Johnson, J. L., DeMatos, P., Seigler, H. F., Analysis of prognosis and disease progression after local recurrence of melanoma, Cancer, 2000. 88(5): p. 1063-71., http://www.ncbi.nlm.nih.gov/pubmed/10699896

88. Garbe, C, Eigentler, TK, Treatment of malignant melanoma at the stage of distant metastasis, Hautarzt, 2004. 55(2): p. 195-212.

89. Testori, A., Rutkowski, P., Marsden, J., Bastholt, L., Chiarion-Sileni, V., Hauschild, A., et.al. Surgery and radiotherapy in the treatment of cutaneous melanoma, Ann Oncol, 2009. 20 Suppl 6: p. vi22-9., http://www.ncbi.nlm.nih.gov/pubmed/19617294

90. Wornom, I. L., Smith, J. W., Soong, S. J., Mcelvein, R., Urist, M. M., Balch, C. M., Surgery as Palliative Treatment for Distant Metastases of Melanoma, Annals of Surgery, 1986. 204(2): p. 181-185.

91. Young, S. E., Martinez, S. R., Faries, M. B., Essner, R., Wanek, L. A., Morton, D. L., Can surgical therapy alone achieve long-term cure of melanoma metastatic to regional nodes?, Cancer journal (Sudbury, Mass.), 2006. 12(3): p. 207-211.

92. Martinez, S. R., Young, S. E., A rational surgical approach to the treatment of distant melanoma metastases, Cancer Treat Rev, 2008. 34(7): p. 614-20., http://www.ncbi.nlm.nih.gov/pubmed/18556133

93. Schwager, S. S., Leiter, U., Buettner, P. G., Voit, C., Marsch, W., Gutzmer, R., et.al. Management of primary and metastasized melanoma in Germany in the time period 1976-2005: an analysis of the Central Malignant Melanoma Registry of the German Dermatological Society, Melanoma Res, 2008. 18(2): p. 112-9., http://www.ncbi.nlm.nih.gov/pubmed/18337647

94. Schmid-Wendtner, M. H., Brunner, B., Konz, B., Kaudewitz, P., Wendtner, C. M., Peter, R. U., et.al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients, J Am Acad Dermatol, 2000. 43(3): p. 477-82., http://www.ncbi.nlm.nih.gov/pubmed/10954659

95. Seegenschmiedt, M. H., Keilholz, L., Altendorf-Hofmann, A., Urban, A., Schell, H., Hohenberger, W., et.al. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience, Int J Radiat Oncol Biol Phys, 1999. 44(3): p. 607-18., http://www.ncbi.nlm.nih.gov/pubmed/10348291

96. Foote, M. C., Burmeister, B., Burmeister, E., Bayley, G., Smithers, B. M., Desmoplastic melanoma: the role of radiotherapy in improving local control, ANZ J Surg, 2008. 78(4): p. 273-6., http://www.ncbi.nlm.nih.gov/pubmed/18366400

97. Vongtama, R., Safa, A., Gallardo, D., Calcaterra, T., Juillard, G., Efficacy of radiation therapy in the local control of desmoplastic malignant melanoma, Head Neck, 2003. 25(6): p. 423-8., http://www.ncbi.nlm.nih.gov/pubmed/12784232

98. Rule, W. G., Allred, J. B., Pockaj, B. A., Markovic, S. N., DiCaudo, D. J., Erickson, L. A., et.al. Results of NCCTG N0275 (Alliance) - a phase II trial evaluating resection followed by adjuvant radiation therapy for patients with desmoplastic melanoma, Cancer Med, 2016. 5(8): p. 1890-6.

99. Chen, J. Y., Hruby, G., Scolyer, R. A., Murali, R., Hong, A., Fitzgerald, P., et.al. Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 128 cases, Cancer, 2008. 113(10): p. 2770-2778.

100. Arora, A., Lowe, L., Su, L., Rees, R., Bradford, C., Cimmino, V. C., et.al. Wide excision without radiation for desmoplastic melanoma, Cancer, 2005. 104(7): p. 1462-1467.

101. Stevens, G., Thompson, J. F., Firth, I., O'Brien, C. J., McCarthy, W. H., Quinn, M. J., Locally advanced melanoma: results of postoperative hypofractionated radiation therapy, Cancer, 2000. 88(1): p. 88-94.

102. Storper, I. S., Lee, S. P., Abemayor, E., Juillard, G., The role of radiation therapy in the treatment of head and neck cutaneous melanoma, Am J Otolaryngol, 1993. 14(6): p. 426-31., http://www.ncbi.nlm.nih.gov/pubmed/8285314

103. Ang, K. K., Peters, L. J., Weber, R. S., Morrison, W. H., Frankenthaler, R. A., Garden, A. S., et.al. Postoperative radiotherapy for cutaneous melanoma of the head and neck region, Int J Radiat Oncol Biol Phys, 1994. 30(4): p. 795-8., http://www.ncbi.nlm.nih.gov/pubmed/7960981

104. LeBoit, Philip E., Burg, Gunter, Weedon, David, Pathology and Genetics of Skin TumoursWorld Health Organization, 2005. p. 356., http://www.amazon.de/Pathology-Genetics-Skin-Tumours-Classification/dp/9283224140/ref=sr_1_1?ie=UTF8&qid=1456823917&sr=8-1&keywords=WHO+Classification+of+tumours+Pathology+and+genetics+of+skin+tumours

105. Garbe, C., Eigentler, T. K., Bauer, J., Blodorn-Schlicht, N., Fend, F., Hantschke, M., et.al. Histopathological diagnostics of malignant melanoma in accordance with the recent AJCC classification 2009: Review of the literature and recommendations for general practice, J Dtsch Dermatol Ges, 2011. 9(9): p. 690-9., http://www.ncbi.nlm.nih.gov/pubmed/21651721

106. Piris, A., Mihm, M. C., Jr., Duncan, L. M., AJCC melanoma staging update: impact on dermatopathology practice and patient management, J Cutan Pathol, 2011. 38(5): p. 394-400., http://www.ncbi.nlm.nih.gov/pubmed/21385199

107. Guitart, J., Lowe, L., Piepkorn, M., Prieto, V. G., Rabkin, M. S., Ronan, S. G., et.al. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases, Arch Dermatol, 2002. 138(5): p. 603-8., http://www.ncbi.nlm.nih.gov/pubmed/12020220

108. Morris, K. T., Busam, K. J., Bero, S., Patel, A., Brady, M. S., Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy, Ann Surg Oncol, 2008. 15(1): p. 316-22., http://www.ncbi.nlm.nih.gov/pubmed/18004626

109. Kashani-Sabet, M., Sagebiel, R. W., Ferreira, C. M., Nosrati, M., Miller, J. R., 3rd, Vascular involvement in the prognosis of primary cutaneous melanoma, Arch Dermatol, 2001. 137(9): p. 1169-73., http://www.ncbi.nlm.nih.gov/pubmed/11559212

110. Sawyer, A., McGoldrick, R. B., Mackey, S. P., Allan, R., Powell, B., Does staging computered tomography change management in thick malignant melanoma?, J Plast Reconstr Aesthet Surg, 2009. 62(4): p. 453-6., http://www.ncbi.nlm.nih.gov/pubmed/18468970

111. Yancovitz, M., Finelt, N., Warycha, M. A., Christos, P. J., Mazumdar, M., Shapiro, R. L., et.al. Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma, Cancer, 2007. 110(5): p. 1107-1114.

112. Xing, Y., Bronstein, Y., Ross, M. I., Askew, R. L., Lee, J. E., Gershenwald, J. E., et.al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis, J Natl Cancer Inst, 2011. 103(2): p. 129-42., http://www.ncbi.nlm.nih.gov/pubmed/21081714

113. Terhune, M. H., Swanson, N., Johnson, T. M., Use of chest radiography in the initial evaluation of patients with localized melanoma, Archives of Dermatology, 1998. 134(5): p. 569-572.

114. Voit, C., Van Akkooi, A. C., Schafer-Hesterberg, G., Schoengen, A., Kowalczyk, K., Roewert, J. C., et.al. Ultrasound morphology criteria predict metastatic disease of the sentinel nodes in patients with melanoma, J Clin Oncol, 2010. 28(5): p. 847-52., http://www.ncbi.nlm.nih.gov/pubmed/20065175

115. Bafounta, M. L., Beauchet, A., Chagnon, S., Saiag, P., Ultrasonography or palpation for detection of melanoma nodal invasion: a meta-analysis, Lancet Oncol, 2004. 5(11): p. 673-80., http://www.ncbi.nlm.nih.gov/pubmed/15522655

116. Mocellin, S., Zavagno, G., Nitti, D., The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-analysis, Int J Cancer, 2008. 123(10): p. 2370-6., http://www.ncbi.nlm.nih.gov/pubmed/18752249

117. Bosserhoff, A. K., Kaufmann, M., Kaluza, B., Bartke, I., Zirngibl, H., Hein, R., et.al. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma, Cancer Res, 1997. 57(15): p. 3149-53., http://www.ncbi.nlm.nih.gov/pubmed/9242442

118. Garbe, C., Leiter, U., Ellwanger, U., Blaheta, H. J., Meier, F., Rassner, G., et.al. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients, Cancer, 2003. 97(7): p. 1737-1745.

119. Hofmann, M. A., Gussmann, F., Fritsche, A., Biesold, S., Schicke, B., Kuchler, I., et.al. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma, Melanoma Res, 2009. 19(1): p. 17-23., http://www.ncbi.nlm.nih.gov/pubmed/19104451

120. Krahn, G., Kaskel, P., Sander, S., Waizenhofer, P. J., Wortmann, S., Leiter, U., et.al. S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase, Anticancer Research, 2001. 21(2B): p. 1311-1316.

121. Auge, J. M., Molina, R., Filella, X., Bosch, E., Gonzalez Cao, M., Puig, S., et.al. S-100beta and MIA in advanced melanoma in relation to prognostic factors, Anticancer Res, 2005. 25(3A): p. 1779-82., http://www.ncbi.nlm.nih.gov/pubmed/16033099

122. Schmitz, C., Brenner, W., Henze, E., Christophers, E., Hauschild, A., Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients, Anticancer Research, 2000. 20(6D): p. 5059-5063.

123. Dumitrascu, G., Constantin, C., Manda, G., Hristescu, S., Margaritescu, I., Chirita, D., et.al. Serum markers in skin melanoma--preliminary study, Roumanian archives of microbiology and immunology, 2009. 68(3): p. 125-135.

124. Meral, R., Duranyildiz, D., Tas, F., Camlica, H., Yasasever, V., Kurul, S., et.al. Prognostic significance of melanoma inhibiting activity levels in malignant melanoma, Melanoma Res, 2001. 11(6): p. 627-32., http://www.ncbi.nlm.nih.gov/pubmed/11725209

125. Tas, F., Yasasever, V., Duranyildiz, D., Camlica, H., Ustuner, Z., Aydiner, A., et.al. Clinical value of protein S100 and melanoma-inhibitory activity (MIA) in malignant melanoma, Am J Clin Oncol, 2004. 27(3): p. 225-8., http://www.ncbi.nlm.nih.gov/pubmed/15170138

126. Juergensen, A., Holzapfel, U., Hein, R., Stolz, W., Buettner, R., Bosserhoff, A., Comparison of two prognostic markers for malignant melanoma: MIA and S100 beta, Tumour Biol, 2001. 22(1): p. 54-8., http://www.ncbi.nlm.nih.gov/pubmed/11054027

127. Garnier, J. P., Letellier, S., Cassinat, B., Lebbe, C., Kerob, D., Baccard, M., et.al. Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma, Eur J Cancer, 2007. 43(4): p. 816-21., http://www.ncbi.nlm.nih.gov/pubmed/17276671

128. Wang, T. S., Johnson, T. M., Cascade, P. N., Redman, B. G., Sondak, V. K., Schwartz, J. L., Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma, J Am Acad Dermatol, 2004. 51(3): p. 399-405., http://www.ncbi.nlm.nih.gov/pubmed/15337983

129. Minn, H., Vihinen, P., Melanoma imaging with highly specific PET probes: ready for prime time?, J Nucl Med, 2011. 52(1): p. 5-7., http://www.ncbi.nlm.nih.gov/pubmed/21149485

130. Jimenez-Requena, F., Delgado-Bolton, R. C., Fernandez-Perez, C., Gambhir, S. S., Schwimmer, J., Perez-Vazquez, J. M., et.al. Meta-analysis of the performance of (18)F-FDG PET in cutaneous melanoma, Eur J Nucl Med Mol Imaging, 2010. 37(2): p. 284-300., http://www.ncbi.nlm.nih.gov/pubmed/19727717

131. Krug, B., Pirson, A. S., Crott, R., Vander Borght, T., The diagnostic accuracy of 18F-FDG PET in cutaneous malignant melanoma, Eur J Nucl Med Mol Imaging, 2010. 37(7): p. 1434-5; author reply 1436-7., http://www.ncbi.nlm.nih.gov/pubmed/20503045

132. Veit-Haibach, P., Vogt, F. M., Jablonka, R., Kuehl, H., Bockisch, A., Beyer, T., et.al. Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma, Eur J Nucl Med Mol Imaging, 2009. 36(6): p. 910-8., http://www.ncbi.nlm.nih.gov/pubmed/19156409

133. Clark, P. B., Soo, V., Kraas, J., Shen, P., Levine, E. A., Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma, Arch Surg, 2006. 141(3): p. 284-8., http://www.ncbi.nlm.nih.gov/pubmed/16549694

134. El-Maraghi, R. H., Kielar, A. Z., PET vs sentinel lymph node biopsy for staging melanoma: a patient intervention, comparison, outcome analysis, J Am Coll Radiol, 2008. 5(8): p. 924-31., http://www.ncbi.nlm.nih.gov/pubmed/18657789

135. Klode, J., Dissemond, J., Grabbe, S., Hillen, U., Poeppel, T., Boeing, C., Sentinel lymph node excision and PET-CT in the initial stage of malignant melanoma: a retrospective analysis of 61 patients with malignant melanoma in American Joint Committee on Cancer stages I and II, Dermatol Surg, 2010. 36(4): p. 439-45., http://www.ncbi.nlm.nih.gov/pubmed/20187901

136. Maubec, E., Lumbroso, J., Masson, F., Suciu, V., Kolb, F., Mamelle, G., et.al. F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm, Melanoma Res, 2007. 17(3): p. 147-54., http://www.ncbi.nlm.nih.gov/pubmed/17505260

137. Revel, A., Revel, C., Dolivet, G., Gillet, N., Didot, N., Meneroux, B., et.al. La TEP-TDM au 18FDG a-t-elle un intérêt dans la stadification ganglionnaire des mélanomes malins cutanés cervicofaciaux bénéficiant de la technique du ganglion sentinelle ? À propos de 22 cas, Médecine Nucléaire, 2010. 34(9): p. 528-539.

138. Singh, B., Ezziddin, S., Palmedo, H., Reinhardt, M., Strunk, H., Tuting, T., et.al. Preoperative 18F-FDG-PET/CT imaging and sentinel node biopsy in the detection of regional lymph node metastases in malignant melanoma, Melanoma Res, 2008. 18(5): p. 346-52., http://www.ncbi.nlm.nih.gov/pubmed/18781133

139. van der Ploeg, I. M., Valdes Olmos, R. A., Kroon, B. B., Wouters, M. W., van den Brekel, M. W., Vogel, W. V., et.al. The yield of SPECT/CT for anatomical lymphatic mapping in patients with melanoma, Ann Surg Oncol, 2009. 16(6): p. 1537-42., http://www.ncbi.nlm.nih.gov/pubmed/19184226

140. Morton, D. L., Thompson, J. F., Cochran, A. J., Mozzillo, N., Elashoff, R., Essner, R., et.al. Sentinel-node biopsy or nodal observation in melanoma, N Engl J Med, 2006. 355(13): p. 1307-17., http://www.ncbi.nlm.nih.gov/pubmed/17005948

141. Valsecchi, M. E., Silbermins, D., de Rosa, N., Wong, S. L., Lyman, G. H., Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis, J Clin Oncol, 2011. 29(11): p. 1479-87., http://www.ncbi.nlm.nih.gov/pubmed/21383281

142. Leiter, U., Buettner, P. G., Bohnenberger, K., Eigentler, T., Meier, F., Moehrle, M., et.al. Sentinel lymph node dissection in primary melanoma reduces subsequent regional lymph node metastasis as well as distant metastasis after nodal involvement, Ann Surg Oncol, 2010. 17(1): p. 129-37., http://www.ncbi.nlm.nih.gov/pubmed/19866238

143. Satzger, I., Meier, A., Hoy, L., Volker, B., Kapp, A., Hauschild, A., et.al. Sentinel node dissection delays recurrence and prolongs melanoma-related survival: an analysis of 673 patients from a single center with long-term follow-up, Ann Surg Oncol, 2011. 18(2): p. 514-20., http://www.ncbi.nlm.nih.gov/pubmed/20839060

144. Kretschmer, L., Thoms, K. M., Peeters, S., Haenssle, H., Bertsch, H. P., Emmert, S., Postoperative morbidity of lymph node excision for cutaneous melanoma-sentinel lymphonodectomy versus complete regional lymph node dissection, Melanoma Res, 2008. 18(1): p. 16-21., http://www.ncbi.nlm.nih.gov/pubmed/18227703

145. Morton, D. L., Cochran, A. J., Thompson, J. F., Elashoff, R., Essner, R., Glass, E. C., et.al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial, Ann Surg, 2005. 242(3): p. 302-11; discussion 311-3., http://www.ncbi.nlm.nih.gov/pubmed/16135917

146. Roaten, J. B., Pearlman, N., Gonzalez, R., Gonzalez, R., McCarter, M. D., Identifying risk factors for complications following sentinel lymph node biopsy for melanoma, Arch Surg, 2005. 140(1): p. 85-9., http://www.ncbi.nlm.nih.gov/pubmed/15655211

147. McMasters, K. M., Wong, S. L., Edwards, M. J., Ross, M. I., Chao, C., Noyes, R. D., et.al. Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma, Surgery, 2001. 130(2): p. 151-156.

148. Testori, A., De Salvo, G. L., Montesco, M. C., Trifiro, G., Mocellin, S., Landi, G., et.al. Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI), Ann Surg Oncol, 2009. 16(7): p. 2018-27., http://www.ncbi.nlm.nih.gov/pubmed/19132446

149. Nguyen, C. L., McClay, E. F., Cole, D. J., O'Brien, P. H., Gillanders, W. E., Metcalf, J. S., et.al. Melanoma thickness and histology predict sentinel lymph node status, Am J Surg, 2001. 181(1): p. 8-11., http://www.ncbi.nlm.nih.gov/pubmed/11248167

150. Taylor, R. C., Patel, A., Panageas, K. S., Busam, K. J., Brady, M. S., Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007. 25(7): p. 869-875.

151. Warycha, M., Polsky, D., Osman, I., Mazumdar, M., Metaanalysis of sentinel lymph node positivity in thin melanoma (≤1 mm), Journal of the American Academy of Dermatology, 2009. 60(3): p. AB10.

152. Kretschmer, L., Starz, H., Thoms, K. M., Satzger, I., Volker, B., Jung, K., et.al. Age as a key factor influencing metastasizing patterns and disease-specific survival after sentinel lymph node biopsy for cutaneous melanoma, Int J Cancer, 2011. 129(6): p. 1435-42., http://www.ncbi.nlm.nih.gov/pubmed/21064111

153. Kunte, C., Geimer, T., Baumert, J., Konz, B., Volkenandt, M., Flaig, M., et.al. Prognostic factors associated with sentinel lymph node positivity and effect of sentinel status on survival: an analysis of 1049 patients with cutaneous melanoma, Melanoma Res, 2010. 20(4): p. 330-7., http://www.ncbi.nlm.nih.gov/pubmed/20526218

154. Mays, M. P., Martin, R. C., Burton, A., Ginter, B., Edwards, M. J., Reintgen, D. S., et.al. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?, Cancer, 2010. 116(6): p. 1535-1544.

155. Gutzmer, R., Satzger, I., Thoms, K. M., Volker, B., Mitteldorf, C., Kapp, A., et.al. Sentinel lymph node status is the most important prognostic factor for thick (> or = 4 mm) melanomas, J Dtsch Dermatol Ges, 2008. 6(3): p. 198-203., http://www.ncbi.nlm.nih.gov/pubmed/18093216

156. Scoggins, C. R., Bowen, A. L., Martin, R. C., 2nd, Edwards, M. J., Reintgen, D. S., Ross, M. I., et.al. Prognostic information from sentinel lymph node biopsy in patients with thick melanoma, Arch Surg, 2010. 145(7): p. 622-7., http://www.ncbi.nlm.nih.gov/pubmed/20644123

157. Dadras, S. S., Lange-Asschenfeldt, B., Velasco, P., Nguyen, L., Vora, A., Muzikansky, A., et.al. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2005. 18(9): p. 1232-1242.

158. Doeden, K., Ma, Z., Narasimhan, B., Swetter, S. M., Detmar, M., Dadras, S. S., Lymphatic invasion in cutaneous melanoma is associated with sentinel lymph node metastasis, J Cutan Pathol, 2009. 36(7): p. 772-80., http://www.ncbi.nlm.nih.gov/pubmed/19032379

159. Massi, D., Puig, S., Franchi, A., Malvehy, J., Vidal-Sicart, S., Gonzalez-Cao, M., et.al. Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: a case-control study, J Clin Pathol, 2006. 59(2): p. 166-73., http://www.ncbi.nlm.nih.gov/pubmed/16443733

160. Paek, S. C., Griffith, K. A., Johnson, T. M., Sondak, V. K., Wong, S. L., Chang, A. E., et.al. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma, Cancer, 2007. 109(1): p. 100-108.

161. Puleo, C. A., Messina, J. L., Riker, A. I., Glass, L. F., Nelson, C., Cruse, C. W., et.al. Sentinel node biopsy for thin melanomas: which patients should be considered?, Cancer control : journal of the Moffitt Cancer Center, 2005. 12(4): p. 230-235.

162. Socrier, Y., Lauwers-Cances, V., Lamant, L., Garrido, I., Lauwers, F., Lopez, R., et.al. Histological regression in primary melanoma: not a predictor of sentinel lymph node metastasis in a cohort of 397 patients, Br J Dermatol, 2010. 162(4): p. 830-4., http://www.ncbi.nlm.nih.gov/pubmed/20030641

163. Kaur, M. R., Colloby, P. S., Martin-Clavijo, A., Marsden, J. R., Melanoma histopathology reporting: are we complying with the National Minimum Dataset?, J Clin Pathol, 2007. 60(10): p. 1121-3., http://www.ncbi.nlm.nih.gov/pubmed/17182660

164. Leong, W. L., Ghazarian, D. M., McCready, D. R., Previous wide local excision of primary melanoma is not a contraindication for sentinel lymph node biopsy of the trunk and extremity, J Surg Oncol, 2003. 82(3): p. 143-6., http://www.ncbi.nlm.nih.gov/pubmed/12619055

165. McCready, D. R., Ghazarian, D. M., Hershkop, M. S., Walker, J. A., Ambus, U., Quirt, I. C., Sentinel lymph-node biopsy after previous wide local excision for melanoma, Can J Surg, 2001. 44(6): p. 432-4., http://www.ncbi.nlm.nih.gov/pubmed/11764876

166. Alazraki, N., Glass, E. C., Castronovo, F., Olmos, R. A. V., Podoloff, D., Procedure guideline for lymphoscintigraphy and the use of Intraoperative gamma probe for sentinel lymph node localization in melanoma of intermediate thickness 1.0, Journal of Nuclear Medicine, 2002. 43(10): p. 1414-1418.

167. Chakera, A. H., Hesse, B., Burak, Z., Ballinger, J. R., Britten, A., Caraco, C., et.al. EANM-EORTC general recommendations for sentinel node diagnostics in melanoma, Eur J Nucl Med Mol Imaging, 2009. 36(10): p. 1713-42., http://www.ncbi.nlm.nih.gov/pubmed/19714329

168. Cochran, A. J., Balda, B. R., Starz, H., Bachter, D., Krag, D. N., Cruse, C. W., et.al. The Augsburg Consensus. Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies, Cancer, 2000. 89(2): p. 236-241.

169. Satzger, I., Klein, M., Loser, C., Reske, S., Kapp, A., Gutzmer, R., Sentinel node biopsy in malignant melanoma, Onkologe, 2010. 16(12): p. 1140-1149.

170. Vogt, H., Schmidt, M., Bares, R., Brenner, W., Grunwald, F., Kopp, J., et.al. [Procedure guideline for sentinel lymph node diagnosis], Nuklearmedizin, 2010. 49(4): p. 167-72; quiz N19.

171. Morton, D. L., Wen, D. R., Wong, J. H., Economou, J. S., Cagle, L. A., Storm, F. K., et.al. Technical details of intraoperative lymphatic mapping for early stage melanoma, Arch Surg, 1992. 127(4): p. 392-9., http://www.ncbi.nlm.nih.gov/pubmed/1558490

172. Even-Sapir, E., Lerman, H., Lievshitz, G., Khafif, A., Fliss, D. M., Schwartz, A., et.al. Lymphoscintigraphy for sentinel node mapping using a hybrid SPECT/CT system, Journal of Nuclear Medicine, 2003. 44(9): p. 1413-1420.

173. Mar, M. V., Miller, S. A., Kim, E. E., Macapinlac, H. A., Evaluation and localization of lymphatic drainage and sentinel lymph nodes in patients with head and neck melanomas by hybrid SPECT/CT lymphoscintigraphic imaging, J Nucl Med Technol, 2007. 35(1): p. 10-6; quiz 17-20., http://www.ncbi.nlm.nih.gov/pubmed/17337652

174. Dengel, L. T., More, M. J., Judy, P. G., Petroni, G. R., Smolkin, M. E., Rehm, P. K., et.al. Intraoperative imaging guidance for sentinel node biopsy in melanoma using a mobile gamma camera, Ann Surg, 2011. 253(4): p. 774-8., http://www.ncbi.nlm.nih.gov/pubmed/21475019

175. Vidal-Sicart, S., Paredes, P., Zanon, G., Pahisa, J., Martinez-Roman, S., Caparros, X., et.al. Added value of intraoperative real-time imaging in searches for difficult-to-locate sentinel nodes, J Nucl Med, 2010. 51(8): p. 1219-25., http://www.ncbi.nlm.nih.gov/pubmed/20660385

176. Chakera, A. H., Lock-Andersen, J., Hesse, U., Nurnberg, B. M., Juhl, B. R., Stokholm, K. H., et.al. One-day or two-day procedure for sentinel node biopsy in melanoma?, Eur J Nucl Med Mol Imaging, 2009. 36(6): p. 928-37., http://www.ncbi.nlm.nih.gov/pubmed/19153733

177. Wendler, T., Herrmann, K., Schnelzer, A., Lasser, T., Traub, J., Kutter, O., et.al. First demonstration of 3-D lymphatic mapping in breast cancer using freehand SPECT, Eur J Nucl Med Mol Imaging, 2010. 37(8): p. 1452-61., http://www.ncbi.nlm.nih.gov/pubmed/20354851

178. Bostick, P., Essner, R., Glass, E., Kelley, M., Sarantou, T., Foshag, L. J., et.al. Comparison of blue dye and probe-assisted intraoperative lymphatic mapping in melanoma to identify sentinel nodes in 100 lymphatic basins, Arch Surg, 1999. 134(1): p. 43-9., http://www.ncbi.nlm.nih.gov/pubmed/9927129

179. Kretschmer, L., Peeters, S., Beckmann, I., Thoms, K. M., Mitteldorf, C., Emmert, S., et.al. [Intraoperative detection of sentinel lymph nodes in cutaneous malignant melanoma -- blue dye alone versus blue dye plus gamma detection], J Dtsch Dermatol Ges, 2005. 3(8): p. 615-22., http://www.ncbi.nlm.nih.gov/pubmed/16033480

180. King, T. A., Fey, J. V., Van Zee, K. J., Heerdt, A. S., Gemignani, M. L., Port, E. R., et.al. A prospective analysis of the effect of blue-dye volume on sentinel lymph node mapping success and incidence of allergic reaction in patients with breast cancer, Ann Surg Oncol, 2004. 11(5): p. 535-41., http://www.ncbi.nlm.nih.gov/pubmed/15123464

181. Lloyd, M. S., Topping, A., Allan, R., Powell, B., Contraindications to sentinel lymph node biopsy in cutaneous malignant melanoma, Br J Plast Surg, 2004. 57(8): p. 725-7., http://www.ncbi.nlm.nih.gov/pubmed/15544768

182. Abrahamsen, H. N., Hamilton-Dutoit, S. J., Larsen, J., Steiniche, T., Sentinel lymph nodes in malignant melanoma: extended histopathologic evaluation improves diagnostic precision, Cancer, 2004. 100(8): p. 1683-1691.

183. Cook, M. G., Green, M. A., Anderson, B., Eggermont, A. M., Ruiter, D. J., Spatz, A., et.al. The development of optimal pathological assessment of sentinel lymph nodes for melanoma, J Pathol, 2003. 200(3): p. 314-9., http://www.ncbi.nlm.nih.gov/pubmed/12845627

184. Gietema, H. A., Vuylsteke, R. J., de Jonge, I. A., van Leeuwen, P. A., Molenkamp, B. G., van der Sijp, J. R., et.al. Sentinel lymph node investigation in melanoma: detailed analysis of the yield from step sectioning and immunohistochemistry, J Clin Pathol, 2004. 57(6): p. 618-20., http://www.ncbi.nlm.nih.gov/pubmed/15166267

185. Spanknebel, K., Coit, D. G., Bieligk, S. C., Gonen, M., Rosai, J., Klimstra, D. S., Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis, Am J Surg Pathol, 2005. 29(3): p. 305-17., http://www.ncbi.nlm.nih.gov/pubmed/15725798

186. Mitteldorf, C., Bertsch, H. P., Zapf, A., Neumann, C., Kretschmer, L., Cutting a sentinel lymph node into slices is the optimal first step for examination of sentinel lymph nodes in melanoma patients, Mod Pathol, 2009. 22(12): p. 1622-7., http://www.ncbi.nlm.nih.gov/pubmed/19801968

187. Satzger, I., Volker, B., Al Ghazal, M., Meier, A., Kapp, A., Gutzmer, R., Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients, Histopathology, 2007. 50(6): p. 764-772.

188. Starz, H., Balda, B. R., Kramer, K. U., Buchels, H., Wang, H., A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma, Cancer, 2001. 91(11): p. 2110-2121.

189. van Akkooi, A. C., Spatz, A., Eggermont, A. M., Mihm, M., Cook, M. G., Expert opinion in melanoma: the sentinel node; EORTC Melanoma Group recommendations on practical methodology of the measurement of the microanatomic location of metastases and metastatic tumour burden, Eur J Cancer, 2009. 45(16): p. 2736-42., http://www.ncbi.nlm.nih.gov/pubmed/19767199

190. Meier, A., Satzger, I., Volker, B., Kapp, A., Gutzmer, R., Comparison of classification systems in melanoma sentinel lymph nodes--an analysis of 697 patients from a single center, Cancer, 2010. 116(13): p. 3178-88., http://www.ncbi.nlm.nih.gov/pubmed/20564647

191. Starz, H., Siedlecki, K., Balda, B. R., Sentinel lymphonodectomy and s-classification: a successful strategy for better prediction and improvement of outcome of melanoma, Ann Surg Oncol, 2004. 11(3 Suppl): p. 162S-8S., http://www.ncbi.nlm.nih.gov/pubmed/15023745

192. van Akkooi, A. C., de Wilt, J. H., Verhoef, C., Schmitz, P. I., van Geel, A. N., Eggermont, A. M., et.al. Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative?, Ann Oncol, 2006. 17(10): p. 1578-85., http://www.ncbi.nlm.nih.gov/pubmed/16968875

193. Negrier, S., Saiag, P., Guillot, B., Verola, O., Avril, M. F., Bailly, C., et.al. [Guidelines for clinical practice: Standards, Options and Recommendations 2005 for the management of adult patients exhibiting an M0 cutaneous melanoma, full report. National Federation of Cancer Campaign Centers. French Dermatology Society. Update of the 1995 Consensus Conference and the 1998 Standards, Options, and Recommendations], Ann Dermatol Venereol, 2005. 132(12 Pt 2): p. 10S3-10S85., http://www.ncbi.nlm.nih.gov/pubmed/16521904

194. Stojadinovic, A., Allen, P. J., Clary, B. M., Busam, K. J., Coit, D. G., Value of frozen-section analysis of sentinel lymph nodes for primary cutaneous malignant melanoma, Ann Surg, 2002. 235(1): p. 92-8., http://www.ncbi.nlm.nih.gov/pubmed/11753047

195. Blaheta, H. J., Ellwanger, U., Schittek, B., Sotlar, K., MacZey, E., Breuninger, H., et.al. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma, J Invest Dermatol, 2000. 114(4): p. 637-42., http://www.ncbi.nlm.nih.gov/pubmed/10733666

196. Kuo, C. T., Hoon, D. S., Takeuchi, H., Turner, R., Wang, H. J., Morton, D. L., et.al. Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes, J Clin Oncol, 2003. 21(19): p. 3566-72., http://www.ncbi.nlm.nih.gov/pubmed/12913098

197. Palmieri, G., Ascierto, P. A., Cossu, A., Mozzillo, N., Motti, M. L., Satriano, S. M. R., et.al. Detection of occult melanoma cells in paraffin-embedded histologically negative sentinel lymph nodes using a reverse transcriptase polymerase chain reaction assay, Journal of Clinical Oncology, 2001. 19(5): p. 1437-1443.

198. Ribuffo, D., Gradilone, A., Vonella, M., Chiummariello, S., Cigna, E., Haliassos, N., et.al. Prognostic significance of reverse transcriptase-polymerase chain reaction-negative sentinel nodes in malignant melanoma, Ann Surg Oncol, 2003. 10(4): p. 396-402., http://www.ncbi.nlm.nih.gov/pubmed/12734088

199. Rimoldi, D., Lemoine, R., Kurt, A. M., Salvi, S., Berset, M., Matter, M., et.al. Detection of micrometastases in sentinel lymph nodes from melanoma patients: direct comparison of multimarker molecular and immunopathological methods, Melanoma Res, 2003. 13(5): p. 511-20., http://www.ncbi.nlm.nih.gov/pubmed/14512793

200. Gutzmer, R., Kaspari, M., Brodersen, J. P., Mommert, S., Volker, B., Kapp, A., et.al. Specificity of tyrosinase and HMB45 PCR in the detection of melanoma metastases in sentinel lymph node biopsies, Histopathology, 2002. 41(6): p. 510-518.

201. Murali, R., Desilva, C., Thompson, J. F., Scolyer, R. A., Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes, J Clin Oncol, 2010. 28(29): p. 4441-9., http://www.ncbi.nlm.nih.gov/pubmed/20823419

202. Satzger, I., Volker, B., Meier, A., Kapp, A., Gutzmer, R., Criteria in sentinel lymph nodes of melanoma patients that predict involvement of nonsentinel lymph nodes, Ann Surg Oncol, 2008. 15(6): p. 1723-32., http://www.ncbi.nlm.nih.gov/pubmed/18389323

203. Scolyer, R. A., Li, L. X., McCarthy, S. W., Shaw, H. M., Stretch, J. R., Sharma, R., et.al. Micromorphometric features of positive sentinel lymph nodes predict involvement of nonsentinel nodes in patients with melanoma, Am J Clin Pathol, 2004. 122(4): p. 532-9., http://www.ncbi.nlm.nih.gov/pubmed/15487450

204. Dewar, D. J., Newell, B., Green, M. A., Topping, A. P., Powell, B. W., Cook, M. G., The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement, J Clin Oncol, 2004. 22(16): p. 3345-9., http://www.ncbi.nlm.nih.gov/pubmed/15310779

205. Frankel, T. L., Griffith, K. A., Lowe, L., Wong, S. L., Bichakjian, C. K., Chang, A. E., et.al. Do micromorphometric features of metastatic deposits within sentinel nodes predict nonsentinel lymph node involvement in melanoma?, Ann Surg Oncol, 2008. 15(9): p. 2403-11., http://www.ncbi.nlm.nih.gov/pubmed/18626721

206. Kappauf, H. W., Kommunikation in der Onkologie, Der Onkologe, 2004. 10(11): p. 1251-1260.

207. Schroder, C., Schmutzer, G., Brahler, E., [Representative survey of german people concerning enlightenment and patient directive in a case of terminal illness], Psychother Psychosom Med Psychol, 2002. 52(5): p. 236-43., http://www.ncbi.nlm.nih.gov/pubmed/12012266

208. Baile, W. F., Buckman, R., Lenzi, R., Glober, G., Beale, E. A., Kudelka, A. P., SPIKES-A six-step protocol for delivering bad news: application to the patient with cancer, Oncologist, 2000. 5(4): p. 302-11., http://www.ncbi.nlm.nih.gov/pubmed/10964998

209. Keller, M., Werner, A., Aufklärung und Begleitung von Tumorpatienten, Der Onkologe, 2006. 12(1): p. 55-61.

210. Harrison, J. D., Young, J. M., Price, M. A., Butow, P. N., Solomon, M. J., What are the unmet supportive care needs of people with cancer? A systematic review, Support Care Cancer, 2009. 17(8): p. 1117-28., http://www.ncbi.nlm.nih.gov/pubmed/19319577

211. Kleeberg, U. R., Tews, J. T., Ruprecht, T., Hoing, M., Kuhlmann, A., Runge, C., Patient satisfaction and quality of life in cancer outpatients: results of the PASQOC study, Support Care Cancer, 2005. 13(5): p. 303-10., http://www.ncbi.nlm.nih.gov/pubmed/15729552

212. Sanson-Fisher, R., Girgis, A., Boyes, A., Bonevski, B., Burton, L., Cook, P., The unmet supportive care needs of patients with cancer. Supportive Care Review Group, Cancer, 2000. 88(1): p. 226-237.

213. de Haes, H., Teunissen, S., Communication in palliative care: a review of recent literature, Curr Opin Oncol, 2005. 17(4): p. 345-50., http://www.ncbi.nlm.nih.gov/pubmed/15933465

214. Fallowfield, L., Jenkins, V., Communicating sad, bad, and difficult news in medicine, Lancet, 2004. 363(9405): p. 312-319.

215. Fukui, S., Ogawa, K., Ohtsuka, M., Fukui, N., A randomized study assessing the efficacy of communication skill training on patients' psychologic distress and coping: nurses' communication with patients just after being diagnosed with cancer, Cancer, 2008. 113(6): p. 1462-1470.

216. Ong, L. M., Visser, M. R., Lammes, F. B., de Haes, J. C., Doctor-patient communication and cancer patients' quality of life and satisfaction, Patient Educ Couns, 2000. 41(2): p. 145-56., http://www.ncbi.nlm.nih.gov/pubmed/12024540

217. Schofield, P. E., Butow, P. N., Thompson, J. F., Tattersall, M. H., Beeney, L. J., Dunn, S. M., Psychological responses of patients receiving a diagnosis of cancer, Ann Oncol, 2003. 14(1): p. 48-56., http://www.ncbi.nlm.nih.gov/pubmed/12488292

218. Lienard, A., Merckaert, I., Libert, Y., Delvaux, N., Marchal, S., Boniver, J., et.al. Factors that influence cancer patients' and relatives' anxiety following a three-person medical consultation: impact of a communication skills training program for physicians, Psychooncology, 2008. 17(5): p. 488-96., http://www.ncbi.nlm.nih.gov/pubmed/17879970

219. Razavi, D., Merckaert, I., Marchal, S., Libert, Y., Conradt, S., Boniver, J., et.al. How to optimize physicians' communication skills in cancer care: results of a randomized study assessing the usefulness of posttraining consolidation workshops, J Clin Oncol, 2003. 21(16): p. 3141-9., http://www.ncbi.nlm.nih.gov/pubmed/12915605

220. Butow, P., Juraskova, I., Chang, S., Lopez, A. L., Brown, R., Bernhard, J., Shared decision making coding systems: how do they compare in the oncology context?, Patient Educ Couns, 2010. 78(2): p. 261-8., http://www.ncbi.nlm.nih.gov/pubmed/19647966

221. Edwards, A., Elwyn, G., Inside the black box of shared decision making: distinguishing between the process of involvement and who makes the decision, Health Expect, 2006. 9(4): p. 307-20., http://www.ncbi.nlm.nih.gov/pubmed/17083558

222. Back, A. L., Arnold, R. M., Tulsky, J. A., Baile, W. F., Fryer-Edwards, K. A., Teaching communication skills to medical oncology fellows, J Clin Oncol, 2003. 21(12): p. 2433-6., http://www.ncbi.nlm.nih.gov/pubmed/12805343

223. Dowsett, S. M., Saul, J. L., Butow, P. N., Dunn, S. M., Boyer, M. J., Findlow, R., et.al. Communication styles in the cancer consultation: preferences for a patient-centred approach, Psychooncology, 2000. 9(2): p. 147-56.

224. Stiefel, F., Favre, N., Despland, J. N., Communication skills training in oncology: it works!, Recent Results Cancer Res, 2006. 168: p. 113-9., http://www.ncbi.nlm.nih.gov/pubmed/17073197

225. Fallowfield, L., Jenkins, V., Effective communication skills are the key to good cancer care, Eur J Cancer, 1999. 35(11): p. 1592-7., http://www.ncbi.nlm.nih.gov/pubmed/10673967

226. Fawzy, N. W., A psychoeducational nursing intervention to enhance coping and affective state in newly diagnosed malignant melanoma patients, Cancer Nurs, 1995. 18(6): p. 427-38., http://www.ncbi.nlm.nih.gov/pubmed/8564938

227. Derdiarian, A. K., Effects of information on recently diagnosed cancer patients' and spouses' satisfaction with care, Cancer Nurs, 1989. 12(5): p. 285-92., http://www.ncbi.nlm.nih.gov/pubmed/2804964

228. Martinez, L. S., Schwartz, J. S., Freres, D., Fraze, T., Hornik, R. C., Patient-clinician information engagement increases treatment decision satisfaction among cancer patients through feeling of being informed, Patient Educ Couns, 2009. 77(3): p. 384-90., http://www.ncbi.nlm.nih.gov/pubmed/19815365

229. Belvedere, O., Minisini, A., Ramello, M., Sobrero, A., Grossi, F., Information given to cancer patients on diagnosis, prognosis and treatment: the clinical oncologist's perspective, Eur J Cancer, 2004. 40(12): p. 1850-4., http://www.ncbi.nlm.nih.gov/pubmed/15288286

230. Innes, S., Payne, S., Advanced cancer patients' prognostic information preferences: a review, Palliat Med, 2009. 23(1): p. 29-39., http://www.ncbi.nlm.nih.gov/pubmed/18952746

231. Kaplowitz, S. A., Campo, S., Chiu, W. T., Cancer patients' desires for communication of prognosis information, Health Commun, 2002. 14(2): p. 221-41., http://www.ncbi.nlm.nih.gov/pubmed/12046799

232. Adams, E., Boulton, M., Watson, E., The information needs of partners and family members of cancer patients: a systematic literature review, Patient Educ Couns, 2009. 77(2): p. 179-86., http://www.ncbi.nlm.nih.gov/pubmed/19406609

233. Ankem, K., Factors influencing information needs among cancer patients: A meta-analysis, Library & Information Science Research, 2006. 28(1): p. 7-23.

234. Cox, A., Jenkins, V., Catt, S., Langridge, C., Fallowfield, L., Information needs and experiences: an audit of UK cancer patients, Eur J Oncol Nurs, 2006. 10(4): p. 263-72., http://www.ncbi.nlm.nih.gov/pubmed/16376146

235. Elkin, E. B., Kim, S. H., Casper, E. S., Kissane, D. W., Schrag, D., Desire for information and involvement in treatment decisions: elderly cancer patients' preferences and their physicians' perceptions, J Clin Oncol, 2007. 25(33): p. 5275-80.

236. Jansen, J., Butow, P. N., van Weert, J. C., van Dulmen, S., Devine, R. J., Heeren, T. J., et.al. Does age really matter? Recall of information presented to newly referred patients with cancer, J Clin Oncol, 2008. 26(33): p. 5450-7., http://www.ncbi.nlm.nih.gov/pubmed/18936478

237. Jenkins, V., Fallowfield, L., Saul, J., Information needs of patients with cancer: results from a large study in UK cancer centres, Br J Cancer, 2001. 84(1): p. 48-51., http://www.ncbi.nlm.nih.gov/pubmed/11139312

238. Kirschning, S., von Kardorff, E., [Which information relatives of patients with cancer are searching for? Are the findings helpful for coping and care?], Med Klin (Munich), 2007. 102(2): p. 136-40., http://www.ncbi.nlm.nih.gov/pubmed/17323020

239. Pinquart, M., Duberstein, P. R., Information needs and decision-making processes in older cancer patients, Crit Rev Oncol Hematol, 2004. 51(1): p. 69-80., http://www.ncbi.nlm.nih.gov/pubmed/15207255

240. Arraras, J. I., Greimel, E., Sezer, O., Chie, W. C., Bergenmar, M., Costantini, A., et.al. An international validation study of the EORTC QLQ-INFO25 questionnaire: an instrument to assess the information given to cancer patients, Eur J Cancer, 2010. 46(15): p. 2726-38., http://www.ncbi.nlm.nih.gov/pubmed/20674333

241. Arraras, J. I., Kuljanic-Vlasic, K., Bjordal, K., Yun, Y. H., Efficace, F., Holzner, B., et.al. EORTC QLQ-INFO26: a questionnaire to assess information given to cancer patients a preliminary analysis in eight countries, Psychooncology, 2007. 16(3): p. 249-54., http://www.ncbi.nlm.nih.gov/pubmed/16858744

242. Arraras, J. I., Wright, S., Greimel, E., Holzner, B., Kuljanic-Vlasic, K., Velikova, G., et.al. Development of a questionnaire to evaluate the information needs of cancer patients: the EORTC questionnaire, Patient Educ Couns, 2004. 54(2): p. 235-41., http://www.ncbi.nlm.nih.gov/pubmed/15288920

243. Manne, S., Lessin, S., Prevalence and correlates of sun protection and skin self-examination practices among cutaneous malignant melanoma survivors, J Behav Med, 2006. 29(5): p. 419-34., http://www.ncbi.nlm.nih.gov/pubmed/16855870

244. Uliasz, A., Lebwohl, M., Patient education and regular surveillance results in earlier diagnosis of second primary melanoma, Int J Dermatol, 2007. 46(6): p. 575-7., http://www.ncbi.nlm.nih.gov/pubmed/17550554

245. Manne, S., Fasanella, N., Connors, J., Floyd, B., Wang, H., Lessin, S., Sun protection and skin surveillance practices among relatives of patients with malignant melanoma: prevalence and predictors, Prev Med, 2004. 39(1): p. 36-47., http://www.ncbi.nlm.nih.gov/pubmed/15207984

246. Parker, P. A., Baile, W. F., de Moor, C., Lenzi, R., Kudelka, A. P., Cohen, L., Breaking bad news about cancer: Patients' preferences for communication, Journal of Clinical Oncology, 2001. 19(7): p. 2049-2056., , to, ISI>://WOS:000167920300021

247. Voogt, E., van Leeuwen, A. F., Visser, A. P., van der Heide, A., van der Maas, P. J., Information needs of patients with incurable cancer, Support Care Cancer, 2005. 13(11): p. 943-8., http://www.ncbi.nlm.nih.gov/pubmed/15856332

248. Feldman-Stewart, D., Brennenstuhl, S., Brundage, M. D., Siemens, D. R., Overall information needs of early-stage prostate cancer patients over a decade: highly variable and remarkably stable, Support Care Cancer, 2009. 17(4): p. 429-35., http://www.ncbi.nlm.nih.gov/pubmed/18830718

249. Frojd, C., Von Essen, L., Is doctors' ability to identify cancer patients' worry and wish for information related to doctors' self-efficacy with regard to communicating about difficult matters?, Eur J Cancer Care (Engl), 2006. 15(4): p. 371-8., http://www.ncbi.nlm.nih.gov/pubmed/16968320

250. Katz, V. L., Farmer, R. M., Dotters, D., Focus on primary care: from nevus to neoplasm: myths of melanoma in pregnancy, Obstet Gynecol Surv, 2002. 57(2): p. 112-9., http://www.ncbi.nlm.nih.gov/pubmed/11832787

251. Schwartz, J. L., Mozurkewich, E. L., Johnson, T. M., Current management of patients with melanoma who are pregnant, want to get pregnant, or do not want to get pregnant, Cancer, 2003. 97(9): p. 2130-2133.

252. Wallace, W. Hamish B., Anderson, Richard A., Irvine, D. Stewart, Fertility preservation for young patients with cancer: who is at risk and what can be offered?, The Lancet Oncology, 2005. 6(4): p. 209-218.

253. Bramlette, T. B., Lawson, D. H., Washington, C. V., Veledar, E., Johns, B. R., Brisman, S. F., et.al. Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment, Dermatol Surg, 2007. 33(1): p. 11-6., http://www.ncbi.nlm.nih.gov/pubmed/17214673

254. Brandberg, Y., Bergenmar, M., Michelson, H., Mansson-Brahme, E., Sjoden, P. O., Six-month follow-up of effects of an information programme for patients with malignant melanoma, Patient Educ Couns, 1996. 28(2): p. 201-8., http://www.ncbi.nlm.nih.gov/pubmed/8852095

255. Passalacqua, R., Caminiti, C., Salvagni, S., Barni, S., Beretta, G. D., Carlini, P., et.al. Effects of media information on cancer patients' opinions, feelings, decision-making process and physician-patient communication, Cancer, 2004. 100(5): p. 1077-1084.

256. Boesen, E. H., Ross, L., Frederiksen, K., Thomsen, B. L., Dahlstrom, K., Schmidt, G., et.al. Psychoeducational intervention for patients with cutaneous malignant melanoma: a replication study, J Clin Oncol, 2005. 23(6): p. 1270-7., http://www.ncbi.nlm.nih.gov/pubmed/15718325

257. Fawzy, F.I., et al., Malignant melanoma - Effects of a brief, structured psychiatric intervention on survival and recurrence at 10-year follow-up, 2003., ://WOS:000180286800012

258. Trask, P.C., et al., Cognitive-behavioral intervention for distress in patients with melanoma: comparison with standard medical care and impact on quality of life, 2003., https://www.ncbi.nlm.nih.gov/pubmed/12910531

259. Buhles, N., Sander, C., [Dermato-oncological rehabilitation], Hautarzt, 2005. 56(7): p. 659-64., http://www.ncbi.nlm.nih.gov/pubmed/15889229

260. Lehmann, C., Koch, U., Mehnert, A., Die Bedeutung der Arzt-Patient-Kommunikation für die psychische Belastung und Inanspruchnahme von Unterstützungsangeboten bei Krebspatienten. Ein Literaturüberblick über den gegenwärtigen Forschungsstand unter besonderer Berücksichtigung patientenseitiger Präferenzen.l, PPmP, 2009. p. 253-263.

261. Mager, W. M., Andrykowski, M. A., Communication in the cancer 'bad news' consultation: patient perceptions and psychological adjustment, Psycho-oncology, 2002. 11(1): p. 35-46.

262. Bergelt, C., Härter, M., Partizipative Entscheidungsfindung: der Patient als Partner, best practice onkologie, 2010. p. 49-55.

263. Keller, M., Zwingmann, J., Arzt-Patient-Kommunikation in der Onkologie, Forum, 2009. p. 39-42.

264. Ramirez, A. J., Graham, J., Richards, M. A., Cull, A., Gregory, W. M., Leaning, M. S., et.al. Burnout and psychiatric disorder among cancer clinicians, British journal of cancer, 1995. 71(6): p. 1263-1269.

265. Bartsch, H. H., Kommunikation und gemeinsame Entscheidungsfindung mit dem Krebspatienten, Forum, 2005. p. 43-46.

266. Fallowfield, L., Jenkins, V., Farewell, V., Saul, J., Duffy, A., Eves, R., Efficacy of a Cancer Research UK communication skills training model for oncologists: a randomised controlled trial, Lancet, 2002. 359(9307): p. 650-656.

267. Gysels, M., Richardson, A., Higginson, I. J., Communication training for health professionals who care for patients with cancer: a systematic review of effectiveness, Support Care Cancer, 2004. 12(10): p. 692-700., http://www.ncbi.nlm.nih.gov/pubmed/15258839

268. Hack, T. F., Degner, L. F., Parker, P. A., Team, Scrn Communication, The communication goals and needs of cancer patients: a review, Psychooncology, 2005. 14(10): p. 831-45; discussion 846-7., http://www.ncbi.nlm.nih.gov/pubmed/16200519

269. Fallowfield, L., Ratcliffe, D., Jenkins, V., Saul, J., Psychiatric morbidity and its recognition by doctors in patients with cancer, Br J Cancer, 2001. 84(8): p. 1011-5., http://www.ncbi.nlm.nih.gov/pubmed/11308246

270. Keller, M., Sommerfeldt, S., Fischer, C., Knight, L., Riesbeck, M., Lowe, B., et.al. Recognition of distress and psychiatric morbidity in cancer patients: a multi-method approach, Ann Oncol, 2004. 15(8): p. 1243-9., http://www.ncbi.nlm.nih.gov/pubmed/15277265

271. Sollner, W., Zingg-Schir, M., Rumpold, G., Mairinger, G., Fritsch, P., Need for supportive counselling--the professionals' versus the patients' perspective. A survey in a representative sample of 236 melanoma patients, Psychother Psychosom, 1998. 67(2): p. 94-104., http://www.ncbi.nlm.nih.gov/pubmed/9556201

272. Girgis, A., Sanson-Fisher, R. W., Breaking bad news: consensus guidelines for medical practitioners, J Clin Oncol, 1995. 13(9): p. 2449-56., http://www.ncbi.nlm.nih.gov/pubmed/7666105

273. Ptacek, J. T., Eberhardt, T. L., Breaking bad news. A review of the literature, JAMA, 1996. 276(6): p. 496-502., http://www.ncbi.nlm.nih.gov/pubmed/8691562

274. Schofield, P. E., Beeney, L. J., Thompson, J. F., Butow, P. N., Tattersall, M. H., Dunn, S. M., Hearing the bad news of a cancer diagnosis: the Australian melanoma patient's perspective, Ann Oncol, 2001. 12(3): p. 365-71., http://www.ncbi.nlm.nih.gov/pubmed/11332150

275. Holland, J. C., Rowland, J. H., Handbook of Psychooncology. Psychological Care of the Patient with Cancer, Oxford University Press ., 1989.

276. Erim, Y., Interkulturelle Kommunikation in der psychoonkologischen Arbeit mit Migranten, FORUM, 2009. p. 43-47.

277. Ptacek, J. T., Ptacek, J. J., Patients' perceptions of receiving bad news about cancer, Journal of Clinical Oncology, 2001. 19(21): p. 4160-4164.

278. Kissane, D. W., Bloch, S., Burns, W. I., McKenzies, D., Posterino, M., Psychological morbidity in the families of patients with cancer, Psychooncology, 1994. p. 47-56.

279. Kneier, A. W., Coping with melanoma - ten strategies that promote psychological adjustment, Surgical Clinics of North America, 2003. 83(2): p. 417-+.

280. Merckaert, I., Libert, Y., Messin, S., Milani, M., Slachmuylder, J. L., Razavi, D., Cancer patients' desire for psychological support: prevalence and implications for screening patients' psychological needs, Psychooncology, 2010. 19(2): p. 141-9., http://www.ncbi.nlm.nih.gov/pubmed/19382112

281. Strittmatter, G., Einbeziehung der Familie in die Krankenbetreuung und begleitende Familientherapie, Schattauer Verlag; (im Druck)., 2011. 3. Auflage:

282. Gebest, H. J., Hiller, B., Kommunikationsmedium Internet, FORUM, 2009. p. 54-57.

283. Balch, C. M., Gershenwald, J. E., Soong, S. J., Thompson, J. F., Ding, S., Byrd, D. R., et.al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases, J Clin Oncol, 2010. 28(14): p. 2452-9., http://www.ncbi.nlm.nih.gov/pubmed/20368546

284. Herman, K., Wysocki, W. M., Skotnicki, P., Tabor, J., Luczynska, E., Komorowski, A. L., Stage III thick (>4.0 mm) lower extremity melanoma: is timing of lymph node involvement a prognostic factor?, World J Surg, 2009. 33(3): p. 469-74., http://www.ncbi.nlm.nih.gov/pubmed/19148700

285. Roses, D. F., Karp, N. S., Oratz, R., Dubin, N., Harris, M. N., Speyer, J., et.al. Survival with regional and distant metastases from cutaneous malignant melanoma, Surg Gynecol Obstet, 1991. 172(4): p. 262-8., http://www.ncbi.nlm.nih.gov/pubmed/2006449

286. Weide, Benjamin, Eigentler, Thomas Kurt, Pflugfelder, Annette, Leiter, Ulrike, Meier, Friedegund, Bauer, Juergen, et.al. Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up, Cancer Immunology Immunotherapy, 2011. 60(4): p. 487-493.

287. Balch, C. M., Buzaid, A. C., Soong, S. J., Atkins, M. B., Cascinelli, N., Coit, D. G., et.al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma, J Clin Oncol, 2001. 19(16): p. 3635-48., http://www.ncbi.nlm.nih.gov/pubmed/11504745

288. Kim, C. J., Reintgen, D. S., Balch, C. M., Committee, Ajcc Melanoma Staging, The new melanoma staging system, Cancer Control, 2002. 9(1): p. 9-15., http://www.ncbi.nlm.nih.gov/pubmed/11907461

289. Francken, A. B., Accortt, N. A., Shaw, H. M., Colman, M. H., Wiener, M., Soong, S. J., et.al. Follow-up schedules after treatment for malignant melanoma, Br J Surg, 2008. 95(11): p. 1401-7., http://www.ncbi.nlm.nih.gov/pubmed/18844268

290. Leiter, U., Buettner, P. G., Eigentler, T. K., Brocker, E. B., Voit, C., Gollnick, H., et.al. Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry, J Am Acad Dermatol, 2012. 66(1): p. 37-45., http://www.ncbi.nlm.nih.gov/pubmed/21700361

291. Tsao, H., Feldman, M., Fullerton, J. E., Sober, A. J., Rosenthal, D., Goggins, W., Early detection of asymptomatic pulmonary melanoma metastases by routine chest radiographs is not associated with improved survival, Arch Dermatol, 2004. 140(1): p. 67-70., http://www.ncbi.nlm.nih.gov/pubmed/14732662

292. Hafner, J., Schmid, M. H., Kempf, W., Burg, G., Kunzi, W., Meuli-Simmen, C., et.al. Baseline staging in cutaneous malignant melanoma, Br J Dermatol, 2004. 150(4): p. 677-86., http://www.ncbi.nlm.nih.gov/pubmed/15099363

293. Uren, R. F., Howman-Giles, R., Thompson, J. F., Shaw, H. M., Roberts, J. M., Bernard, E., et.al. High-resolution ultrasound to diagnose melanoma metastases in patients with clinically palpable lymph nodes, Australas Radiol, 1999. 43(2): p. 148-52., http://www.ncbi.nlm.nih.gov/pubmed/10901892

294. Pfannenberg, C., Aschoff, P., Schanz, S., Eschmann, S. M., Plathow, C., Eigentler, T. K., et.al. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma, Eur J Cancer, 2007. 43(3): p. 557-64., http://www.ncbi.nlm.nih.gov/pubmed/17224266

295. Muller-Horvat, C., Radny, P., Eigentler, T. K., Schafer, J., Pfannenberg, C., Horger, M., et.al. Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma, Eur J Cancer, 2006. 42(3): p. 342-50., http://www.ncbi.nlm.nih.gov/pubmed/16364631

296. Fogarty, G. B., Tartaguia, C., The utility of magnetic resonance imaging in the detection of brain metastases in the staging of cutaneous melanoma, Clin Oncol (R Coll Radiol), 2006. 18(4): p. 360-2., http://www.ncbi.nlm.nih.gov/pubmed/16703756

297. Schlamann, M., Loquai, C., Goericke, S., Forsting, M., Wanke, I., [Cerebral MRI in neurological asymptomatic patients with malignant melanoma], Rofo, 2008. 180(2): p. 143-7., http://www.ncbi.nlm.nih.gov/pubmed/18098094

298. Kruijff, S., Bastiaannet, E., Kobold, A. C., van Ginkel, R. J., Suurmeijer, A. J., Hoekstra, H. J., S-100B concentrations predict disease-free survival in stage III melanoma patients, Ann Surg Oncol, 2009. 16(12): p. 3455-62., http://www.ncbi.nlm.nih.gov/pubmed/19636631

299. Brouard, M., Quillien, V., Ollivier, I., Lesimple, T., Adamski, H., Chevrant-Breton, J., [Serum S100B protein and stage of cutaneous melanoma: a prospective study], Ann Dermatol Venereol, 2000. 127(1): p. 56-9., http://www.ncbi.nlm.nih.gov/pubmed/10717564

300. Schultz, E. S., Diepgen, T. L., Von Den Driesch, P., Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma, Br J Dermatol, 1998. 138(3): p. 426-30., http://www.ncbi.nlm.nih.gov/pubmed/9580794

301. Kaskel, P., Berking, C., Sander, S., Volkenandt, M., Peter, R. U., Krahn, G., S-100 protein in peripheral blood: a marker for melanoma metastases: a prospective 2-center study of 570 patients with melanoma, J Am Acad Dermatol, 1999. 41(6): p. 962-9., http://www.ncbi.nlm.nih.gov/pubmed/10570381

302. Nowecki, Z. I., Rutkowski, P., Kulik, J., Siedlecki, J. A., Ruka, W., Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level, Br J Dermatol, 2008. 159(3): p. 597-605., http://www.ncbi.nlm.nih.gov/pubmed/18616789

303. Stahlecker, J., Gauger, A., Bosserhoff, A., Buttner, R., Ring, J., Hein, R., MIA as a reliable tumor marker in the serum of patients with malignant melanoma, Anticancer Research, 2000. 20(6D): p. 5041-5044.

304. Guba, M., Steinbauer, M., Ruhland, V., Schutz, A., Geissler, E. K., Anthuber, M., et.al. Elevated MIA serum levels are predictors of poor prognosis after surgical resection of metastatic malignant melanoma, Oncol Rep, 2002. 9(5): p. 981-4., http://www.ncbi.nlm.nih.gov/pubmed/12168059

305. Lens, M. B., Dawes, M., Goodacre, T., Newton-Bishop, J. A., Elective lymph node dissection in patients with melanoma: systematic review and meta-analysis of randomized controlled trials, Arch Surg, 2002. 137(4): p. 458-61., http://www.ncbi.nlm.nih.gov/pubmed/11926952

306. O'Brien, C. J., Gianoutsos, M. P., Morgan, M. J., Neck dissection for cutaneous malignant melanoma, World J Surg, 1992. 16(2): p. 222-6., http://www.ncbi.nlm.nih.gov/pubmed/1561802

307. Morton, D. L., Wanek, L., Nizze, J. A., Elashoff, R. M., Wong, J. H., Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic, Ann Surg, 1991. 214(4): p. 491-9; discussion 499-501., http://www.ncbi.nlm.nih.gov/pubmed/1953101

308. Hofmann, U., Szedlak, M., Rittgen, W., Jung, E. G., Schadendorf, D., Primary staging and follow-up in melanoma patients--monocenter evaluation of methods, costs and patient survival, Br J Cancer, 2002. 87(2): p. 151-7., http://www.ncbi.nlm.nih.gov/pubmed/12107834

309. Fink, A. M., Holle-Robatsch, S., Herzog, N., Mirzaei, S., Rappersberger, K., Lilgenau, N., et.al. Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II, Melanoma research, 2004. 14(2): p. 141-145.

310. Starritt, E. C., Uren, R. F., Scolyer, R. A., Quinn, M. J., Thompson, J. F., Ultrasound examination of sentinel nodes in the initial assessment of patients with primary cutaneous melanoma, Ann Surg Oncol, 2005. 12(1): p. 18-23., http://www.ncbi.nlm.nih.gov/pubmed/15827773

311. van der Ploeg, I. M., Kroon, B. B., Antonini, N., Valdes Olmos, R. A., Nieweg, O. E., Is completion lymph node dissection needed in case of minimal melanoma metastasis in the sentinel node?, Ann Surg, 2009. 249(6): p. 1003-7., http://www.ncbi.nlm.nih.gov/pubmed/19474678

312. S, t, a, r, r, i, et.al. Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma, 2013., https://www.ncbi.nlm.nih.gov/pubmed/23569313

313. Satzger, I., Meier, A., Zapf, A., Niebuhr, M., Kapp, A., Gutzmer, R., Is there a therapeutic benefit of complete lymph node dissection in melanoma patients with low tumor burden in the sentinel node?, Melanoma Res, 2014. 24(5): p. 454-61.

314. R, i, b, e, r, -, et.al. Nodal distribution, stage migration due to diameter measurement and the prognostic significance of metastasis volume in melanoma sentinel lymph nodes: a validation study, 2014., https://www.ncbi.nlm.nih.gov/pubmed/24628500

315. Van Der Ploeg, A. P., Van Akkooi, A. C., Rutkowski, P., Nowecki, Z. I., Michej, W., Mitra, A., et.al. Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria, J Clin Oncol, 2011. 29(16): p. 2206-14., http://www.ncbi.nlm.nih.gov/pubmed/21519012

316. Van Der Ploeg, A. P., Van Akkooi, A. C., Rutkowski, P., Cook, M., Nieweg, O. E., Rossi, C. R., et.al. Prognosis in patients with sentinel node-positive melanoma without immediate completion lymph node dissection, Br J Surg, 2012. 99(10): p. 1396-405., http://onlinelibrary.wiley.com/doi/10.1002/bjs.8878/abstract, http://onlinelibrary.wiley.com/store/10.1002/bjs.8878/asset/8878_ftp.pdf?v=1&t=if87vuzd&s=058a7fc7a85ff08a3ab1d678b1b1bfabe22033fd

317. Debarbieux, S., Duru, G., Dalle, S., Beatrix, O., Balme, B., Thomas, L., Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection, Br J Dermatol, 2007. 157(1): p. 58-67.

318. Satzger, I., Meier, A., Alter, M., Kapp, A., Gutzmer, R., Which parameters to choose for prediction of non-sentinel lymph node positivity in melanoma?, J Clin Oncol, 2011. 29(11): p. e315; author reply e316-7., http://www.ncbi.nlm.nih.gov/pubmed/21383303

319. Riber-Hansen, R., Nyengaard, J. R., Hamilton-Dutoit, S. J., Sjoegren, P., Steiniche, T., Metastatic melanoma volume in sentinel nodes: objective stereology-based measurement predicts disease recurrence and survival, Histopathology, 2009. 54(7): p. 796-803.

320. Egger, M. E., Bower, M. R., Czyszczon, I. A., Farghaly, H., Noyes, R. D., Reintgen, D. S., et.al. Comparison of sentinel lymph node micrometastatic tumor burden measurements in melanoma, J Am Coll Surg, 2014. 218(4): p. 519-28., http://ac.els-cdn.com/S1072751513013008/1-s2.0-S1072751513013008-main.pdf?_tid=108cd0c8-6839-11e5-835b-00000aab0f6c&acdnat=1443703180_193865af061433200eef48b7b5505e70

321. Murali, R., Desilva, C., Thompson, J. F., Scolyer, R. A., Factors predicting recurrence and survival in sentinel lymph node-positive melanoma patients, Ann Surg, 2011. 253(6): p. 1155-64., http://www.ncbi.nlm.nih.gov/pubmed/21412144

322. Bamboat, Z. M., Konstantinidis, I. T., Kuk, D., Ariyan, C. E., Brady, M. S., Coit, D. G., Observation after a positive sentinel lymph node biopsy in patients with melanoma, Ann Surg Oncol, 2014. 21(9): p. 3117-23.

323. Leiter, U., Stadler, R., Mauch, C., Hohenberger, W., Brockmeyer, N., Berking, C., et.al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial, Lancet Oncol, 2016. 17(6): p. 757-67.

324. Faries, M. B., Thompson, J. F., Cochran, A. J., Andtbacka, R. H., Mozzillo, N., Zager, J. S., et.al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma, N Engl J Med, 2017. 376(23): p. 2211-2222.

325. Fritsch, V. A., Cunningham, J. E., Lentsch, E. J., Completion Lymph Node Dissection Based on Risk of Nonsentinel Metastasis in Cutaneous Melanoma of the Head and Neck, Otolaryngol Head Neck Surg, 2016. 154(1): p. 94-103.

326. Smith, V. A., Cunningham, J. E., Lentsch, E. J., Completion node dissection in patients with sentinel node-positive melanoma of the head and neck, Otolaryngol Head Neck Surg, 2012. 146(4): p. 591-9.

327. Fadaki, N., Li, R., Parrett, B., Sanders, G., Thummala, S., Martineau, L., et.al. Is head and neck melanoma different from trunk and extremity melanomas with respect to sentinel lymph node status and clinical outcome?, Ann Surg Oncol, 2013. 20(9): p. 3089-97.

328. Al Ghazal, P., Gutzmer, R., Satzger, I., Starz, H., Bader, C., Thoms, K. M., et.al. Lower prevalence of lymphatic metastasis and poorer survival of the sentinel node-negative patients limit the prognostic value of sentinel node biopsy for head or neck melanomas, Melanoma Res, 2014. 24(2): p. 158-64.

329. Satzger, I., Volker, B., Meier, A., Schenck, F., Kapp, A., Gutzmer, R., Prognostic significance of isolated HMB45 or Melan A positive cells in Melanoma sentinel lymph nodes, Am J Surg Pathol, 2007. 31(8): p. 1175-80., http://www.ncbi.nlm.nih.gov/pubmed/17667539

330. Easson, A. M., Rotstein, L. E., McCready, D. R., Lymph node assessment in melanoma, J Surg Oncol, 2009. 99(4): p. 176-85., http://www.ncbi.nlm.nih.gov/pubmed/19065639

331. Jakub, J. W., Reintgen, D. S., Shivers, S., Pendas, S., Regional node dissection for melanoma: techniques and indication, Surg Oncol Clin N Am, 2007. 16(1): p. 247-61., http://www.ncbi.nlm.nih.gov/pubmed/17336247

332. Mack, L. A., McKinnon, J. G., Controversies in the management of metastatic melanoma to regional lymphatic basins, J Surg Oncol, 2004. 86(4): p. 189-99., http://www.ncbi.nlm.nih.gov/pubmed/15221926

333. Spillane, A. J., Cheung, B. L., Stretch, J. R., Scolyer, R. A., Shannon, K. F., Quinn, M. J., et.al. Proposed quality standards for regional lymph node dissections in patients with melanoma, Ann Surg, 2009. 249(3): p. 473-80., http://www.ncbi.nlm.nih.gov/pubmed/19247037

334. Neuss, H., Reetz, C., Raue, W., Koplin, G., Mall, J. W., Postoperative surgical complications after radical axillary lymph node dissection in melanoma disease result in increased pain, Int Surg, 2010. 95(2): p. 166-71., http://www.ncbi.nlm.nih.gov/pubmed/20718325

335. Byers, R. M., Treatment of the neck in melanoma, Otolaryngol Clin North Am, 1998. 31(5): p. 833-9., http://www.ncbi.nlm.nih.gov/pubmed/9735111

336. Medina, J. E., Ferlito, A., Brandwein, M. S., Fisher, S. R., Pellitteri, P. K., Shaha, A. R., et.al. Current management of cutaneous malignant melanoma of the head and neck, Acta Otolaryngol, 2002. 122(8): p. 900-6., http://www.ncbi.nlm.nih.gov/pubmed/12542213

337. O'Brien, C. J., Coates, A. S., Petersen-Schaefer, K., Shannon, K., Thompson, J. F., Milton, G. W., et.al. Experience with 998 cutaneous melanomas of the head and neck over 30 years, Am J Surg, 1991. 162(4): p. 310-4., http://www.ncbi.nlm.nih.gov/pubmed/1951880

338. Schmalbach, C. E., Johnson, T. M., Bradford, C. R., The management of head and neck melanoma, Curr Probl Surg, 2006. 43(11): p. 781-835., http://www.ncbi.nlm.nih.gov/pubmed/17112819

339. Wiener, M., Uren, R. F., Thompson, J. F., Lymphatic drainage patterns from primary cutaneous tumours of the forehead: refining the recommendations for selective neck dissection, J Plast Reconstr Aesthet Surg, 2014. 67(8): p. 1038-44.

340. Reynolds, H. M., Smith, N. P., Uren, R. F., Thompson, J. F., Dunbar, P. R., Three-dimensional visualization of skin lymphatic drainage patterns of the head and neck, Head Neck, 2009. 31(10): p. 1316-25.

341. Robbins, K. T., Medina, J. E., Wolfe, G. T., Levine, P. A., Sessions, R. B., Pruet, C. W., Standardizing neck dissection terminology. Official report of the Academy's Committee for Head and Neck Surgery and Oncology, Arch Otolaryngol Head Neck Surg, 1991. 117(6): p. 601-5., http://www.ncbi.nlm.nih.gov/pubmed/2036180

342. Robbins, K. T., Clayman, G., Levine, P. A., Medina, J., Sessions, R., Shaha, A., et.al. Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery, Arch Otolaryngol Head Neck Surg, 2002. 128(7): p. 751-8., http://www.ncbi.nlm.nih.gov/pubmed/12117328

343. Supriya, M., Narasimhan, V., Henderson, M. A., Sizeland, A., Managing regional metastasis in patients with cutaneous head and neck melanoma - is selective neck dissection appropriate?, Am J Otolaryngol, 2014. 35(5): p. 610-6.

344. Geltzeiler, M., Monroe, M., Givi, B., Vetto, J., Andersen, P., Gross, N., Regional control of head and neck melanoma with selective neck dissection, JAMA Otolaryngol Head Neck Surg, 2014. 140(11): p. 1014-8.

345. Robbins, K., Shaha, A. R., Medina, J. E., et al., Consensus statement on the classification and terminology of neck dissection, Archives of Otolaryngology–Head & Neck Surgery, 2008. 134(5): p. 536-538., http://dx.doi.org/10.1001/archotol.134.5.536

346. O'Brien, C. J., Uren, R. F., Thompson, J. F., Howman-Giles, R. B., Petersen-Schaefer, K., Shaw, H. M., et.al. Prediction of potential metastatic sites in cutaneous head and neck melanoma using lymphoscintigraphy, Am J Surg, 1995. 170(5): p. 461-6.

347. Karakousis, C. P., Hena, M. A., Emrich, L. J., Driscoll, D. L., Axillary node dissection in malignant melanoma: results and complications, Surgery, 1990. 108(1): p. 10-17.

348. Fujiwara, M., Suzuki, A., Mizukami, T., Nagata, T., Ito, T., Fukamizu, H., Mid-arm lymph nodes dissection for melanoma, J Plast Reconstr Aesthet Surg, 2010. 63(9): p. 1561-4., http://www.ncbi.nlm.nih.gov/pubmed/20227935

349. Hochwald, S. N., Kissane, N., Grobmyer, S. R., Lopes, J., Epitrochlear lymph node dissection, Ann Surg Oncol, 2011. 18(2): p. 505., http://www.ncbi.nlm.nih.gov/pubmed/20680692

350. Lawton, G., Rasque, H., Ariyan, S., Preservation of muscle fascia to decrease lymphedema after complete axillary and ilioinguinofemoral lymphadenectomy for melanoma, J Am Coll Surg, 2002. 195(3): p. 339-51., http://www.ncbi.nlm.nih.gov/pubmed/12229941

351. Coit, D. G., Brennan, M. F., Extent of lymph node dissection in melanoma of the trunk or lower extremity, Arch Surg, 1989. 124(2): p. 162-6., http://www.ncbi.nlm.nih.gov/pubmed/2464981

352. Strobbe, L. J., Jonk, A., Hart, A. A., Nieweg, O. E., Kroon, B. B., Positive iliac and obturator nodes in melanoma: survival and prognostic factors, Ann Surg Oncol, 1999. 6(3): p. 255-62., http://www.ncbi.nlm.nih.gov/pubmed/10340884

353. Shen, P., Wanek, L. A., Morton, D. L., Is adjuvant radiotherapy necessary after positive lymph node dissection in head and neck melanomas?, Annals of surgical oncology, 2000. 7(8): p. 554-9; discussion 560-1.

354. Fuhrmann, D., Lippold, A., Borrosch, F., Ellwanger, U., Garbe, C., Suter, L., Should adjuvant radiotherapy be recommended following resection of regional lymph node metastases of malignant melanomas?, The British journal of dermatology, 2001. 144(1): p. 66-70.

355. Creagan, E. T., Cupps, R. E., Ivins, J. C., Pritchard, D. J., Sim, F. H., Soule, E. H., et.al. Adjuvant radiation therapy for regional nodal metastases from malignant melanoma: a randomized, prospective study, Cancer, 1978. 42(5): p. 2206-2210.

356. Henderson, M. A., Burmeister, B. H., Ainslie, J., Fisher, R., Di Iulio, J., Smithers, B. M., et.al. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial, Lancet Oncol, 2015. 16(9): p. 1049-60.

357. Agrawal, S., Kane, J. M., 3rd, Guadagnolo, B. A., Kraybill, W. G., Ballo, M. T., The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma, Cancer, 2009. 115(24): p. 5836-5844.

358. Bibault, J. E., Dewas, S., Mirabel, X., Mortier, L., Penel, N., Vanseymortier, L., et.al. Adjuvant radiation therapy in metastatic lymph nodes from melanomaBioMed Central Ltd. (34 - 42 Cleveland Street, London W1T 4LB, United Kingdom), 2011., http://www.ro-journal.com/content/6/1/12;, http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed10&NEWS=N&AN=2011100138

359. Gojkovic-Horvat, A., Jancar, B., Blas, M., Zumer, B., Karner, K., Hocevar, M., et.al. Adjuvant Radiotherapy for Palpable Melanoma Metastases to the Groin: When to Irradiate?, International journal of radiation oncology, biology, physics, 2011.

360. Hamming-Vrieze, O., Balm, A. J., Heemsbergen, W. D., Hooft van Huysduynen, T., Rasch, C. R., Regional control of melanoma neck node metastasis after selective neck dissection with or without adjuvant radiotherapy, Arch Otolaryngol Head Neck Surg, 2009. 135(8): p. 795-800., http://www.ncbi.nlm.nih.gov/pubmed/19687401

361. O'Brien, C. J., Petersen-Schaefer, K., Stevens, G. N., Bass, P. C., Tew, P., Gebski, V. J., et.al. Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma, Head Neck, 1997. 19(7): p. 589-94., http://www.ncbi.nlm.nih.gov/pubmed/9323147

362. Strojan, P., Jancar, B., Cemazar, M., Perme, M. P., Hocevar, M., Melanoma metastases to the neck nodes: role of adjuvant irradiation, Int J Radiat Oncol Biol Phys, 2010. 77(4): p. 1039-45., http://www.ncbi.nlm.nih.gov/pubmed/19910139

363. Barbour, S., Mark Smithers, B., Allan, C., Bayley, G., Thomas, J., Foote, M., et.al. Patterns of Recurrence in Patients with Stage IIIB/C Cutaneous Melanoma of the Head and Neck Following Surgery With and Without Adjuvant Radiation Therapy: Is Isolated Regional Recurrence Salvageable?, Ann Surg Oncol, 2015. 22(12): p. 4052-9.

364. Danish, H. H., Patel, K. R., Switchenko, J. M., Gillespie, T. W., Jhaveri, J., Chowdhary, M., et.al. The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis, Melanoma Res, 2016. 26(6): p. 595-603.

365. Mendenhall, W. M., Shaw, C., Amdur, R. J., Kirwan, J., Morris, C. G., Werning, J. W., Surgery and adjuvant radiotherapy for cutaneous melanoma considered high-risk for local-regional recurrence, Am J Otolaryngol, 2013. 34(4): p. 320-2.

366. Pinkham, M. B., Foote, M. C., Burmeister, E., Thomas, J., Meakin, J., Smithers, B. M., et.al. Stage III melanoma in the axilla: patterns of regional recurrence after surgery with and without adjuvant radiation therapy, Int J Radiat Oncol Biol Phys, 2013. 86(4): p. 702-8.

367. Moncrieff, M. D., Martin, R., O'Brien, C. J., Shannon, K. F., Clark, J. R., Gao, K., et.al. Adjuvant postoperative radiotherapy to the cervical lymph nodes in cutaneous melanoma: is there any benefit for high-risk patients?, Ann Surg Oncol, 2008. 15(11): p. 3022-7., http://www.ncbi.nlm.nih.gov/pubmed/18958539

368. Henderson, M. A., Burmeister, B., Thompson, J. F., Di Iulio, J., Fisher, R., Hong, A., et.al. Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01), Journal of Clinical Oncology, 2009. 27(18): p. LBA9084.

369. Suciu, S., Eggermont, A. M. M., Lorigan, P., Kirkwood, J. M., Markovic, S. N., Garbe, C., et.al. Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy, J Natl Cancer Inst, 2018. 110(1):, https://www.ncbi.nlm.nih.gov/pubmed/28922786

370. Grob, J. J., Dreno, B., de la Salmoniere, P., Delaunay, M., Cupissol, D., Guillot, B., et.al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma, Lancet, 1998. 351(9120): p. 1905-10.

371. Garbe, C., Eigentler, T. K., Keilholz, U., Hauschild, A., Kirkwood, J. M., Systematic review of medical treatment in melanoma: current status and future prospects, Oncologist, 2011. 16(1): p. 5-24., http://www.ncbi.nlm.nih.gov/pubmed/21212434

372. Lens, M. B., Dawes, M., Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials, J Clin Oncol, 2002. 20(7): p. 1818-25., http://www.ncbi.nlm.nih.gov/pubmed/11919239

373. Mocellin, S., Pasquali, S., Rossi, C. R., Nitti, D., Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis, J Natl Cancer Inst, 2010. 102(7): p. 493-501.

374. Pirard, D., Heenen, M., Melot, C., Vereecken, P., Interferon alpha as adjuvant postsurgical treatment of melanoma: a meta-analysis, Dermatology, 2004. 208(1): p. 43-8.

375. Verma, S., Quirt, I., McCready, D., Bak, K., Charette, M., Iscoe, N., Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma, Cancer, 2006. 106(7): p. 1431-1442.

376. Wheatley, K., Ives, N., Hancock, B., Gore, M., Eggermont, A., Suciu, S., Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials, Cancer treatment reviews, 2003. 29(4): p. 241-252.

377. Ives, N. J., Suciu, S., Eggermont, A. M. M., Kirkwood, J., Lorigan, P., Markovic, S. N., et.al. Adjuvant interferon-alpha for the treatment of high-risk melanoma: An individual patient data meta-analysis, Eur J Cancer, 2017. 82: p. 171-183., https://www.ncbi.nlm.nih.gov/pubmed/28692949

378. Garbe, C., Radny, P., Linse, R., Dummer, R., Gutzmer, R., Ulrich, J., et.al. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis, Ann Oncol, 2008. 19(6): p. 1195-201.

379. Eggermont, A. M., Suciu, S., Santinami, M., Testori, A., Kruit, W. H., Marsden, J., et.al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial, Lancet, 2008. 372(9633): p. 117-26.

380. A, u, b, i, n, ,, et.al. Systematic review and meta-analysis of liver resection for metastatic melanoma., 2013., https://www.ncbi.nlm.nih.gov/pubmed/23775340

381. M, c, M, a, s, t, et.al. Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy., 2016., https://www.ncbi.nlm.nih.gov/pubmed/26858331

382. E, g, g, e, r, m, et.al. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity., 2016., https://www.ncbi.nlm.nih.gov/pubmed/26790144

383. Hansson, J., Aamdal, S., Bastholt, L., Brandberg, Y., Hernberg, M., Nilsson, B., et.al. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial, Lancet Oncol, 2011. 12(2): p. 144-52.

384. Grob, J. J., Jouary, T., Dreno, B., Asselineau, J., Gutzmer, R., Hauschild, A., et.al. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study, Eur J Cancer, 2013. 49(1): p. 166-74.

385. Eigentler, Thomas K., Radny, Peter, Hauschild, Axel, Gutzmer, Ralf, Linse, Ruthild, Pfoehler, Claudia, et.al. Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group, Melanoma Research, 2008. 18(5): p. 353-358.

386. Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., et.al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma, N Engl J Med, 2018. 378(19): p. 1789-1801., https://www.ncbi.nlm.nih.gov/pubmed/29658430

387. Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., et.al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma, N Engl J Med, 2017. 377(19): p. 1824-1835., https://www.ncbi.nlm.nih.gov/pubmed/28891423

388. Long, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandala, M., Chiarion-Sileni, V., et.al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma, N Engl J Med, 2017. 377(19): p. 1813-1823., https://www.ncbi.nlm.nih.gov/pubmed/28891408

389. Maio, M., Lewis, K., Demidov, L., Mandala, M., Bondarenko, I., Ascierto, P. A., et.al. Adjuvant vemurafenib in resected, BRAF(V600) mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial, Lancet Oncol, 2018. 19(4): p. 510-520., https://www.ncbi.nlm.nih.gov/pubmed/29477665

390. Kleeberg, U. R., Suciu, S., Brocker, E. B., Ruiter, D. J., Chartier, C., Lienard, D., et.al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: rIFN-alpha 2b versus rIFN-gamma versus ISCADOR M (R) versus observation after surgery in melanoma patients with either high-risk primary (thickness > 3 mm) or regional lymph node metastasis, European Journal of Cancer, 2004. 40(3): p. 390-402., https://www.ncbi.nlm.nih.gov/pubmed/14746858

391. E, r, n, s, t, ,, et.al. Mistletoe for cancer? A systematic review of randomised clinical trials., 2003., https://www.ncbi.nlm.nih.gov/pubmed/12949804

392. Edler, Lutz, Mistel in der Krebstherapie: Fragwürdige Ergebnisse neuerer klinischer Studien, Dtsch Arztebl International, 2004. 101(1-2): p. 44-., https://www.aerzteblatt.de/archiv/mistel-in-der-krebstherapie-fragwuerdige-ergebnisse-neuerer-klinischer-studien-1f7fe616-a5ee-4ff0-9393-2a0963772cae

393. Horneber, M. A., Bueschel, G., Huber, R., Linde, K., Rostock, M., Mistletoe therapy in oncology, Cochrane Database Syst Rev, 2008. (2)(2): p. CD003297., http://www.ncbi.nlm.nih.gov/pubmed/18425885

394. A, l, b, a, r, r, et.al. Retrospektive Fall-Kontroll-Studie zum Stellenwert der adjuvanten Therapie des malignen Melanoms mit Iscador P.c.Hg, 1998.

395. G, r, o, s, s, a, et.al. Efficacy and safety of the long-term treatment of melanoma with a mistletoe preparation (Iscador)., 2007.

396. A, u, g, u, s, t, et.al. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland., 2005., https://www.ncbi.nlm.nih.gov/pubmed/15727163

397. Schuppli, R., Die adjuvante Behandlung des malignen Melanoms mit Iscador® c.Hg, Krebs und Alternativmedizin II. (Ed. W. F. Jungi andH.-J. Senn) pp. 84-87, Springer-Verlag, Berlin - Heidelberg, 1990.

398. Stumpf, C., Rosenberger, A., Rieger, S., Troger, W., Schietzel, M., Stein, G. M., [Retrospective study of malignant melanoma patients treated with mistletoe extracts], Forsch Komplementarmed Klass Naturheilkd, 2003. 10(5): p. 248-55., http://www.ncbi.nlm.nih.gov/pubmed/14605481

399. Coens, C., Suciu, S., Chiarion-Sileni, V., Grob, J. J., Dummer, R., Wolchok, J. D., et.al. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial, Lancet Oncol, 2017. 18(3): p. 393-403.

400. Lens, M.,, A. Testori, P.F. Ferucci, Ipilimumab targeting CD28-CTLA-4 axis: new hope in the treatment of melanoma, Curr Top Med Chem, 2012. p. 61 - 66.

401. C, o, l, e, ,, , et.al. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study, J Clin Oncol, 1996. 14: p. 2666 - 2673.

402. D, i, x, o, n, ,, et.al. Melanoma Patient-Reported Quality of Life Outcomes Following Sentinel Lymph Node Biopsy, Completion Lymphadenectomy, and Adjuvant Interferon: Results from the Sunbelt Melanoma Trial, Ann Surg Oncol, 2016. 23: p. 1019 - 1025.

403. Gjorup, C. A., Groenvold, M., Hendel, H. W., Dahlstroem, K., Drzewiecki, K. T., Klausen, T. W., et.al. Health-related quality of life in melanoma patients: Impact of melanoma-related limb lymphoedema, Eur J Cancer, 2017. 85: p. 122-132.

404. K, i, l, b, r, i, et.al. Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data, J Clin Oncol, 2002. p. 1311 - 1318.

405. Mueller, T., Voigt, W., Fermented wheat germ extract--nutritional supplement or anticancer drug?, Nutr J, 2011. 10: p. 89 - 89.

406. R, e, u, t, e, r, et.al. Health-related quality of life, fatigue, and depression under low-dose IFN-alpha therapy in melanoma patients, J Immunother, 2014. p. 461 - 467.

407. D, i, x, o, n, ,, et.al. Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial., 2006., https://www.ncbi.nlm.nih.gov/pubmed/16449995

408. R, a, t, a, j, ,, et.al. Quality-of-life evaluation in an interferon therapy after radical surgery in cutaneous melanoma patients., 2005., https://www.ncbi.nlm.nih.gov/pubmed/15915059

409. T, r, a, s, k, ,, et.al. Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon., 2004., https://www.ncbi.nlm.nih.gov/pubmed/15295774

410. Z, i, e, f, l, e, et.al. Health-related quality of life before and during adjuvant interferon-alpha treatment for patients with malignant melanoma (DeCOG-trial), 2011., https://www.ncbi.nlm.nih.gov/pubmed/21499123

411. E, g, g, e, r, m, et.al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy, 2016., https://www.ncbi.nlm.nih.gov/pubmed/27717298

412. C, a, r, r, e, n, et.al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells, 2015., https://www.ncbi.nlm.nih.gov/pubmed/25837513

413. Meier, F., Will, S., Ellwanger, U., Schlagenhauff, B., Schittek, B., Rassner, G., et.al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma, Br J Dermatol, 2002. 147(1): p. 62-70., http://www.ncbi.nlm.nih.gov/pubmed/12100186

414. Kretschmer, L., Beckmann, I., Thoms, K. M., Mitteldorf, C., Bertsch, H. P., Neumann, C., Factors predicting the risk of in-transit recurrence after sentinel lymphonodectomy in patients with cutaneous malignant melanoma, Ann Surg Oncol, 2006. 13(8): p. 1105-12., http://www.ncbi.nlm.nih.gov/pubmed/16865591

415. Turley, R. S., Raymond, A. K., Tyler, D. S., Regional treatment strategies for in-transit melanoma metastasis, Surg Oncol Clin N Am, 2011. 20(1): p. 79-103., http://www.ncbi.nlm.nih.gov/pubmed/21111960

416. Overgaard, J., Overgaard, M., Hyperthermia as an adjuvant to radiotherapy in the treatment of malignant melanoma, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 1987. 3(6): p. 483-501.

417. Chadha, M., Hilaris, B., Nori, D., Shiu, M. H., Anderson, L. L., Role of brachytherapy in malignant melanoma: a preliminary report, J Surg Oncol, 1990. 43(4): p. 223-7., http://www.ncbi.nlm.nih.gov/pubmed/2325420

418. Katz, H. R., The relative effectiveness of radiation therapy, corticosteroids, and surgery in the management of melanoma metastatic to the central nervous system, Int J Radiat Oncol Biol Phys, 1981. 7(7): p. 897-906., http://www.ncbi.nlm.nih.gov/pubmed/6171554

419. Konefal, J. B., Emami, B., Pilepich, M. V., Malignant melanoma: analysis of dose fractionation in radiation therapy, Radiology, 1987. 164(3): p. 607-610.

420. Mameghan, H., Knittel, T., Response of melanoma to heat and radiation therapy--a review of the literature and experience from The Prince of Wales Hospital, Sydney, Med J Aust, 1988. 149(9): p. 474-6, 478-81., http://www.ncbi.nlm.nih.gov/pubmed/3054448

421. O, l, o, f, s, s, et.al. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities--long-term follow-up of a randomised trial, 2014., https://www.ncbi.nlm.nih.gov/pubmed/25144818

422. E, l, -, S, a, f, et.al. Primary malignant melanoma of the urethra: a systematic analysis of the current literature., 2014., https://www.ncbi.nlm.nih.gov/pubmed/24370958

423. D, u, r, y, m, a, et.al. Subcellular trafficking and transfection efficacy of polyethylenimine-polyethylene glycol polyplex nanoparticles with a ligand to melanocortin receptor-1, 2012., https://www.ncbi.nlm.nih.gov/pubmed/22964392

424. Byrne, C. M., Thompson, J. F., Johnston, H., Hersey, P., Quinn, M. J., Hughes, T. M., et.al. Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy), Melanoma Research, 2005. 15(1): p. 45-51.

425. Damian, D. L., Shannon, K. F., Saw, R. P., Thompson, J. F., Topical diphencyprone immunotherapy for cutaneous metastatic melanoma, Australas J Dermatol, 2009. 50(4): p. 266-71., http://www.ncbi.nlm.nih.gov/pubmed/19916970

426. Dehesa, L. A., Vilar-Alejo, J., Valeron-Almazan, P., Carretero, G., [Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis with intralesional interleukin-2], Actas Dermosifiliogr, 2009. 100(7): p. 571-85., http://www.ncbi.nlm.nih.gov/pubmed/19715642

427. Gaudy, C., Richard, M. A., Folchetti, G., Bonerandi, J. J., Grob, J. J., Randomized controlled study of electrochemotherapy in the local treatment of skin metastases of melanoma, J Cutan Med Surg, 2006. 10(3): p. 115-21., http://www.ncbi.nlm.nih.gov/pubmed/17241586

428. Green, D. S., Bodman-Smith, M. D., Dalgleish, A. G., Fischer, M. D., Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma, Br J Dermatol, 2007. 156(2): p. 337-45., http://www.ncbi.nlm.nih.gov/pubmed/17223875

429. Radny, P, Caroli, UM, Bauer, J, Paul, T, Schlegel, C, Eigentler, TK, et.al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases, British Journal of Cancer, 2003. 89(9): p. 1620-1626.

430. Rols, M. P., Bachaud, J. M., Giraud, P., Chevreau, C., Roche, H., Teissie, J., Electrochemotherapy of cutaneous metastases in malignant melanoma, Melanoma Res, 2000. 10(5): p. 468-74., http://www.ncbi.nlm.nih.gov/pubmed/11095408

431. Sersa, G., Stabuc, B., Cemazar, M., Miklavcic, D., Rudolf, Z., Electrochemotherapy with cisplatin: clinical experience in malignant melanoma patients, Clin Cancer Res, 2000. 6(3): p. 863-7., http://www.ncbi.nlm.nih.gov/pubmed/10741708

432. Weide, B., Derhovanessian, E., Pflugfelder, A., Eigentler, T. K., Radny, P., Zelba, H., et.al. High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma, Cancer, 2010. 116(17): p. 4139-46., http://www.ncbi.nlm.nih.gov/pubmed/20564107

433. M, a, r, t, i, n, et.al. Prospects for MEK inhibitors for treating cancer., 2014., https://www.ncbi.nlm.nih.gov/pubmed/24597490

434. Hassan, S., Petrella, T. M., Zhang, T., Kamel-Reid, S., Nordio, F., Baccarelli, A., et.al. Erratum to: Pathologic Complete Response to Intralesional Interleukin-2 Therapy Associated with Improved Survival in Melanoma Patients with In-Transit Disease, Ann Surg Oncol, 2015. 22 Suppl 3: p. S1603.

435. Hassan, Saima, Petrella, Teresa M., Zhang, Tong, Kamel-Reid, Suzanne, Nordio, Francesco, Baccarelli, Andrea, et.al. Pathologic Complete Response to Intralesional Interleukin-2 Therapy Associated with Improved Survival in Melanoma Patients with In-Transit Disease, Annals of Surgical Oncology, 2015. 22(6): p. 1950-1958., http://dx.doi.org/10.1245/s10434-014-4199-z

436. Y, o, k, o, u, c, et.al. Solitary breast metastasis from myxoid liposarcoma., 2014., https://www.ncbi.nlm.nih.gov/pubmed/24994066

437. G, r, u, n, h, a, et.al. Perfusion and infusion for melanoma in-transit metastases in the era of effective systemic therapy, 2015., https://www.ncbi.nlm.nih.gov/pubmed/25993219

438. Strobbe, L. J., Hart, A. A., Rumke, P., Israels, S. P., Nieweg, O. E., Kroon, B. B., Topical dinitrochlorobenzene combined with systemic dacarbazine in the treatment of recurrent melanoma, Melanoma Res, 1997. 7(6): p. 507-12., http://www.ncbi.nlm.nih.gov/pubmed/9464624

439. Terheyden, P., Kortum, A. K., Schulze, H. J., Durani, B., Remling, R., Mauch, C., et.al. Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group, J Cancer Res Clin Oncol, 2007. 133(7): p. 437-44., http://www.ncbi.nlm.nih.gov/pubmed/17334785

440. Campana, L. G., Testori, A., Curatolo, P., Quaglino, P., Mocellin, S., Framarini, M., et.al. Treatment efficacy with electrochemotherapy: A multi-institutional prospective observational study on 376 patients with superficial tumors, Eur J Surg Oncol, 2016.

441. Thompson, J. F., Hersey, P., Wachter, E., Chemoablation of metastatic melanoma using intralesional Rose Bengal, Melanoma Res, 2008. 18(6): p. 405-11., http://www.ncbi.nlm.nih.gov/pubmed/18830132

442. von Wussow, P., Block, B., Hartmann, F., Deicher, H., Intralesional interferon-alpha therapy in advanced malignant melanoma, Cancer, 1988. 61(6): p. 1071-1074.

443. Fierlbeck, G., d'Hoedt, B., Stroebel, W., Stutte, H., Bogenschutz, O., Rassner, G., [Intralesional therapy of melanoma metastases with recombinant interferon-beta], Hautarzt, 1992. 43(1): p. 16-21., http://www.ncbi.nlm.nih.gov/pubmed/1612904

444. Khorana, A. A., Rosenblatt, J. D., Sahasrabudhe, D. M., Evans, T., Ladrigan, M., Marquis, D., et.al. A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma, Cancer Gene Ther, 2003. 10(4): p. 251-9., http://www.ncbi.nlm.nih.gov/pubmed/12679797

445. Storm, F. K., Sparks, F. C., Morton, D. L., Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmette Guerin and hyperthermic perfusion, Surg Gynecol Obstet, 1979. 149(1): p. 17-21., http://www.ncbi.nlm.nih.gov/pubmed/451822

446. Tan, J. K., Ho, V. C., Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma, J Dermatol Surg Oncol, 1993. 19(11): p. 985-90., http://www.ncbi.nlm.nih.gov/pubmed/8245304

447. Hayes, A. J., Clark, M. A., Harries, M., Thomas, J. M., Management of in-transit metastases from cutaneous malignant melanoma, Br J Surg, 2004. 91(6): p. 673-82., http://www.ncbi.nlm.nih.gov/pubmed/15164434

448. Thompson, J. F., Kam, P. C., Waugh, R. C., Harman, C. R., Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion, Semin Surg Oncol, 1998. 14(3): p. 238-47., http://www.ncbi.nlm.nih.gov/pubmed/9548607

449. Beasley, G. M., Petersen, R. P., Yoo, J., McMahon, N., Aloia, T., Petros, W., et.al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion, Ann Surg Oncol, 2008. 15(8): p. 2195-205., http://www.ncbi.nlm.nih.gov/pubmed/18528730

450. Moreno-Ramirez, D., de la Cruz-Merino, L., Ferrandiz, L., Villegas-Portero, R., Nieto-Garcia, A., Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety, Oncologist, 2010. 15(4): p. 416-27., http://www.ncbi.nlm.nih.gov/pubmed/20348274

451. Cornett, W. R., McCall, L. M., Petersen, R. P., Ross, M. I., Briele, H. A., Noyes, R. D., et.al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020, J Clin Oncol, 2006. 24(25): p. 4196-201., http://www.ncbi.nlm.nih.gov/pubmed/16943537

452. Deroose, J. P., Grunhagen, D. J., van Geel, A. N., de Wilt, J. H., Eggermont, A. M., Verhoef, C., Long-term outcome of isolated limb perfusion with tumour necrosis factor-alpha for patients with melanoma in-transit metastases, Br J Surg, 2011. 98(11): p. 1573-80., http://www.ncbi.nlm.nih.gov/pubmed/21739427

453. Marsden, J. R., Newton-Bishop, J. A., Burrows, L., Cook, M., Corrie, P. G., Cox, N. H., et.al. Revised U.K. guidelines for the management of cutaneous melanoma 2010, Br J Dermatol, 2010. 163(2): p. 238-56., http://www.ncbi.nlm.nih.gov/pubmed/20608932

454. Dietlein, M., Krug, B., Groth, W., Smolarz, K., Scheidhauer, K., Psaras, T., et.al. Positron emission tomography using 18F-fluorodeoxyglucose in advanced stages of malignant melanoma: a comparison of ultrasonographic and radiological methods of diagnosis, Nuclear medicine communications, 1999. 20(3): p. 255-261.

455. K, u, a, n, ,, , et.al. Multimodality detection of metastatic melanoma, 1988., https://www.ncbi.nlm.nih.gov/pubmed/3054099

456. Stas, M., Stroobants, S., Dupont, P., Gysen, M., Hoe, L. V., Garmyn, M., et.al. 18-FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impact, Melanoma Res, 2002. 12(5): p. 479-90., http://www.ncbi.nlm.nih.gov/pubmed/12394190

457. Davila, D., Antoniou, A., Chaudhry, M. A., Evaluation of osseous metastasis in bone scintigraphy, Semin Nucl Med, 2015. 45(1): p. 3-15.

458. Paschen, A., Sucker, A., Hill, B., Moll, I., Zapatka, M., Nguyen, X. D., et.al. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B, Clin Cancer Res, 2009. 15(16): p. 5208-15., http://www.ncbi.nlm.nih.gov/pubmed/19671853

459. A, g, a, r, w, a, et.al. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)., 2009., https://www.ncbi.nlm.nih.gov/pubmed/19419855

460. D, e, i, c, h, m, et.al. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma., 1999., https://www.ncbi.nlm.nih.gov/pubmed/10561230

461. A, n, d, r, e, s, et.al. value of serum S-100B in malignant melanoma., 2004., https://www.ncbi.nlm.nih.gov/pubmed/15762365

462. Brouard, M., Quillien, V., Ollivier, I., Lesimple, T., Adamski, H., Chevrant-Breton, J., Serum S100B protein and cutaneous malignant melanoma stage: a prospective study., Annales De Dermatologie Et De Venereologie, 2000. 127(1): p. 56-59.

463. Schlagenhauff, B., Stroebel, W., Ellwanger, U., Meier, F., Zimmermann, C., Breuninger, H., et.al. Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: recommendations for initial staging examinations, Cancer, 1997. 80(1): p. 60-5., http://www.ncbi.nlm.nih.gov/pubmed/9210709

464. Lowes, M. A., Bishop, G. A., Crotty, K., Barnetson, R. S., Halliday, G. M., T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas, Journal of Investigative Dermatology, 1997. 108(6): p. 914-919., , to, ISI>://WOS:A1997XB83600015

465. Prens, S. P., van der Ploeg, A. P., van Akkooi, A. C., van Montfort, C. A., van Geel, A. N., de Wilt, J. H., et.al. Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site, Ann Surg Oncol, 2011. 18(13): p. 3586-92., http://www.ncbi.nlm.nih.gov/pubmed/21611857

466. Tefany, F. J., Barnetson, R. S., Halliday, G. M., McCarthy, S. W., McCarthy, W. H., Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma, J Invest Dermatol, 1991. 97(2): p. 197-202., http://www.ncbi.nlm.nih.gov/pubmed/1712819

467. Lee, C. C., Faries, M. B., Wanek, L. A., Morton, D. L., Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma, J Clin Oncol, 2008. 26(4): p. 535-41., http://www.ncbi.nlm.nih.gov/pubmed/18235114

468. Vijuk, G., Coates, A. S., Survival of patients with visceral metastatic melanoma from an occult primary lesion: a retrospective matched cohort study, Ann Oncol, 1998. 9(4): p. 419-22., http://www.ncbi.nlm.nih.gov/pubmed/9636833

469. Tos, T., Klyver, H., Drzewiecki, K. T., Extensive screening for primary tumor is redundant in melanoma of unknown primary, J Surg Oncol, 2011. 104(7): p. 724-7., http://www.ncbi.nlm.nih.gov/pubmed/21721009

470. Goel, V. K., Lazar, A. J., Warneke, C. L., Redston, M. S., Haluska, F. G., Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma, J Invest Dermatol, 2006. 126(1): p. 154-60., http://www.ncbi.nlm.nih.gov/pubmed/16417231

471. I, v, a, n, o, v, et.al. Acute toxoplasmosis mimicking melanoma metastases: review of conditions causing false-positive results on (18)F-FDG PET/CT, 2012., https://www.ncbi.nlm.nih.gov/pubmed/23406996

472. Carvajal, R. D., Antonescu, C. R., Wolchok, J. D., Chapman, P. B., Roman, R. A., Teitcher, J., et.al. KIT as a therapeutic target in metastatic melanoma, JAMA, 2011. 305(22): p. 2327-34., http://www.ncbi.nlm.nih.gov/pubmed/21642685

473. Leo, F., Cagini, L., Rocmans, P., Cappello, M., Geel, A. N., Maggi, G., et.al. Lung metastases from melanoma: when is surgical treatment warranted?, Br J Cancer, 2000. 83(5): p. 569-72., http://www.ncbi.nlm.nih.gov/pubmed/10944593

474. Delaunay, M. M., Amici, J. M., Avril, M. F., Avril, A., Barrut, D., Blanc, L., et.al. [Surgery of pulmonary metastasis from malignant melanoma. Results and criteria of surgical excision], Ann Dermatol Venereol, 1991. 118(4): p. 287-95., http://www.ncbi.nlm.nih.gov/pubmed/2069340

475. Mathisen, D. J., Flye, M. W., Peabody, J., The role of thoracotomy in the management of pulmonary metastases from malignant melanoma, Ann Thorac Surg, 1979. 27(4): p. 295-9., http://www.ncbi.nlm.nih.gov/pubmed/453996

476. Petersen, R. P., Hanish, S. I., Haney, J. C., Miller, C. C., 3rd, Burfeind, W. R., Jr., Tyler, D. S., et.al. Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma, J Thorac Cardiovasc Surg, 2007. 133(1): p. 104-10., http://www.ncbi.nlm.nih.gov/pubmed/17198792

477. M, o, r, t, o, n, et.al. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites, 2007., http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/8508

478. Manola, J., Atkins, M., Ibrahim, J., Kirkwood, J., Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials, J Clin Oncol, 2000. 18(22): p. 3782-93., http://www.ncbi.nlm.nih.gov/pubmed/11078491

479. Brand, C. U., Ellwanger, U., Stroebel, W., Meier, F., Schlagenhauff, B., Rassner, G., et.al. Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors, Cancer, 1997. 79(12): p. 2345-2353.

480. S, a, n, k, i, ,, et.al. Surgery for melanoma metastases of the gastrointestinal tract: indications and results., 2009., https://www.ncbi.nlm.nih.gov/pubmed/18590949

481. Harpole, D. H., Jr., Johnson, C. M., Wolfe, W. G., George, S. L., Seigler, H. F., Analysis of 945 cases of pulmonary metastatic melanoma, J Thorac Cardiovasc Surg, 1992. 103(4): p. 743-8; discussion 748-50., http://www.ncbi.nlm.nih.gov/pubmed/1548916

482. Andrews, S., Robinson, L., Cantor, A., DeConti, R. C., Survival after surgical resection of isolated pulmonary metastases from malignant melanoma, Cancer Control, 2006. 13(3): p. 218-23., http://www.ncbi.nlm.nih.gov/pubmed/16885918

483. Neuman, H. B., Patel, A., Hanlon, C., Wolchok, J. D., Houghton, A. N., Coit, D. G., Stage-IV melanoma and pulmonary metastases: factors predictive of survival, Ann Surg Oncol, 2007. 14(10): p. 2847-53., http://www.ncbi.nlm.nih.gov/pubmed/17680317

484. Albert, J. G., Fechner, M., Fiedler, E., Voderholzer, W., Lochs, H., Trefzer, U., et.al. Algorithm for detection of small-bowel metastasis in malignant melanoma of the skin, Endoscopy, 2011. 43(6): p. 490-498.

485. Chua, T. C., Saxena, A., Morris, D. L., Surgical metastasectomy in AJCC stage IV M1c melanoma patients with gastrointestinal and liver metastases, Ann Acad Med Singapore, 2010. 39(8): p. 634-9., http://www.ncbi.nlm.nih.gov/pubmed/20838706

486. Berger, A. C., Buell, J. F., Venzon, D., Baker, A. R., Libutti, S. K., Management of symptomatic malignant melanoma of the gastrointestinal tract, Ann Surg Oncol, 1999. 6(2): p. 155-60., http://www.ncbi.nlm.nih.gov/pubmed/10082040

487. Ollila, D. W., Essner, R., Wanek, L. A., Morton, D. L., Surgical resection for melanoma metastatic to the gastrointestinal tract, Arch Surg, 1996. 131(9): p. 975-9; 979-80., http://www.ncbi.nlm.nih.gov/pubmed/8790168

488. Pawlik, T. M., Zorzi, D., Abdalla, E. K., Clary, B. M., Gershenwald, J. E., Ross, M. I., et.al. Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease, Ann Surg Oncol, 2006. 13(5): p. 712-20., http://www.ncbi.nlm.nih.gov/pubmed/16538410

489. Branum, G. D., Epstein, R. E., Leight, G. S., Seigler, H. F., The role of resection in the management of melanoma metastatic to the adrenal gland, Surgery, 1991. 109(2): p. 127-131.

490. Larkin, J., Ascierto, P. A., Dreno, B., Atkinson, V., Liszkay, G., Maio, M., et.al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma, N Engl J Med, 2014. 371(20): p. 1867-76.

491. A, n, f, o, r, t, et.al. Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma., 2015., https://www.ncbi.nlm.nih.gov/pubmed/25380183

492. L, o, n, g, ,, , et.al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma., 2014., https://www.ncbi.nlm.nih.gov/pubmed/25265492

493. Ascierto, P. A., Marincola, F. M., Atkins, M. B., What's new in melanoma? Combination!, J Transl Med, 2015. 13: p. 213., https://www.ncbi.nlm.nih.gov/pubmed/26141621

494. Guo, J., Si, L., Kong, Y., Flaherty, K. T., Xu, X., Zhu, Y., et.al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification, J Clin Oncol, 2011. 29(21): p. 2904-9., http://www.ncbi.nlm.nih.gov/pubmed/21690468

495. Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., et.al. Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 2010. 363(8): p. 711-23., http://www.ncbi.nlm.nih.gov/pubmed/20525992

496. R, o, b, e, r, t, et.al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma, 2011., https://www.ncbi.nlm.nih.gov/pubmed/21639810

497. S, t, o, f, f, e, et.al. Evaluation of a radioactive and fluorescent hybrid tracer for sentinel lymph node biopsy in head and neck malignancies: prospective randomized clinical trial to compare ICG-(99m)Tc-nanocolloid hybrid tracer versus (99m)Tc-nanocolloid, 2015., https://www.ncbi.nlm.nih.gov/pubmed/26025245

498. Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., et.al. Nivolumab in previously untreated melanoma without BRAF mutation, N Engl J Med, 2015. 372(4): p. 320-30., http://www.ncbi.nlm.nih.gov/pubmed/25399552

499. H, o, m, e, t, , et.al. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers., 2015., https://www.ncbi.nlm.nih.gov/pubmed/25856776

500. Hersh, E. M., O'Day, S. J., Powderly, J., Khan, K. D., Pavlick, A. C., Cranmer, L. D., et.al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma, Invest New Drugs, 2011. 29(3): p. 489-98., http://www.ncbi.nlm.nih.gov/pubmed/20082117

501. B, h, a, t, i, a, et.al. Systemic therapy of metastatic melanoma: on the road to cure, 2015., https://www.ncbi.nlm.nih.gov/pubmed/25683834

502. C, a, l, l, a, h, et.al. Immunomodulatory therapy for melanoma: ipilimumab and beyond, 2013., https://www.ncbi.nlm.nih.gov/pubmed/23438382

503. S, p, a, g, n, o, et.al. BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies., 2015., https://www.ncbi.nlm.nih.gov/pubmed/25653539

504. Weber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., et.al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol, 2015. 16(4): p. 375-84., http://www.ncbi.nlm.nih.gov/pubmed/25795410

505. Schadendorf, D., Ugurel, S., Schuler-Thurner, B., Nestle, F. O., Enk, A., Brocker, E. B., et.al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG, Ann Oncol, 2006. 17(4): p. 563-70., http://www.ncbi.nlm.nih.gov/pubmed/16418308

506. Schwartzentruber, D. J., Lawson, D. H., Richards, J. M., Conry, R. M., Miller, D. M., Treisman, J., et.al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma, N Engl J Med, 2011. 364(22): p. 2119-27.

507. Danson, S., Lorigan, P., Arance, A., Clamp, A., Ranson, M., Hodgetts, J., et.al. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma, J Clin Oncol, 2003. 21(13): p. 2551-7., http://www.ncbi.nlm.nih.gov/pubmed/12829675

508. Falkson, C. I., Falkson, G., Falkson, H. C., Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma, J Clin Oncol, 1991. 9(8): p. 1403-8., http://www.ncbi.nlm.nih.gov/pubmed/2072144

509. Kaufmann, R., Spieth, K., Leiter, U., Mauch, C., von den Driesch, P., Vogt, T., et.al. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group, J Clin Oncol, 2005. 23(35): p. 9001-7.

510. Bedikian, A. Y., Millward, M., Pehamberger, H., Conry, R., Gore, M., Trefzer, U., et.al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group, J Clin Oncol, 2006. 24(29): p. 4738-45.

511. Middleton, M. R., Grob, J. J., Aaronson, N., Fierlbeck, G., Tilgen, W., Seiter, S., et.al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma, J Clin Oncol, 2000. 18(1): p. 158-66.

512. Patel, P. M., Suciu, S., Mortier, L., Kruit, W. H., Robert, C., Schadendorf, D., et.al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032), Eur J Cancer, 2011. 47(10): p. 1476-83.

513. Avril, M. F., Aamdal, S., Grob, J. J., Hauschild, A., Mohr, P., Bonerandi, J. J., et.al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study, J Clin Oncol, 2004. 22(6): p. 1118-25.

514. Hersh, E. M., Del Vecchio, M., Brown, M. P., Kefford, R., Loquai, C., Testori, A., et.al. A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma, Ann Oncol, 2015. 26(11): p. 2267-74.

515. D, e, n, e, v, e, et.al. Chemosaturation with percutaneous hepatic perfusion for unresectable isolated hepatic metastases from sarcoma., 2012., https://www.ncbi.nlm.nih.gov/pubmed/22699779

516. T, o, p, a, l, i, et.al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, 2012., https://www.ncbi.nlm.nih.gov/pubmed/22658127

517. Schadendorf, D., Amonkar, M. M., Milhem, M., Grotzinger, K., Demidov, L. V., Rutkowski, P., et.al. Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study, Ann Oncol, 2014. 25(3): p. 700-6.

518. Bedikian, A. Y., DeConti, R. C., Conry, R., Agarwala, S., Papadopoulos, N., Kim, K. B., et.al. Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma, Ann Oncol, 2011. 22(4): p. 787-93.

519. Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., et.al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, 2011. 364(26): p. 2507-16.

520. Chauvergne, J., Bui, N. B., Cappelaere, P., Gary-Bobo, J., Guerrin, J., Armand, J. P., et.al. [Chemotherapy in advanced malignant melanoma. Results of a controlled trial comparing a combination of dacarbazine (DTIC) and detorubicin with dacarbazine alone], Sem Hop, 1982. 58(46): p. 2697-701.

521. Kefford, R. F., Clingan, P. R., Brady, B., Ballmer, A., Morganti, A., Hersey, P., A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy, Mol Cancer, 2010. 9: p. 69.

522. McDermott, D. F., Sosman, J. A., Gonzalez, R., Hodi, F. S., Linette, G. P., Richards, J., et.al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group, J Clin Oncol, 2008. 26(13): p. 2178-85.

523. O'Day, S., Pavlick, A., Loquai, C., Lawson, D., Gutzmer, R., Richards, J., et.al. A randomised, phase II study of intetumumab, an anti-alphav-integrin mAb, alone and with dacarbazine in stage IV melanoma, Br J Cancer, 2011. 105(3): p. 346-52.

524. Ringborg, U., Rudenstam, C. M., Hansson, J., Hafstrom, L., Stenstam, B., Strander, H., Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study, Med Oncol Tumor Pharmacother, 1989. 6(4): p. 285-9.

525. Thomson, D. B., Adena, M., McLeod, G. R., Hersey, P., Gill, P. G., Coates, A. S., et.al. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial, Melanoma Res, 1993. 3(2): p. 133-138.

526. Weber, J. S., Amin, A., Minor, D., Siegel, J., Berman, D., O'Day, S. J., Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial, Melanoma Res, 2011. 21(6): p. 530-4.

527. Eigentler, TK, Caroli, UM, Radny, P, Garbe, C, Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials, Lancet Oncology, 2003. 4(12): p. 748-759.

528. C, h, a, p, m, a, et.al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma., 1999., https://www.ncbi.nlm.nih.gov/pubmed/10561349

529. Chiarion Sileni, V., Nortilli, R., Aversa, S. M., Paccagnella, A., Medici, M., Corti, L., et.al. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients, Melanoma Res, 2001. 11(2): p. 189-96., http://www.ncbi.nlm.nih.gov/pubmed/11333130

530. Luikart, S. D., Kennealey, G. T., Kirkwood, J. M., Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma, J Clin Oncol, 1984. 2(3): p. 164-8., http://www.ncbi.nlm.nih.gov/pubmed/6199481

531. Hauschild, A., Agarwala, S. S., Trefzer, U., Hogg, D., Robert, C., Hersey, P., et.al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma, J Clin Oncol, 2009. 27(17): p. 2823-30., http://www.ncbi.nlm.nih.gov/pubmed/19349552

532. Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., et.al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial, Lancet Oncol, 2015. 16(8): p. 908-18., http://www.ncbi.nlm.nih.gov/pubmed/26115796

533. Atkins, M. B., Hsu, J., Lee, S., Cohen, G. I., Flaherty, L. E., Sosman, J. A., et.al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group, J Clin Oncol, 2008. 26(35): p. 5748-54., http://www.ncbi.nlm.nih.gov/pubmed/19001327

534. Eton, O., Legha, S. S., Bedikian, A. Y., Lee, J. J., Buzaid, A. C., Hodges, C., et.al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial, J Clin Oncol, 2002. 20(8): p. 2045-52., http://www.ncbi.nlm.nih.gov/pubmed/11956264

535. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., et.al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b, Journal of Clinical Oncology, 1999. 17(3): p. 968-975.

536. Cashin, R. P., Lui, P., Machado, M., Hemels, M. E., Corey-Lisle, P. K., Einarson, T. R., Advanced cutaneous malignant melanoma: a systematic review of economic and quality-of-life studies, Value Health, 2008. 11(2): p. 259-71., http://www.ncbi.nlm.nih.gov/pubmed/18380638

537. Kiebert, G. M., Jonas, D. L., Middleton, M. R., Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine, Cancer Invest, 2003. 21(6): p. 821-9., http://www.ncbi.nlm.nih.gov/pubmed/14735685

538. Young, A. M., Marsden, J., Goodman, A., Burton, A., Dunn, J. A., Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma, Clin Oncol (R Coll Radiol), 2001. 13(6): p. 458-65.

539. Sigurdardottir, V., Bolund, C., Sullivan, M., Quality of life evaluation by the EORTC questionnaire technique in patients with generalized malignant melanoma on chemotherapy, Acta Oncol, 1996. 35(2): p. 149-58., http://www.ncbi.nlm.nih.gov/pubmed/8639309

540. Lacouture, M. E., Wolchok, J. D., Yosipovitch, G., Kahler, K. C., Busam, K. J., Hauschild, A., Ipilimumab in patients with cancer and the management of dermatologic adverse events, J Am Acad Dermatol, 2014. 71(1): p. 161-9.

541. Ascierto, P. A., Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies, Tumori, 2013. 99(6): p. 302e-5e., https://www.ncbi.nlm.nih.gov/pubmed/24503809

542. Z, i, m, m, e, r, et.al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma., 2015., https://www.ncbi.nlm.nih.gov/pubmed/25761109

543. L, e, b, b, e, ,, et.al. Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies., 2014., https://www.ncbi.nlm.nih.gov/pubmed/25210016

544. Long, G. V., Atkinson, V., Ascierto, P. A., Robert, C., Hassel, J. C., Rutkowski, P., et.al. Effect of nivolumab on health-related quality of life in patients with treatment-naive advanced melanoma: results from the phase III CheckMate 066 study, Ann Oncol, 2016. 27(10): p. 1940-6.

545. Eigentler, T. K., Hassel, J. C., Berking, C., Aberle, J., Bachmann, O., Grunwald, V., et.al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy, Cancer Treat Rev, 2016. 45: p. 7-18.

546. Spain, L., Diem, S., Larkin, J., Management of toxicities of immune checkpoint inhibitors, Cancer Treat Rev, 2016. 44: p. 51-60., https://www.ncbi.nlm.nih.gov/pubmed/26874776

547. Heinzerling, L., Goldinger, S. M., A review of serious adverse effects under treatment with checkpoint inhibitors, Curr Opin Oncol, 2017. 29(2): p. 136-144.

548. Berman, D., Parker, S. M., Siegel, J., Chasalow, S. D., Weber, J., Galbraith, S., et.al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma, Cancer Immun, 2010. 10: p. 11., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2999944/pdf/1424-9634-10-011.pdf

549. Di Giacomo, A. M., Biagioli, M., Maio, M., The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications, Semin Oncol, 2010. 37(5): p. 499-507.

550. Weber, J., Thompson, J. A., Hamid, O., Minor, D., Amin, A., Ron, I., et.al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma, Clin Cancer Res, 2009. 15(17): p. 5591-8., http://clincancerres.aacrjournals.org/content/clincanres/15/17/5591.full.pdf

551. Kahler, K. C., Hassel, J. C., Heinzerling, L., Loquai, C., Mossner, R., Ugurel, S., et.al. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma, J Dtsch Dermatol Ges, 2016. 14(7): p. 662-81., http://onlinelibrary.wiley.com/store/10.1111/ddg.13047/asset/ddg13047.pdf?v=1&t=iuf95tks&s=5398f4427ff9df12212e3f18e67bdbfe552464db

552. Verschuren, E. C., van den Eertwegh, A. J., Wonders, J., Slangen, R. M., van Delft, F., van Bodegraven, A., et.al. Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis, Clin Gastroenterol Hepatol, 2016. 14(6): p. 836-42.

553. Lankes, K., Hundorfean, G., Harrer, T., Pommer, A. J., Agaimy, A., Angelovska, I., et.al. Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis, Oncoimmunology, 2016. 5(6): p. e1128611.

554. Ascierto, P. A., McArthur, G. A., Dreno, B., Atkinson, V., Liszkay, G., Di Giacomo, A. M., et.al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial, Lancet Oncol, 2016. 17(9): p. 1248-60.

555. Hofmann, L., Forschner, A., Loquai, C., Goldinger, S. M., Zimmer, L., Ugurel, S., et.al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy, Eur J Cancer, 2016. 60: p. 190-209.

556. Wen, X., Wang, Y., Ding, Y., Li, D., Li, J., Guo, Y., et.al. Safety of immune checkpoint inhibitors in Chinese patients with melanoma, Melanoma Res, 2016. 26(3): p. 284-9.

557. Johncilla, M., Misdraji, J., Pratt, D. S., Agoston, A. T., Lauwers, G. Y., Srivastava, A., et.al. Ipilimumab-associated Hepatitis: Clinicopathologic Characterization in a Series of 11 Cases, Am J Surg Pathol, 2015. 39(8): p. 1075-84.

558. Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., et.al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies, Ann Oncol, 2015. 26(12): p. 2375-91.

559. Zimmer, L., Goldinger, S. M., Hofmann, L., Loquai, C., Ugurel, S., Thomas, I., et.al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy, Eur J Cancer, 2016. 60: p. 210-25.

560. R, o, b, e, r, t, et.al. Pembrolizumab versus Ipilimumab in Advanced Melanoma., 2015., https://www.ncbi.nlm.nih.gov/pubmed/25891173

561. Torino, F., Corsello, S. M., Salvatori, R., Endocrinological side-effects of immune checkpoint inhibitors, Curr Opin Oncol, 2016. 28(4): p. 278-87., http://ovidsp.tx.ovid.com/ovftpdfs/FPDDNCOBGHLGJH00/fs047/ovft/live/gv024/00001622/00001622-201607000-00006.pdf

562. Gonzalez-Rodriguez, E., Rodriguez-Abreu, D., Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events, Oncologist, 2016. 21(7): p. 804-16., http://theoncologist.alphamedpress.org/content/21/7/804.long

563. Villadolid, J., Amin, A., Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities, Transl Lung Cancer Res, 2015. 4(5): p. 560-75., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630514/pdf/tlcr-04-05-560.pdf

564. Peuvrel, L., Quereux, G., Saint-Jean, M., Brocard, A., Nguyen, J. M., Khammari, A., et.al. Profile of vemurafenib-induced severe skin toxicities, J Eur Acad Dermatol Venereol, 2016. 30(2): p. 250-7., http://onlinelibrary.wiley.com/store/10.1111/jdv.13443/asset/jdv13443.pdf?v=1&t=ity48rb1&s=38c5b243a444300f4dd6bc20fa35c22e47c8aad7

565. Manousaridis, I., Mavridou, S., Goerdt, S., Leverkus, M., Utikal, J., Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management, J Eur Acad Dermatol Venereol, 2013. 27(1): p. 11-8., http://onlinelibrary.wiley.com/store/10.1111/j.1468-3083.2012.04546.x/asset/j.1468-3083.2012.04546.x.pdf?v=1&t=ity48jjd&s=1a1a06f1a5fac71ee472a95476fd90993233cbbc

566. Fava, P., Marra, E., Astrua, C., Brizio, M., Cavaliere, G., Quaglino, P., et.al. Dermatological approach to vemurafenib skin toxicity: a single centre experience, G Ital Dermatol Venereol, 2016. 151(1): p. 25-31.

567. C, o, r, r, i, e, et.al. Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study, 2014., https://www.ncbi.nlm.nih.gov/pubmed/24745696

568. Khoja, L., Atenafu, E. G., Ye, Q., Gedye, C., Chappell, M., Hogg, D., et.al. Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma, Oncol Lett, 2016. 11(2): p. 1581-1585., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734313/pdf/ol-11-02-1581.pdf

569. Welsh, S. J., Corrie, P. G., Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma, Ther Adv Med Oncol, 2015. 7(2): p. 122-36.

570. Huang, W., Yang, A. H., Matsumoto, D., Collette, W., Marroquin, L., Ko, M., et.al. PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion, J Ocul Pharmacol Ther, 2009. 25(6): p. 519-30., http://www.ncbi.nlm.nih.gov/pubmed/19929595

571. Hahn, L., Pepple, K. L., Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma, J Ophthalmic Inflamm Infect, 2016. 6(1): p. 14., http://www.ncbi.nlm.nih.gov/pubmed/27165193

572. K, i, r, a, t, l, et.al. In vivo Confocal Microscopy in Differentiating Ipilimumab-Induced Anterior Uveitis from Metastatic Uveal Melanoma, 2016., https://www.ncbi.nlm.nih.gov/pubmed/27790127

573. Miserocchi, E., Cimminiello, C., Mazzola, M., Russo, V., Modorati, G. M., New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient, Can J Ophthalmol, 2015. 50(1): p. e2-4., http://www.ncbi.nlm.nih.gov/pubmed/25677296

574. Nallapaneni, N. N., Mourya, R., Bhatt, V. R., Malhotra, S., Ganti, A. K., Tendulkar, K. K., Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash, J Natl Compr Canc Netw, 2014. 12(8): p. 1077-81., http://www.ncbi.nlm.nih.gov/pubmed/25099440

575. Papavasileiou, E., Prasad, S., Freitag, S. K., Sobrin, L., Lobo, A. M., Ipilimumab-induced Ocular and Orbital Inflammation--A Case Series and Review of the Literature, Ocul Immunol Inflamm, 2016. 24(2): p. 140-6., http://www.ncbi.nlm.nih.gov/pubmed/25760920

576. Nguyen, A. T., Elia, M., Materin, M. A., Sznol, M., Chow, J., Cyclosporine for Dry Eye Associated With Nivolumab: A Case Progressing to Corneal Perforation, Cornea, 2016. 35(3): p. 399-401.

577. Crews, J., Agarwal, A., Jack, L., Xu, D., Do, D. V., Nguyen, Q. D., Ipilimumab-Associated Retinopathy, Ophthalmic Surg Lasers Imaging Retina, 2015. 46(6): p. 658-60.

578. McElnea, E., Ni Mhealoid, A., Moran, S., Kelly, R., Fulcher, T., Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab, Orbit, 2014. 33(6): p. 424-7., http://www.ncbi.nlm.nih.gov/pubmed/25207976

579. Borodic, G., Hinkle, D. M., Cia, Y., Drug-induced graves disease from CTLA-4 receptor suppression, Ophthal Plast Reconstr Surg, 2011. 27(4): p. e87-8., http://www.ncbi.nlm.nih.gov/pubmed/21242854

580. Renouf, D. J., Velazquez-Martin, J. P., Simpson, R., Siu, L. L., Bedard, P. L., Ocular toxicity of targeted therapies, J Clin Oncol, 2012. 30(26): p. 3277-86., http://www.ncbi.nlm.nih.gov/pubmed/22649132

581. Medina, T. M., Lewis, K. D., The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib, Onco Targets Ther, 2016. 9: p. 3739-52., http://www.ncbi.nlm.nih.gov/pubmed/27382311

582. Infante, J. R., Fecher, L. A., Falchook, G. S., Nallapareddy, S., Gordon, M. S., Becerra, C., et.al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial, Lancet Oncol, 2012. 13(8): p. 773-81., http://www.ncbi.nlm.nih.gov/pubmed/22805291

583. Overgaard, J., von der Maase, H., Overgaard, M., A randomized study comparing two high-dose per fraction radiation schedules in recurrent or metastatic malignant melanoma, Int J Radiat Oncol Biol Phys, 1985. 11(10): p. 1837-9., http://www.ncbi.nlm.nih.gov/pubmed/4044346

584. H, e, r, b, e, r, et.al. The effect of palliative radiation therapy on epidural compression due to metastatic malignant melanoma, 1991.

585. Engin, K., Tupchong, L., Waterman, F. M., Moylan, D. J., Nerlinger, R. E., Leeper, D. B., Hyperthermia and radiation in advanced malignant melanoma, Int J Radiat Oncol Biol Phys, 1993. 25(1): p. 87-94., http://www.ncbi.nlm.nih.gov/pubmed/8416885

586. Pyrhonen, S. O., Kajanti, M. J., The Use of Large Fractions in Radiotherapy for Malignant-Melanoma, Radiotherapy and Oncology, 1992. 24(3): p. 195-197., , to, ISI>://WOS:A1992JL59000009

587. Doss, L. L., Memula, N., The radioresponsiveness of melanoma, Int J Radiat Oncol Biol Phys, 1982. 8(7): p. 1131-4., http://www.ncbi.nlm.nih.gov/pubmed/7118615

588. Rate, W. R., Solin, L. J., Turrisi, A. T., Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression, Int J Radiat Oncol Biol Phys, 1988. 15(4): p. 859-64., http://www.ncbi.nlm.nih.gov/pubmed/2460420

589. Overgaard, J., Gonzalez, Gonzalez D., Hulshof, M. C. C. H., Arcangeli, G., Dahl, O., Mella, O., et.al. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology, Int J Hyperthermia, 2009. 25(Web Page): p. 323-334., http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed9&NEWS=N&AN=2009616623

590. Katz, H. R., The results of different fractionation schemes in the palliative irradiation of metastatic melanoma, Int J Radiat Oncol Biol Phys, 1981. 7(7): p. 907-11., http://www.ncbi.nlm.nih.gov/pubmed/6171555

591. Lobo, P. A., Liebner, E. J., Chao, J. J., Kanji, A. M., Radiotherapy in the management of malignant melanoma, Int J Radiat Oncol Biol Phys, 1981. 7(1): p. 21-6., http://www.ncbi.nlm.nih.gov/pubmed/6167560

592. Richtig, E., Ludwig, R., Kerl, H., Smolle, J., Organ- and treatment-specific local response rates to systemic and local treatment modalities in stage IV melanoma, Br J Dermatol, 2005. 153(5): p. 925-31., http://www.ncbi.nlm.nih.gov/pubmed/16225601

593. Rounsaville, M. C., Cantril, S. T., Fontanesi, J., Vaeth, J. M., Green, J. P., Radiotherapy in the management of cutaneous melanoma: effect of time, dose, and fractionation, Front Radiat Ther Oncol, 1988. 22: p. 62-78., http://www.ncbi.nlm.nih.gov/pubmed/3280415

594. Strauss, A., Dritschilo, A., Nathanson, L., Piro, A. J., Radiation-Therapy of Malignant Melanomas - an Evaluation of Clinically Used Fractionation Schemes, Cancer, 1981. 47(6): p. 1262-1266., , to, ISI>://WOS:A1981LF18100005

595. Seegenschmiedt, M. H., Keilholz, L., Altendorf-Hofmann, A., Pieritz, A., Urban, A., Schell, H., et.al. [Long term results following radiation therapy of locally recurrent and metastatic malignant melanoma], Hautarzt, 1999. 50(8): p. 572-9., http://www.ncbi.nlm.nih.gov/pubmed/10460301

596. Kirova, Y. M., Chen, J., Rabarijaona, L. I., Piedbois, Y., Le Bourgeois, J. P., Radiotherapy as palliative treatment for metastatic melanoma, Melanoma research, 1999. 9(6): p. 611-613.

597. Konefal, J. B., Emami, B., Pilepich, M. V., Analysis of dose fractionation in the palliation of metastases from malignant melanoma, Cancer, 1988. 61(2): p. 243-246.

598. Caralt, M., Marti, J., Cortes, J., Fondevila, C., Bilbao, I., Fuster, J., et.al. Outcome of patients following hepatic resection for metastatic cutaneous and ocular melanoma, J Hepatobiliary Pancreat Sci, 2011. 18(2): p. 268-75., http://www.ncbi.nlm.nih.gov/pubmed/21057964

599. Frenkel, S., Nir, I., Hendler, K., Lotem, M., Eid, A., Jurim, O., et.al. Long-term survival of uveal melanoma patients after surgery for liver metastases, Br J Ophthalmol, 2009. 93(8): p. 1042-6., http://www.ncbi.nlm.nih.gov/pubmed/19429579

600. Herman, P., Machado, M. A., Montagnini, A. L., D'Albuquerque, L. A., Saad, W. A., Machado, M. C., Selected patients with metastatic melanoma may benefit from liver resection, World J Surg, 2007. 31(1): p. 171-4., http://www.ncbi.nlm.nih.gov/pubmed/17171491

601. Mariani, P., Piperno-Neumann, S., Servois, V., Berry, M. G., Dorval, T., Plancher, C., et.al. Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie, Eur J Surg Oncol, 2009. 35(11): p. 1192-7., http://www.ncbi.nlm.nih.gov/pubmed/19329272

602. Rose, D. M., Essner, R., Hughes, T. M., Tang, P. C., Bilchik, A., Wanek, L. A., et.al. Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience, Arch Surg, 2001. 136(8): p. 950-5., http://www.ncbi.nlm.nih.gov/pubmed/11485537

603. Salmon, R. J., Levy, C., Plancher, C., Dorval, T., Desjardins, L., Leyvraz, S., et.al. Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy, Eur J Surg Oncol, 1998. 24(2): p. 127-30., http://www.ncbi.nlm.nih.gov/pubmed/9591028

604. Woon, W. W., Haghighi, K. S., Zuckerman, R. S., Morris, D. L., Liver resection and cryotherapy for metastatic melanoma, Int Surg, 2008. 93(5): p. 274-7., http://www.ncbi.nlm.nih.gov/pubmed/19943429

605. Hughes, M. S., Zager, J., Faries, M., Alexander, H. R., Royal, R. E., Wood, B., et.al. Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases, Ann Surg Oncol, 2016. 23(4): p. 1309-19.

606. Agarwala, S. S., Panikkar, R., Kirkwood, J. M., Phase I/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver, Melanoma Res, 2004. 14(3): p. 217-22., http://www.ncbi.nlm.nih.gov/pubmed/15179192

607. Ahrar, J., Gupta, S., Ensor, J., Ahrar, K., Madoff, D. C., Wallace, M. J., et.al. Response, survival, and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cutaneous melanoma, Cancer Invest, 2011. 29(1): p. 49-55., http://www.ncbi.nlm.nih.gov/pubmed/21166498

608. Alexander, H. R., Jr., Libutti, S. K., Pingpank, J. F., Steinberg, S. M., Bartlett, D. L., Helsabeck, C., et.al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver, Clinical cancer research : an official journal of the American Association for Cancer Research, 2003. 9(17): p. 6343-6349.

609. Becker, J. C., Terheyden, P., Kampgen, E., Wagner, S., Neumann, C., Schadendorf, D., et.al. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2, Br J Cancer, 2002. 87(8): p. 840-5., http://www.ncbi.nlm.nih.gov/pubmed/12373596

610. Fiorentini, G., Aliberti, C., Del Conte, A., Tilli, M., Rossi, S., Ballardini, P., et.al. Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study, In vivo (Athens, Greece), 2009. 23(1): p. 131-137.

611. Huppert, P. E., Fierlbeck, G., Pereira, P., Schanz, S., Duda, S. H., Wietholtz, H., et.al. Transarterial chemoembolization of liver metastases in patients with uveal melanoma, Eur J Radiol, 2010. 74(3): p. e38-44., http://www.ncbi.nlm.nih.gov/pubmed/19467811

612. Kennedy, A. S., Nutting, C., Jakobs, T., Cianni, R., Notarianni, E., Ofer, A., et.al. A first report of radioembolization for hepatic metastases from ocular melanoma, Cancer Invest, 2009. 27(6): p. 682-90., http://www.ncbi.nlm.nih.gov/pubmed/19219675

613. Khayat, D., Cour, V., Bizzari, J. P., Aigner, K., Borel, C., Cohen-Alloro, G., et.al. Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A phase II Study, Am J Clin Oncol, 1991. 14(5): p. 400-4., http://www.ncbi.nlm.nih.gov/pubmed/1951178

614. Melichar, B., Voboril, Z., Lojik, M., Krajina, A., Liver metastases from uveal melanoma: clinical experience of hepatic arterial infusion of cisplatin, vinblastine and dacarbazine, Hepatogastroenterology, 2009. 56(93): p. 1157-62., http://www.ncbi.nlm.nih.gov/pubmed/19760961

615. Patel, K., Sullivan, K., Berd, D., Mastrangelo, M. J., Shields, C. L., Shields, J. A., et.al. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study, Melanoma Res, 2005. 15(4): p. 297-304., http://www.ncbi.nlm.nih.gov/pubmed/16034309

616. Peters, S., Voelter, V., Zografos, L., Pampallona, S., Popescu, R., Gillet, M., et.al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients, Ann Oncol, 2006. 17(4): p. 578-83., http://www.ncbi.nlm.nih.gov/pubmed/16469752

617. Rizell, M., Mattson, J., Cahlin, C., Hafstrom, L., Lindner, P., Olausson, M., Isolated hepatic perfusion for liver metastases of malignant melanoma, Melanoma Res, 2008. 18(2): p. 120-6., http://www.ncbi.nlm.nih.gov/pubmed/18337648

618. Schuster, R., Lindner, M., Wacker, F., Krossin, M., Bechrakis, N., Foerster, M. H., et.al. Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome, Melanoma Res, 2010. 20(3): p. 191-6., http://www.ncbi.nlm.nih.gov/pubmed/20335820

619. Sharma, K. V., Gould, J. E., Harbour, J. W., Linette, G. P., Pilgram, T. K., Dayani, P. N., et.al. Hepatic arterial chemoembolization for management of metastatic melanoma, AJR Am J Roentgenol, 2008. 190(1): p. 99-104., http://www.ncbi.nlm.nih.gov/pubmed/18094299

620. Siegel, R., Hauschild, A., Kettelhack, C., Kahler, K. C., Bembenek, A., Schlag, P. M., Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma, Eur J Surg Oncol, 2007. 33(5): p. 627-32., http://www.ncbi.nlm.nih.gov/pubmed/17196362

621. Storm, F. K., Kaiser, L. R., Goodnight, J. E., Harrison, W. H., Elliott, R. S., Gomes, A. S., et.al. Thermochemotherapy for melanoma metastases in liver, Cancer, 1982. 49(6): p. 1243-1248.

622. Vogl, T., Eichler, K., Zangos, S., Herzog, C., Hammerstingl, R., Balzer, J., et.al. Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival, J Cancer Res Clin Oncol, 2007. 133(3): p. 177-84., http://www.ncbi.nlm.nih.gov/pubmed/17021903

623. Yamamoto, A., Chervoneva, I., Sullivan, K. L., Eschelman, D. J., Gonsalves, C. F., Mastrangelo, M. J., et.al. High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma, Radiology, 2009. 252(1): p. 290-298.

624. Edelhauser, G., Schicher, N., Berzaczy, D., Beitzke, D., Hoeller, C., Lammer, J., et.al. Fotemustine chemoembolization of hepatic metastases from uveal melanoma: a retrospective single-center analysis, AJR Am J Roentgenol, 2012. 199(6): p. 1387-92.

625. Devaux, S., Du Thanh, A., Gallix, B., Girard, C., Dereure, O., Guillot, B., Hepatic transarterial chemoembolization (HACE) with cisplatin in liver metastases from cutaneous melanoma: a prospective study of three patients, J Eur Acad Dermatol Venereol, 2013. 27(2): p. e261-2.

626. Farshid, P., Darvishi, A., Naguib, N., Bazrafshan, B., Paul, J., Mbalisike, E., et.al. Repetitive chemoembolization of hypovascular liver metastases from the most common primary sites, Future Oncol, 2013. 9(3): p. 419-26.

627. Klingenstein, A., Haug, A. R., Zech, C. J., Schaller, U. C., Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients, Cardiovasc Intervent Radiol, 2013. 36(1): p. 158-65.

628. Venturini, M., Pilla, L., Agostini, G., Cappio, S., Losio, C., Orsi, M., et.al. Transarterial chemoembolization with drug-eluting beads preloaded with irinotecan as a first-line approach in uveal melanoma liver metastases: tumor response and predictive value of diffusion-weighted MR imaging in five patients, J Vasc Interv Radiol, 2012. 23(7): p. 937-41.

629. Noter, S. L., Rothbarth, J., Pijl, M. E., Keunen, J. E., Hartgrink, H. H., Tijl, F. G., et.al. Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver, Melanoma Res, 2004. 14(1): p. 67-72., http://www.ncbi.nlm.nih.gov/pubmed/15091197

630. van Etten, B., de Wilt, J. H., Brunstein, F., Eggermont, A. M., Verhoef, C., Isolated hypoxic hepatic perfusion with melphalan in patients with irresectable ocular melanoma metastases, Eur J Surg Oncol, 2009. 35(5): p. 539-45., http://www.ncbi.nlm.nih.gov/pubmed/18760560

631. Cantore, M., Fiorentini, G., Aitini, E., Davitti, B., Cavazzini, G., Rabbi, C., et.al. Intra-arterial hepatic carboplatin-based chemotherapy for ocular melanoma metastatic to the liver. Report of a phase II study, Tumori, 1994. 80(1): p. 37-9., http://www.ncbi.nlm.nih.gov/pubmed/8191596

632. Egerer, G., Lehnert, T., Max, R., Naeher, H., Keilholz, U., Ho, A. D., Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: a single-center experience with seven patients, Int J Clin Oncol, 2001. 6(1): p. 25-8., http://www.ncbi.nlm.nih.gov/pubmed/11706523

633. Melichar, B., Dvorak, J., Jandik, P., Touskova, M., Solichova, D., Megancova, J., et.al. Intraarterial chemotherapy of malignant melanoma metastatic to the liver, Hepatogastroenterology, 2001. 48(42): p. 1711-5., http://www.ncbi.nlm.nih.gov/pubmed/11813606

634. Mornex, F., Thomas, L., Mohr, P., Hauschild, A., Delaunay, M. M., Lesimple, T., et.al. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma, Melanoma Res, 2003. 13(1): p. 97-103., http://www.ncbi.nlm.nih.gov/pubmed/12569292

635. Eigentler, T. K., Figl, A., Krex, D., Mohr, P., Mauch, C., Rass, K., et.al. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanomaJohn Wiley and Sons Inc. (P.O.Box 18667, Newark NJ 07191-8667, United States), 2011. p. 1697-1703.

636. Fife, K. M., Colman, M. H., Stevens, G. N., Firth, I. C., Moon, D., Shannon, K. F., et.al. Determinants of outcome in melanoma patients with cerebral metastases, J Clin Oncol, 2004. 22(7): p. 1293-300., http://www.ncbi.nlm.nih.gov/pubmed/15051777

637. Raizer, J. J., Hwu, W. J., Panageas, K. S., Wilton, A., Baldwin, D. E., Bailey, E., et.al. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features, Neuro Oncol, 2008. 10(2): p. 199-207., http://www.ncbi.nlm.nih.gov/pubmed/18287337

638. Wronski, M., Arbit, E., Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients, J Neurosurg, 2000. 93(1): p. 9-18., http://www.ncbi.nlm.nih.gov/pubmed/10883899

639. Staudt, M., Lasithiotakis, K., Leiter, U., Meier, F., Eigentler, T., Bamberg, M., et.al. Determinants of survival in patients with brain metastases from cutaneous melanoma, Br J Cancer, 2010. 102(8): p. 1213-8., http://www.ncbi.nlm.nih.gov/pubmed/20372154

640. Stevens, G., Firth, I., Coates, A., Cerebral metastases from malignant melanoma, Radiother Oncol, 1992. 23(3): p. 185-91., http://www.ncbi.nlm.nih.gov/pubmed/1574597

641. Goyal, S., Silk, A. W., Tian, S., Mehnert, J., Danish, S., Ranjan, S., et.al. Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review, JAMA Oncol, 2015. 1(5): p. 668-76., http://oncology.jamanetwork.com/data/Journals/ONCOLOGY/934279/crv150006.pdf

642. Knisely, J. P., Yu, J. B., Flanigan, J., Sznol, M., Kluger, H. M., Chiang, V. L., Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival, J Neurosurg, 2012. 117(2): p. 227-33.

643. Silk, A. W., Bassetti, M. F., West, B. T., Tsien, C. I., Lao, C. D., Ipilimumab and radiation therapy for melanoma brain metastases, Cancer Med, 2013. 2(6): p. 899-906.

644. Mathew, M., Tam, M., Ott, P. A., Pavlick, A. C., Rush, S. C., Donahue, B. R., et.al. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery, Melanoma Res, 2013. 23(3): p. 191-5.

645. Sambade, M. J., Peters, E. C., Thomas, N. E., Kaufmann, W. K., Kimple, R. J., Shields, J. M., Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032, Radiother Oncol, 2011. 98(3): p. 394-9.

646. Anker, C. J., Ribas, A., Grossmann, A. H., Chen, X., Narra, K. K., Akerley, W., et.al. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma, J Clin Oncol, 2013. 31(17): p. e283-7.

647. Peuvrel, L., Ruellan, A. L., Thillays, F., Quereux, G., Brocard, A., Saint-Jean, M., et.al. Severe radiotherapy-induced extracutaneous toxicity under vemurafenib, Eur J Dermatol, 2013. 23(6): p. 879-81.

648. Patel, K. R., Chowdhary, M., Switchenko, J. M., Kudchadkar, R., Lawson, D. H., Cassidy, R. J., et.al. BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis, Melanoma Res, 2016. 26(4): p. 387-94.

649. Ly, D., Bagshaw, H. P., Anker, C. J., Tward, J. D., Grossmann, K. F., Jensen, R. L., et.al. Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment, J Neurosurg, 2015. 123(2): p. 395-401.

650. Hecht, M., Zimmer, L., Loquai, C., Weishaupt, C., Gutzmer, R., Schuster, B., et.al. Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients, Ann Oncol, 2015. 26(6): p. 1238-44.

651. Anker, C. J., Grossmann, K. F., Atkins, M. B., Suneja, G., Tarhini, A. A., Kirkwood, J. M., Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG), Int J Radiat Oncol Biol Phys, 2016. 95(2): p. 632-46.

652. Agarwala, S. S., Kirkwood, J. M., Gore, M., Dreno, B., Thatcher, N., Czarnetski, B., et.al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study, J Clin Oncol, 2004. 22(11): p. 2101-7., http://www.ncbi.nlm.nih.gov/pubmed/15169796

653. Bafaloukos, D., Tsoutsos, D., Fountzilas, G., Linardou, H., Christodoulou, C., Kalofonos, H. P., et.al. The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma, Melanoma Res, 2004. 14(4): p. 289-94., http://www.ncbi.nlm.nih.gov/pubmed/15305160

654. Schadendorf, D., Hauschild, A., Ugurel, S., Thoelke, A., Egberts, F., Kreissig, M., et.al. Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study, Ann Oncol, 2006. 17(10): p. 1592-7., http://www.ncbi.nlm.nih.gov/pubmed/17005632

655. Amaravadi, R. K., Schuchter, L. M., McDermott, D. F., Kramer, A., Giles, L., Gramlich, K., et.al. Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases, Clin Cancer Res, 2009. 15(24): p. 7711-7718., http://www.ncbi.nlm.nih.gov/pubmed/19996224

656. Hwu, W. J., Lis, E., Menell, J. H., Panageas, K. S., Lamb, L. A., Merrell, J., et.al. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study, Cancer, 2005. 103(12): p. 2590-2597.

657. Larkin, J. M., Hughes, S. A., Beirne, D. A., Patel, P. M., Gibbens, I. M., Bate, S. C., et.al. A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma, Br J Cancer, 2007. 96(1): p. 44-8., http://www.ncbi.nlm.nih.gov/pubmed/17146474

658. Chang, J., Atkinson, H., A'Hern, R., Lorentzos, A., Gore, M. E., A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma, Eur J Cancer, 1994. 30A(14): p. 2093-5., http://www.ncbi.nlm.nih.gov/pubmed/7857710

659. Jacquillat, C., Khayat, D., Banzet, P., Weil, M., Fumoleau, P., Avril, M. F., et.al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases, Cancer, 1990. 66(9): p. 1873-8., http://www.ncbi.nlm.nih.gov/pubmed/2224783

660. Vestermark, L. W., Larsen, S., Lindelov, B., Bastholt, L., A phase II study of thalidomide in patients with brain metastases from malignant melanoma, Acta Oncol, 2008. 47(8): p. 1526-30., http://www.ncbi.nlm.nih.gov/pubmed/18607876

661. Long, G. V., Trefzer, U., Davies, M. A., Kefford, R. F., Ascierto, P. A., Chapman, P. B., et.al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial, Lancet Oncol, 2012. 13(11): p. 1087-95.

662. Dummer, R., Goldinger, S. M., Turtschi, C. P., Eggmann, N. B., Michielin, O., Mitchell, L., et.al. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study, Eur J Cancer, 2014. 50(3): p. 611-21.

663. Margolin, K., Ipilimumab in a Phase II trial of melanoma patients with brain metastases, Oncoimmunology, 2012. 1(7): p. 1197-1199.

664. Spagnolo, F., Picasso, V., Lambertini, M., Ottaviano, V., Dozin, B., Queirolo, P., Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review, Cancer Treat Rev, 2016. 45: p. 38-45.

665. Garbe, C., Paul, A., Kohler-Spath, H., Ellwanger, U., Stroebel, W., Schwarz, M., et.al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy, J Clin Oncol, 2003. 21(3): p. 520-9., http://www.ncbi.nlm.nih.gov/pubmed/12560444

666. Dicker, T. J., Kavanagh, G. M., Herd, R. M., Ahmad, T., McLaren, K. M., Chetty, U., et.al. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group, Br J Dermatol, 1999. 140(2): p. 249-54., http://www.ncbi.nlm.nih.gov/pubmed/10233217

667. Hohnheiser, A. M., Gefeller, O., Gohl, J., Schuler, G., Hohenberger, W., Merkel, S., Malignant melanoma of the skin: long-term follow-up and time to first recurrence, World J Surg, 2011. 35(3): p. 580-9., https://www.ncbi.nlm.nih.gov/pubmed/21125274

668. Poo-Hwu, W. J., Ariyan, S., Lamb, L., Papac, R., Zelterman, D., Hu, G. L., et.al. Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma, Cancer, 1999. 86(11): p. 2252-2258.

669. Rueth, N. M., Groth, S. S., Tuttle, T. M., Virnig, B. A., Al-Refaie, W. B., Habermann, E. B., Conditional survival after surgical treatment of melanoma: an analysis of the Surveillance, Epidemiology, and End Results database, Ann Surg Oncol, 2010. 17(6): p. 1662-8., http://www.ncbi.nlm.nih.gov/pubmed/20165985

670. Trotter, S. C., Sroa, N., Winkelmann, R. R., Olencki, T., Bechtel, M., A Global Review of Melanoma Follow-up Guidelines, J Clin Aesthet Dermatol, 2013. 6(9): p. 18-26.

671. Moloney, F. J., Guitera, P., Coates, E., Haass, N. K., Ho, K., Khoury, R., et.al. Detection of primary melanoma in individuals at extreme high risk: a prospective 5-year follow-up study, JAMA Dermatol, 2014. 150(8): p. 819-27.

672. Ferrone, C. R., Ben Porat, L., Panageas, K. S., Berwick, M., Halpern, A. C., Patel, A., et.al. Clinicopathological features of and risk factors for multiple primary melanomas, Jama, 2005. 294(13): p. 1647-54.

673. Rychetnik, L., McCaffery, K., Morton, R. L., Thompson, J. F., Menzies, S. W., Irwig, L., Follow-up of early stage melanoma: specialist clinician perspectives on the functions of follow-up and implications for extending follow-up intervals, J Surg Oncol, 2013. 107(5): p. 463-8.

674. Mitchell, J., Callaghan, P., Street, J., Neuhaus, S., Bessen, T., The experience of melanoma follow-up care: an online survey of patients in australia, J Skin Cancer, 2014. 2014: p. 429149.

675. Baughan, C. A., Hall, V. L., Leppard, B. J., Perkins, P. J., Follow-up in stage I cutaneous malignant melanoma: an audit, Clin Oncol (R Coll Radiol), 1993. 5(3): p. 174-80., http://www.ncbi.nlm.nih.gov/pubmed/8347541

676. Coit, D. G., Thompson, J. A., Algazi, A., Andtbacka, R., Bichakjian, C. K., Carson, W. E., 3rd, et.al. NCCN Guidelines Insights: Melanoma, Version 3.2016, J Natl Compr Canc Netw, 2016. 14(8): p. 945-58.

677. Dummer, R., Hauschild, A., Guggenheim, M., Jost, L., Pentheroudakis, G., Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 2010. 21 Suppl 5: p. v194-7.

678. Bichakjian, C. K., Halpern, A. C., Johnson, T. M., Foote Hood, A., Grichnik, J. M., Swetter, S. M., et.al. Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology, J Am Acad Dermatol, 2011. 65(5): p. 1032-47., http://ac.els-cdn.com/S0190962211005548/1-s2.0-S0190962211005548-main.pdf?_tid=f288a60e-5c78-11e5-9c92-00000aab0f6c&acdnat=1442411204_8d7d4566d30e7dc862e4abbb1ded83cf

679. S, a, g, a, ,, , et.al. Systemic administration of a novel immune-stimulatory pseudovirion suppresses lung metastatic melanoma by regionally enhancing IFN-gamma production, 2013., https://www.ncbi.nlm.nih.gov/pubmed/23251005

680. Francken, A. B., Bastiaannet, E., Hoekstra, H. J., Follow-up in patients with localised primary cutaneous melanoma, Lancet Oncol, 2005. 6(8): p. 608-21., http://www.ncbi.nlm.nih.gov/pubmed/16054572

681. Johnson, T. M., Hamilton, T., Lowe, L., Multiple primary melanomas, J Am Acad Dermatol, 1998. 39(3): p. 422-7., http://www.ncbi.nlm.nih.gov/pubmed/9738776

682. Kang, S., Barnhill, R. L., Mihm, M. C., Jr., Sober, A. J., Multiple primary cutaneous melanomas, Cancer, 1992. 70(7): p. 1911-1916.

683. Stucky, C. C., Gray, R. J., Dueck, A. C., Wasif, N., Laman, S. D., Sekulic, A., et.al. Risk factors associated with local and in-transit recurrence of cutaneous melanoma, Am J Surg, 2010. 200(6): p. 770-4; discussion 774-5., http://www.ncbi.nlm.nih.gov/pubmed/21146019

684. Jones, E. L., Jones, T. S., Pearlman, N. W., Gao, D., Stovall, R., Gajdos, C., et.al. Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result, JAMA Surg, 2013. 148(5): p. 456-61.

685. Maroti, M., Ulff, E., Lyth, J., Falkmer, U., A prospective population-based study, aiming to support decision-making in a follow-up programme for patients with cutaneous malignant melanoma, based on patterns of recurrence, Eur J Dermatol, 2016. 26(6): p. 586-591.

686. E, l, s, a, s, s, et.al. Antigen-specific CD4 T cells are induced after intravesical BCG-instillation therapy in patients with bladder cancer and show similar cytokine profiles as in active tuberculosis., 2013., https://www.ncbi.nlm.nih.gov/pubmed/24039703

687. Brobeil, A., Rapaport, D., Wells, K., Cruse, C. W., Glass, F., Fenske, N., et.al. Multiple primary melanomas: implications for screening and follow-up programs for melanoma, Ann Surg Oncol, 1997. 4(1): p. 19-23., http://www.ncbi.nlm.nih.gov/pubmed/8985513

688. Francken, A. B., Shaw, H. M., Accortt, N. A., Soong, S. J., Hoekstra, H. J., Thompson, J. F., Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines, Ann Surg Oncol, 2007. 14(6): p. 1924-33., http://www.ncbi.nlm.nih.gov/pubmed/17357855

689. Fusi, S., Ariyan, S., Sternlicht, A., Data on first recurrence after treatment for malignant melanoma in a large patient population, Plast Reconstr Surg, 1993. 91(1): p. 94-8., http://www.ncbi.nlm.nih.gov/pubmed/8416544

690. Kelly, J. W., Blois, M. S., Sagebiel, R. W., Frequency and duration of patient follow-up after treatment of a primary malignant melanoma, J Am Acad Dermatol, 1985. 13(5 Pt 1): p. 756-60., http://www.ncbi.nlm.nih.gov/pubmed/4078070

691. Martini, L., Brandani, P., Chiarugi, C., Reali, U. M., First recurrence analysis of 840 cutaneous melanomas: a proposal for a follow-up schedule, Tumori, 1994. 80(3): p. 188-197.

692. Zogakis, T. G., Essner, R., Wang, H. J., Foshag, L. J., Morton, D. L., Natural history of melanoma in 773 patients with tumor-negative sentinel lymph nodes, Ann Surg Oncol, 2007. 14(5): p. 1604-11., http://www.ncbi.nlm.nih.gov/pubmed/17333418

693. Romano, E., Scordo, M., Dusza, S. W., Coit, D. G., Chapman, P. B., Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines, J Clin Oncol, 2010. 28(18): p. 3042-7., http://www.ncbi.nlm.nih.gov/pubmed/20479405

694. Goggins, W. B., Tsao, H., A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors, Cancer, 2003. 97(3): p. 639-643.

695. Dancey, A., Rayatt, S., Courthold, J., Roberts, J., Views of UK melanoma patients on routine follow-up care, Br J Plast Surg, 2005. 58(2): p. 245-50., http://www.ncbi.nlm.nih.gov/pubmed/15710122

696. Murchie, P., Nicolson, M. C., Hannaford, P. C., Raja, E. A., Lee, A. J., Campbell, N. C., Patient satisfaction with GP-led melanoma follow-up: a randomised controlled trial, Br J Cancer, 2010. 102(10): p. 1447-55., http://www.ncbi.nlm.nih.gov/pubmed/20461089

697. Livingstone, E., Krajewski, C., Eigentler, T. K., Windemuth-Kieselbach, C., Benson, S., Elsenbruch, S., et.al. Prospective evaluation of follow-up in melanoma patients in Germany - results of a multicentre and longitudinal study, Eur J Cancer, 2015. 51(5): p. 653-67.

698. Petrella T, Verma S, Spithoff K, Quirt I, McCready D, Melanoma Disease Site Group,, Systemic Adjuvant Therapy for Patients at High Risk for Recurrent Melanoma: Updated Guideline Recommendations 2009, 2009.

699. Francken, A. B., Thompson, J. F., Bastiaannet, E., Hoekstra, H. J., [Detection of the first recurrence in patients with melanoma: three quarters by the patient, one quarter during outpatient follow-up], Ned Tijdschr Geneeskd, 2008. 152(10): p. 557-62., http://www.ncbi.nlm.nih.gov/pubmed/18402322

700. Podlipnik, S., Carrera, C., Sanchez, M., Arguis, P., Olondo, M. L., Vilana, R., et.al. Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: A prospective cohort study, J Am Acad Dermatol, 2016. 75(3): p. 516-24.

701. NICE, Improving Outcomes for People with Skin Tumours including MelanomaNICE, The Manual. National Institute for Health and Clinical Excellence, 2006.

702. Watts, C. G., Dieng, M., Morton, R. L., Mann, G. J., Menzies, S. W., Cust, A. E., Clinical practice guidelines for identification, screening and follow-up of individuals at high risk of primary cutaneous melanoma: a systematic review, Br J Dermatol, 2015. 172(1): p. 33-47.

703. Idorn, L. W., Datta, P., Heydenreich, J., Philipsen, P. A., Wulf, H. C., A 3-year follow-up of sun behavior in patients with cutaneous malignant melanoma, JAMA Dermatol, 2014. 150(2): p. 163-8., http://archderm.jamanetwork.com/data/Journals/DERM/929764/doi130032.pdf

704. M, u, r, c, h, i, et.al. Designing an integrated follow-up programme for people treated for cutaneous malignant melanoma: a practical application of the MRC framework for the design and evaluation of complex interventions to improve health, 2007., https://www.ncbi.nlm.nih.gov/pubmed/17449893

705. Scally, C. P., Wong, S. L., Intensity of follow-up after melanoma surgery, Ann Surg Oncol, 2014. 21(3): p. 752-7.

706. McCarthy, W. H., Shaw, H. M., Thompson, J. F., Milton, G. W., Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study, Surg Gynecol Obstet, 1988. 166(6): p. 497-502., http://www.ncbi.nlm.nih.gov/pubmed/3375961

707. Hengge, U. R., Wallerand, A., Stutzki, A., Kockel, N., Cost-effectiveness of reduced follow-up in malignant melanoma, J Dtsch Dermatol Ges, 2007. 5(10): p. 898-907., http://www.ncbi.nlm.nih.gov/pubmed/17910672

708. Leiter, U., Marghoob, A. A., Lasithiotakis, K., Eigentler, T. K., Meier, F., Meisner, C., et.al. Costs of the detection of metastases and follow-up examinations in cutaneous melanoma, Melanoma Research, 2009. 19(1): p. 50-57.

709. Basseres, N., Grob, J. J., Richard, M. A., Thirion, X., Zarour, H., Noe, C., et.al. Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France, Dermatology, 1995. 191(3): p. 199-203., http://www.ncbi.nlm.nih.gov/pubmed/8534937

710. Turner, R. M., Bell, K. J., Morton, R. L., Hayen, A., Francken, A. B., Howard, K., et.al. Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma, J Clin Oncol, 2011. 29(35): p. 4641-6., http://www.ncbi.nlm.nih.gov/pubmed/22067399

711. Leiter, U., Buettner, P., Eigentler, T., Forschner, A., Meier, F., Garbe, C., Follow-up of cutaneous melanoma: Stage-dependent hazard rates of recurrence and coupled melanoma, Journal Der Deutschen Dermatologischen Gesellschaft, 2009. 7: p. 166-167.

712. Rutkowski, P., Lugowska, I., Follow-up in melanoma patients, Memo, 2014. 7(2): p. 83-86.

713. Wevers, K. P., Hoekstra-Weebers, J. E., Speijers, M. J., Bergman, W., Gruis, N. A., Hoekstra, H. J., Cutaneous melanoma: medical specialists' opinions on follow-up and sentinel lymph node biopsy, Eur J Surg Oncol, 2014. 40(10): p. 1276-83.

714. Salama, A. K., de Rosa, N., Scheri, R. P., Pruitt, S. K., Herndon, J. E., 2nd, Marcello, J., et.al. Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy, PLoS One, 2013. 8(3): p. e57665.

715. Husson, O., Holterhues, C., Mols, F., Nijsten, T., van de Poll-Franse, L. V., Melanoma survivors are dissatisfied with perceived information about their diagnosis, treatment and follow-up care, Br J Dermatol, 2010. 163(4): p. 879-81., http://www.ncbi.nlm.nih.gov/pubmed/20854404

716. Johnson, R. C., Fenn, N. J., Horgan, K., Mansel, R. E., Follow-up of patients with a thin melanoma, Br J Surg, 1999. 86(5): p. 619-21., http://www.ncbi.nlm.nih.gov/pubmed/10361181

717. DiFronzo, L. A., Wanek, L. A., Elashoff, R., Morton, D. L., Increased incidence of second primary melanoma in patients with a previous cutaneous melanoma, Ann Surg Oncol, 1999. 6(7): p. 705-11., http://www.ncbi.nlm.nih.gov/pubmed/10560858

718. Voit, C., Mayer, T., Kron, M., Schoengen, A., Sterry, W., Weber, L., et.al. Efficacy of ultrasound B-scan compared with physical examination in follow-up of melanoma patients, Cancer, 2001. 91(12): p. 2409-2416.

719. Egberts, F., Hitschler, W. N., Weichenthal, M., Hauschild, A., Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse, Melanoma Res, 2009. 19(1): p. 31-5., http://www.ncbi.nlm.nih.gov/pubmed/19104452

720. Schlagenhauff, B., Schittek, B., Ellwanger, U., Stroebel, W., Blum, A., Schwarz, M., et.al. Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of melanoma recurrence?, Melanoma research, 2000. 10(5): p. 451-459.

721. Brown, R. E., Stromberg, A. J., Hagendoorn, L. J., Hulsewede, D. Y., Ross, M. I., Noyes, R. D., et.al. Surveillance after surgical treatment of melanoma: futility of routine chest radiography, Surgery, 2010. 148(4): p. 711-6; discussion 716-7.

722. Morton, R. L., Craig, J. C., Thompson, J. F., The role of surveillance chest X-rays in the follow-up of high-risk melanoma patients, Ann Surg Oncol, 2009. 16(3): p. 571-7., http://www.ncbi.nlm.nih.gov/pubmed/19030934

723. Cromwell, K. D., Ross, M. I., Xing, Y., Gershenwald, J. E., Royal, R. E., Lucci, A., et.al. Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review, Melanoma Res, 2012. 22(5): p. 376-85.

724. Kaufmann, P. M., Crone-Munzebrock, W., Tumor follow-up using sonography and computed tomography in the abdominal region of patients with malignant melanoma], Aktuelle Radiologie, 1992. 2(2): p. 81-85.

725. Rinne, D., Baum, R. P., Hor, G., Kaufmann, R., Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients, Cancer, 1998. 82(9): p. 1664-1671.

726. DeRose, E. R., Pleet, A., Wang, W., Seery, V. J., Lee, M. Y., Renzi, S., et.al. Utility of 3-year torso computed tomography and head imaging in asymptomatic patients with high-risk melanoma, Melanoma Res, 2011. 21(4): p. 364-9., http://www.ncbi.nlm.nih.gov/pubmed/21540750

727. Hausmann, D., Jochum, S., Utikal, J., Hoffmann, R. C., Zechmann, C., Neff, K. W., et.al. Comparison of the diagnostic accuracy of whole-body MRI and whole-body CT in stage III/IV malignant melanomaBlackwell Publishing Ltd (9600 Garsington Road, Oxford OX4 2XG, United Kingdom), 2011. p. 212-222., http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed10&NEWS=N&AN=2011123422

728. S, t, r, o, b, e, et.al. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases., 2007., https://www.ncbi.nlm.nih.gov/pubmed/17641374

729. Hausmann, D., Jochum, S., Utikal, J., Hoffmann, R. C., Zechmann, C., Neff, K. W., et.al. Comparison of the diagnostic accuracy of whole-body MRI and whole-body CT in stage III/IV malignant melanoma, J Dtsch Dermatol Ges, 2011. 9(3): p. 212-22., http://www.ncbi.nlm.nih.gov/pubmed/21352483

730. Kersey, P.A.., et al., The value of staging and serial follow-up investigations in patients with completely resected, primary, cutaneous malignant melanoma, 1985., https://www.ncbi.nlm.nih.gov/pubmed/4027532

731. Leiter, Ulrike, Stroebel, Waltraud, Sozialmedizinische Maßnahmen nach Melanomdiagnose, in Management des Melanoms, 2006, Springer Berlin Heidelberg: Berlin, Heidelberg. p. 401-404., http://dx.doi.org/10.1007/3-540-28988-7_37

732. Aster-Schenck, Ingrid, Berger, Dieter, Pottins, Ingrid, Voss, Ingrid-Beate, Anforderungsprofil für eine stationäre Einrichtung zur onkologischen Rehabilitation ErwachsenerDeutsche Rentenversicherung Bund, 2010.

733. Bilsing, B, Anger, B, Rehabilitation von Patienten mit malignem Melanom, HAUT, 2011. 5(3): p. 108-111.

734. Kurrat, W, Buhles, N, Reha-Maßnahmen bei Hauttumoren, Ästhetische Dermatologie, 2010. p. 8-14.

735. Blanchard, C. M., Courneya, K. S., Stein, K., American Cancer Society's, S. C. S., II, Cancer survivors' adherence to lifestyle behavior recommendations and associations with health-related quality of life: results from the American Cancer Society's SCS-II, J Clin Oncol, 2008. 26(13): p. 2198-204., http://www.ncbi.nlm.nih.gov/pubmed/18445845

736. Ugurel, Selma, Enk, Alexander, Skin cancer: Follow-Up, rehabilitation, palliative and supportive care, JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2008. 6(6): p. 492-499., http://dx.doi.org/10.1111/j.1610-0387.2008.06675.x

737. Carvajal, R. D., Spencer, S. A., Lydiatt, W., Mucosal melanoma: a clinically and biologically unique disease entity, J Natl Compr Canc Netw, 2012. 10(3): p. 345-56.

738. Gru, A. A., Becker, N., Dehner, L. P., Pfeifer, J. D., Mucosal melanoma: correlation of clinicopathologic, prognostic, and molecular features, Melanoma Res, 2014. 24(4): p. 360-70.

739. Casiraghi, O., Lefevre, M., [Undifferentiated malignant round cell tumors of the sinonasal tract and nasopharynx], Ann Pathol, 2009. 29(4): p. 296-312.

740. Gondak, R. O., da Silva-Jorge, R., Jorge, J., Lopes, M. A., Vargas, P. A., Oral pigmented lesions: Clinicopathologic features and review of the literature, Med Oral Patol Oral Cir Bucal, 2012. 17(6): p. e919-24.

741. Song, H., Wu, Y., Ren, G., Guo, W., Wang, L., Prognostic factors of oral mucosal melanoma: histopathological analysis in a retrospective cohort of 82 cases, Histopathology, 2015. 67(4): p. 548-56.

742. Thompson, L. D., Wieneke, J. A., Miettinen, M., Sinonasal tract and nasopharyngeal melanomas: a clinicopathologic study of 115 cases with a proposed staging system, Am J Surg Pathol, 2003. 27(5): p. 594-611.

743. Chung, A. F., Woodruff, J. M., Lewis, J. L., Jr., Malignant melanoma of the vulva: A report of 44 cases, Obstet Gynecol, 1975. 45(6): p. 638-46.

744. Podratz, K. C., Gaffey, T. A., Symmonds, R. E., Johansen, K. L., O'Brien, P. C., Melanoma of the vulva: an update, Gynecol Oncol, 1983. 16(2): p. 153-68.

745. Zambo, K., Szabo, Z., Schmidt, E., Koppan, M., Repasy, I., Bodis, J., Is the clinical staging system a good choice in the staging of vulvar malignancies?, Eur J Nucl Med Mol Imaging, 2007. 34(11): p. 1878-9; author reply 1880.

746. Tcheung, W. J., Selim, M. A., Herndon, J. E., 2nd, Abernethy, A. P., Nelson, K. C., Clinicopathologic study of 85 cases of melanoma of the female genitalia, J Am Acad Dermatol, 2012. 67(4): p. 598-605.

747. Heinzelmann-Schwarz, V. A., Nixdorf, S., Valadan, M., Diczbalis, M., Olivier, J., Otton, G., et.al. A clinicopathological review of 33 patients with vulvar melanoma identifies c-KIT as a prognostic marker, Int J Mol Med, 2014. 33(4): p. 784-94.

748. Buchanan, D. J., Schlaerth, J., Kurosaki, T., Primary vaginal melanoma: thirteen-year disease-free survival after wide local excision and review of recent literature, Am J Obstet Gynecol, 1998. 178(6): p. 1177-84.

749. Petru, E., Nagele, F., Czerwenka, K., Graf, A. H., Lax, S., Bauer, M., et.al. Primary malignant melanoma of the vagina: long-term remission following radiation therapy, Gynecol Oncol, 1998. 70(1): p. 23-6.

750. Leitao, M. M., Jr., Cheng, X., Hamilton, A. L., Siddiqui, N. A., Jurgenliemk-Schulz, I., Mahner, S., et.al. Gynecologic Cancer InterGroup (GCIG) consensus review for vulvovaginal melanomas, Int J Gynecol Cancer, 2014. 24(9 Suppl 3): p. S117-22.

751. Tacastacas, J. D., Bray, J., Cohen, Y. K., Arbesman, J., Kim, J., Koon, H. B., et.al. Update on primary mucosal melanoma, J Am Acad Dermatol, 2014. 71(2): p. 366-75., http://www.ncbi.nlm.nih.gov/pubmed/24815565

752. Samstein, R. M., Carvajal, R. D., Postow, M. A., Callahan, M. K., Shoushtari, A. N., Patel, S. G., et.al. Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response, Head Neck, 2016. 38(9): p. 1310-7., http://www.ncbi.nlm.nih.gov/pubmed/27043023

753. Frakes, J. M., Strom, T. J., Naghavi, A. O., Trotti, A., Rao, N. G., McCaffrey, J. C., et.al. Outcomes of mucosal melanoma of the head and neck, J Med Imaging Radiat Oncol, 2016. 60(2): p. 268-73., http://www.ncbi.nlm.nih.gov/pubmed/26597431

754. Sun, C. Z., Chen, Y. F., Jiang, Y. E., Hu, Z. D., Yang, A. K., Song, M., Treatment and prognosis of oral mucosal melanoma, Oral Oncol, 2012. 48(7): p. 647-52., http://www.ncbi.nlm.nih.gov/pubmed/22349277

755. Luna-Ortiz, K., Aguilar-Romero, M., Villavicencio-Valencia, V., Zepeda-Castilla, E., Vidrio-Morgado, H., Peteuil, N., et.al. Comparative study between two different staging systems (AJCC TNM VS BALLANTYNE'S) for mucosal melanomas of the Head & Neck, Med Oral Patol Oral Cir Bucal, 2016. 21(4): p. e425-30., http://www.ncbi.nlm.nih.gov/pubmed/27031071

756. Pfister, D. G., Ang, K. K., Brizel, D. M., Burtness, B., Cmelak, A. J., Colevas, A. D., et.al. Mucosal melanoma of the head and neck, J Natl Compr Canc Netw, 2012. 10(3): p. 320-38., http://www.ncbi.nlm.nih.gov/pubmed/22393194

757. Moreno, M. A., Roberts, D. B., Kupferman, M. E., DeMonte, F., El-Naggar, A. K., Williams, M., et.al. Mucosal melanoma of the nose and paranasal sinuses, a contemporary experience from the M. D. Anderson Cancer Center, Cancer, 2010. 116(9): p. 2215-23., http://www.ncbi.nlm.nih.gov/pubmed/20198705

758. Lopez, F., Rodrigo, J. P., Cardesa, A., Triantafyllou, A., Devaney, K. O., Mendenhall, W. M., et.al. Update on primary head and neck mucosal melanoma, Head Neck, 2016. 38(1): p. 147-55., http://www.ncbi.nlm.nih.gov/pubmed/25242350

759. Houette, A., Gilain, L., Mulliez, A., Mom, T., Saroul, N., Prognostic value of two tumour staging classifications in patients with sinonasal mucosal melanoma, Eur Ann Otorhinolaryngol Head Neck Dis, 2016. 133(5): p. 313-317., http://www.ncbi.nlm.nih.gov/pubmed/27291483

760. Wechter, M. E., Gruber, S. B., Haefner, H. K., Lowe, L., Schwartz, J. L., Reynolds, K. R., et.al. Vulvar melanoma: a report of 20 cases and review of the literature, J Am Acad Dermatol, 2004. 50(4): p. 554-62.

761. Chae, W. Y., Lee, J. L., Cho, D. H., Yu, C. S., Roh, J., Kim, J. C., Preliminary Suggestion about Staging of Anorectal Malignant Melanoma May Be Used to Predict Prognosis, Cancer Res Treat, 2016. 48(1): p. 240-9., http://www.ncbi.nlm.nih.gov/pubmed/25761474

762. Lutzky, J., Bauer, J., Bastian, B. C., Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation, Pigment Cell Melanoma Res, 2008. 21(4): p. 492-3., http://www.ncbi.nlm.nih.gov/pubmed/18510589

763. Hodi, F. S., Friedlander, P., Corless, C. L., Heinrich, M. C., Mac Rae, S., Kruse, A., et.al. Major response to imatinib mesylate in KIT-mutated melanoma, J Clin Oncol, 2008. 26(12): p. 2046-51., http://www.ncbi.nlm.nih.gov/pubmed/18421059

764. Handolias, D., Hamilton, A. L., Salemi, R., Tan, A., Moodie, K., Kerr, L., et.al. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT, Br J Cancer, 2010. 102(8): p. 1219-23., http://www.ncbi.nlm.nih.gov/pubmed/20372153

765. Cullinane, C., Natoli, A., Hui, Y., Conus, N., Jackson, S., Bruggen, J., et.al. Preclinical evaluation of nilotinib efficacy in an imatinib-resistant KIT-driven tumor model, Mol Cancer Ther, 2010. 9(5): p. 1461-8., http://www.ncbi.nlm.nih.gov/pubmed/20442311

766. Carvajal, R. D., Lawrence, D. P., Weber, J. S., Gajewski, T. F., Gonzalez, R., Lutzky, J., et.al. Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition, Clin Cancer Res, 2015. 21(10): p. 2289-96.

767. Lee, S. J., Kim, T. M., Kim, Y. J., Jang, K. T., Lee, H. J., Lee, S. N., et.al. Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06), Oncologist, 2015. 20(11): p. 1312-9., http://www.ncbi.nlm.nih.gov/pubmed/26424760

768. Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., et.al. Distinct sets of genetic alterations in melanoma, N Engl J Med, 2005. 353(20): p. 2135-47., http://www.ncbi.nlm.nih.gov/pubmed/16291983

769. Gore, M. R., Zanation, A. M., Survival in Sinonasal Melanoma: A Meta-analysis, J Neurol Surg B Skull Base, 2012. 73(3): p. 157-62., http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424013/pdf/jnlsb73157.pdf

770. Ciarrocchi, A., Pietroletti, R., Carlei, F., Amicucci, G., Extensive surgery and lymphadenectomy do not improve survival in primary melanoma of the anorectum: results from analysis of a large database (SEER), Colorectal Dis, 2016., http://www.ncbi.nlm.nih.gov/pubmed/27317493

771. Lund, V. J., Stammberger, H., Nicolai, P., Castelnuovo, P., Beal, T., Beham, A., et.al. European position paper on endoscopic management of tumours of the nose, paranasal sinuses and skull base, Rhinol Suppl, 2010. p. 1-143., http://www.ncbi.nlm.nih.gov/pubmed/20502772

772. Yen, C. I., Chen, H. H., Chiang, S. F., Yeh, C. Y., Chen, J. S., Hsieh, P. S., et.al. Anorectal melanoma: review of 22 consecutive cases, Hepatogastroenterology, 2013. 60(121): p. 89-93., http://www.ncbi.nlm.nih.gov/pubmed/22829553

773. Ferraioli, D., Lamblin, G., Mathevet, P., Hetu, J., Berakdar, I., Beurrier, F., et.al. Genital melanoma: prognosis factors and treatment modality, Arch Gynecol Obstet, 2016. 294(5): p. 1037-1045.

774. van Geel, A. N., den Bakker, M. A., Kirkels, W., Horenblas, S., Kroon, B. B., de Wilt, J. H., et.al. Prognosis of primary mucosal penile melanoma: a series of 19 Dutch patients and 47 patients from the literature, Urology, 2007. 70(1): p. 143-7., http://www.ncbi.nlm.nih.gov/pubmed/17656225

775. Sanchez-Ortiz, R., Huang, S. F., Tamboli, P., Prieto, V. G., Hester, G., Pettaway, C. A., Melanoma of the penis, scrotum and male urethra: a 40-year single institution experience, J Urol, 2005. 173(6): p. 1958-65., http://www.ncbi.nlm.nih.gov/pubmed/15879790

776. Penel, N., Mallet, Y., Mirabel, X., Van, J. T., Lefebvre, J. L., Primary mucosal melanoma of head and neck: prognostic value of clear margins, Laryngoscope, 2006. 116(6): p. 993-5.

777. Krengli, M., Masini, L., Kaanders, J. H., Maingon, P., Oei, S. B., Zouhair, A., et.al. Radiotherapy in the treatment of mucosal melanoma of the upper aerodigestive tract: analysis of 74 cases. A Rare Cancer Network study, Int J Radiat Oncol Biol Phys, 2006. 65(3): p. 751-9., http://www.ncbi.nlm.nih.gov/pubmed/16647223

778. Medina, J. E., Ferlito, A., Pellitteri, P. K., Shaha, A. R., Khafif, A., Devaney, K. O., et.al. Current management of mucosal melanoma of the head and neck, J Surg Oncol, 2003. 83(2): p. 116-22., http://www.ncbi.nlm.nih.gov/pubmed/12772206

779. Starek, I., Koranda, P., Benes, P., Sentinel lymph node biopsy: A new perspective in head and neck mucosal melanoma?, Melanoma Res, 2006. 16(5): p. 423-7., http://www.ncbi.nlm.nih.gov/pubmed/17013091

780. Kobayashi, K., Ramirez, P. T., Kim, E. E., Levenback, C. F., Rohren, E. M., Frumovitz, M., et.al. Sentinel node mapping in vulvovaginal melanoma using SPECT/CT lymphoscintigraphy, Clin Nucl Med, 2009. 34(12): p. 859-61., http://www.ncbi.nlm.nih.gov/pubmed/20139817

781. Meleti, M., Leemans, C. R., de Bree, R., Vescovi, P., Sesenna, E., van der Waal, I., Head and neck mucosal melanoma: experience with 42 patients, with emphasis on the role of postoperative radiotherapy, Head Neck, 2008. 30(12): p. 1543-51., https://www.ncbi.nlm.nih.gov/pubmed/18704960

782. Benlyazid, A., Thariat, J., Temam, S., Malard, O., Florescu, C., Choussy, O., et.al. Postoperative radiotherapy in head and neck mucosal melanoma: a GETTEC study, Arch Otolaryngol Head Neck Surg, 2010. 136(12): p. 1219-25., https://www.ncbi.nlm.nih.gov/pubmed/21173371

783. Vandenhende, C., Leroy, X., Chevalier, D., Mortuaire, G., Sinonasal mucosal melanoma: retrospective survival study of 25 patients, J Laryngol Otol, 2012. 126(2): p. 147-51., https://www.ncbi.nlm.nih.gov/pubmed/22018280

784. Nakashima, J. P., Viegas, C. M., Fassizoli, A. L., Rodrigues, M., Chamon, L. A., Silva, J. H., et.al. Postoperative adjuvant radiation therapy in the treatment of primary head and neck mucosal melanomas, ORL J Otorhinolaryngol Relat Spec, 2008. 70(6): p. 344-51., https://www.ncbi.nlm.nih.gov/pubmed/18984969

785. Owens, J. M., Roberts, D. B., Myers, J. N., The role of postoperative adjuvant radiation therapy in the treatment of mucosal melanomas of the head and neck region, Arch Otolaryngol Head Neck Surg, 2003. 129(8): p. 864-8., https://www.ncbi.nlm.nih.gov/pubmed/12925346

786. Saigal, K., Weed, D. T., Reis, I. M., Markoe, A. M., Wolfson, A. H., Nguyen-Sperry, J., Mucosal melanomas of the head and neck: the role of postoperative radiation therapy, ISRN Oncol, 2012. 2012: p. 785131., http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3345242/pdf/ISRN.ONCOLOGY2012-785131.pdf

787. Temam, S., Mamelle, G., Marandas, P., Wibault, P., Avril, M. F., Janot, F., et.al. Postoperative radiotherapy for primary mucosal melanoma of the head and neck, Cancer, 2005. 103(2): p. 313-9., https://www.ncbi.nlm.nih.gov/pubmed/15578718

788. Li, W., Yu, Y., Wang, H., Yan, A., Jiang, X., Evaluation of the prognostic impact of postoperative adjuvant radiotherapy on head and neck mucosal melanoma: a meta-analysis, BMC Cancer, 2015. 15: p. 758., https://www.ncbi.nlm.nih.gov/pubmed/26490539

789. Wushou, A., Hou, J., Zhao, Y. J., Miao, X. C., Postoperative adjuvant radiotherapy improves loco-regional recurrence of head and neck mucosal melanoma, J Craniomaxillofac Surg, 2015. 43(4): p. 553-8., https://www.ncbi.nlm.nih.gov/pubmed/25797388

790. Del Vecchio, M., Di Guardo, L., Ascierto, P. A., Grimaldi, A. M., Sileni, V. C., Pigozzo, J., et.al. Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma, Eur J Cancer, 2014. 50(1): p. 121-7., http://www.ncbi.nlm.nih.gov/pubmed/24100024

791. Postow, M. A., Luke, J. J., Bluth, M. J., Ramaiya, N., Panageas, K. S., Lawrence, D. P., et.al. Ipilimumab for patients with advanced mucosal melanoma, Oncologist, 2013. 18(6): p. 726-32., http://www.ncbi.nlm.nih.gov/pubmed/23716015

792. Shoushtari, A. N., Munhoz, R. R., Kuk, D., Ott, P. A., Johnson, D. B., Tsai, K. K., et.al. The efficacy of anti-PD-1 agents in acral and mucosal melanoma, Cancer, 2016. 122(21): p. 3354-3362., http://www.ncbi.nlm.nih.gov/pubmed/27533633

793. Zimmer, L., Eigentler, T. K., Kiecker, F., Simon, J., Utikal, J., Mohr, P., et.al. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma, J Transl Med, 2015. 13: p. 351., http://www.ncbi.nlm.nih.gov/pubmed/26541511

794. Ugurel, S., Hildenbrand, R., Zimpfer, A., La Rosee, P., Paschka, P., Sucker, A., et.al. Lack of clinical efficacy of imatinib in metastatic melanoma, Br J Cancer, 2005. 92(8): p. 1398-405., http://www.ncbi.nlm.nih.gov/pubmed/15846297

795. Wyman, K., Atkins, M. B., Prieto, V., Eton, O., McDermott, D. F., Hubbard, F., et.al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy, Cancer, 2006. 106(9): p. 2005-11., http://www.ncbi.nlm.nih.gov/pubmed/16565971

796. Kim, K. B., Eton, O., Davis, D. W., Frazier, M. L., McConkey, D. J., Diwan, A. H., et.al. Phase II trial of imatinib mesylate in patients with metastatic melanoma, Br J Cancer, 2008. 99(5): p. 734-40., http://www.ncbi.nlm.nih.gov/pubmed/18728664

797. Quintas-Cardama, A., Lazar, A. J., Woodman, S. E., Kim, K., Ross, M., Hwu, P., Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib, Nat Clin Pract Oncol, 2008. 5(12): p. 737-40., http://www.ncbi.nlm.nih.gov/pubmed/18936790

798. Woodman, S. E., Trent, J. C., Stemke-Hale, K., Lazar, A. J., Pricl, S., Pavan, G. M., et.al. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates, Mol Cancer Ther, 2009. 8(8): p. 2079-85., http://www.ncbi.nlm.nih.gov/pubmed/19671763

799. Bartell, H. L., Bedikian, A. Y., Papadopoulos, N. E., Dett, T. K., Ballo, M. T., Myers, J. N., et.al. Biochemotherapy in patients with advanced head and neck mucosal melanoma, Head Neck, 2008. 30(12): p. 1592-8., http://www.ncbi.nlm.nih.gov/pubmed/18798304

800. Harting, M. S., Kim, K. B., Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma, Melanoma Res, 2004. 14(6): p. 517-20., http://www.ncbi.nlm.nih.gov/pubmed/15577323

801. Kim, K. B., Sanguino, A. M., Hodges, C., Papadopoulos, N. E., Eton, O., Camacho, L. H., et.al. Biochemotherapy in patients with metastatic anorectal mucosal melanoma, Cancer, 2004. 100(7): p. 1478-83., http://www.ncbi.nlm.nih.gov/pubmed/15042682

802. Horneber, M., Büschel, G., Kaiser, G., Kappauf, H., Wilhelm, M., Gallmeier, W. M., Unkonventionelle Verfahren ‒ Chancen für die Arzt-Patient- Beziehung [Unconventional methods. Chances for the physician-patient relationship], Der Onkologe, 2003. 9(12): p. 1335-1342.

803. Dewey, A., Baughan, C., Dean, T., Higgins, B., Johnson, I., Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia, Cochrane Database Syst Rev, 2007. (1)(1): p. CD004597., http://www.ncbi.nlm.nih.gov/pubmed/17253515

804. Taixiang, W., Munro, A. J., Guanjian, L., Chinese medical herbs for chemotherapy side effects in colorectal cancer patients, Cochrane Database Syst Rev, 2005. (1)(1): p. CD004540., http://www.ncbi.nlm.nih.gov/pubmed/15674951

805. Zhang, M., Liu, X., Li, J., He, L., Tripathy, D., Chinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patients, Cochrane Database Syst Rev, 2007. (2)(2): p. CD004921., http://www.ncbi.nlm.nih.gov/pubmed/17443560

806. Cascinelli, N., Clemente, C., Bufalino, R., Baldini, M., Mascheroni, L., Zurrida, S., et.al. Perinodular injection of thymopentin (TP5) in cutaneous and subcutaneous metastases of melanoma, Melanoma Res, 1993. 3(6): p. 471-6., http://www.ncbi.nlm.nih.gov/pubmed/8161886

807. Cascinelli, N., Belli, F., Mascheroni, L., Lenisa, L., Clemente, C., Evaluation of clinical efficacy and tolerability of intravenous high dose thymopentin in advanced melanoma patients, Melanoma Res, 1998. 8(1): p. 83-9., http://www.ncbi.nlm.nih.gov/pubmed/9508382

808. Clemente, C., Belli, F., Mascheroni, L., Bufalino, R., Rao, S., Baldini, M. T., et.al. Biological activity and clinical efficacy of intravenous high-dose thymopentin in metastatic melanoma patients, Melanoma Res, 1996. 6(1): p. 63-9., http://www.ncbi.nlm.nih.gov/pubmed/8640072

809. Trevisan, G., Agolzer, A., [Thymopentin in the treatment of cutaneous melanoma], G Ital Dermatol Venereol, 1989. 124(5): p. 245-9., http://www.ncbi.nlm.nih.gov/pubmed/2695455

810. Ezzo, J. M., Richardson, M. A., Vickers, A., Allen, C., Dibble, S. L., Issell, B. F., et.al. Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting, Cochrane Database Syst Rev, 2006. (2)(2): p. CD002285., http://www.ncbi.nlm.nih.gov/pubmed/16625560

811. Kassab, S., Cummings, M., Berkovitz, S., van Haselen, R., Fisher, P., Homeopathic medicines for adverse effects of cancer treatments, Cochrane Database Syst Rev, 2009. (2)(2): p. CD004845., http://www.ncbi.nlm.nih.gov/pubmed/19370613

812. Weiger, W. A., Smith, M., Boon, H., Richardson, M. A., Kaptchuk, T. J., Eisenberg, D. M., Advising patients who seek complementary and alternative medical therapies for cancer, Ann Intern Med, 2002. 137(11): p. 889-903.

813. Cohen, L., Cohen, M. H., Kirkwood, C., Russell, N. C., Discussing complementary therapies in an oncology setting, J Soc Integr Oncol, 2007. 5(1): p. 18-24., http://www.ncbi.nlm.nih.gov/pubmed/17309810

814. Adler, S. R., Fosket, J. R., Disclosing complementary and alternative medicine use in the medical encounter - A qualitative study in women with breast cancer, Journal of Family Practice, 1999. 48(6): p. 453-458.

815. Montbriand, M. J., Abandoning biomedicine for alternate therapies: oncology patients' stories, Cancer Nurs, 1998. 21(1): p. 36-45., http://www.ncbi.nlm.nih.gov/pubmed/9494229

816. Tasaki, K., Maskarinec, G., Shumay, D. M., Tatsumura, Y., Kakai, H., Communication between physicians and cancer patients about complementary and alternative medicine: exploring patients' perspectives, Psychooncology, 2002. 11(3): p. 212-20., http://www.ncbi.nlm.nih.gov/pubmed/12112481

817. Cornish, D., Holterhues, C., van de Poll-Franse, L. V., Coebergh, J. W., Nijsten, T., A systematic review of health-related quality of life in cutaneous melanoma, Ann Oncol, 2009. 20 Suppl 6: p. vi51-8., http://www.ncbi.nlm.nih.gov/pubmed/19617298

818. Kasparian, N. A., McLoone, J. K., Butow, P. N., Psychological responses and coping strategies among patients with malignant melanoma: a systematic review of the literature, Arch Dermatol, 2009. 145(12): p. 1415-27., http://www.ncbi.nlm.nih.gov/pubmed/20026852

819. Augustin, M.; Zschocke, I.; Dieterle, W.; Schöpf, E.; Muthny, F, Bedarf und Motivation zu psychosozialen Interventionen bei Patienten mit malignen Hauttumoren, Zeitschrift für Hautkrankheiten, 1997. p. 333-338.

820. Blum, A., Blum, D., Stroebel, W., Rassner, G., Garbe, C., Hautzinger, M., [Psychosocial burden and subjective experience of melanoma patients in the ambulant follow-up], Psychother Psychosom Med Psychol, 2003. 53(6): p. 258-66., http://www.ncbi.nlm.nih.gov/pubmed/12813660

821. Brandberg, Y.; Bolund, C.; Sigurdardottir, V.; Sjoden, PO.; Sullivan, M, Anxiety and depressive symptoms at different stages of malignant melanoma, Psychooncology, 1992. p. 71-78.

822. Sollner, W., Zschocke, I., Augustin, M., [Melanoma patients: psychosocial stress, coping with illness and social support. A systematic review], Psychother Psychosom Med Psychol, 1998. 48(9-10): p. 338-48., http://www.ncbi.nlm.nih.gov/pubmed/9785963

823. Strittmatter, G., Mawick, R., Tilkorn, M., [Need for psychosocial management of facial and skin tumor patients], Psychother Psychosom Med Psychol, 1998. 48(9-10): p. 349-57., http://www.ncbi.nlm.nih.gov/pubmed/9785964

824. Trask, P. C., Paterson, A. G., Hayasaka, S., Dunn, R. L., Riba, M., Johnson, T., Psychosocial characteristics of individuals with non-stage IV melanoma, J Clin Oncol, 2001. 19(11): p. 2844-50., http://www.ncbi.nlm.nih.gov/pubmed/11387356

825. Sigurdardottir, V., Bolund, C., Brandberg, Y., Sullivan, M., The impact of generalized malignant melanoma on quality of life evaluated by the EORTC questionnaire technique, Qual Life Res, 1993. 2(3): p. 193-203., http://www.ncbi.nlm.nih.gov/pubmed/8401455

826. Rumpold, G., Augustin, M., Zschocke, I., Strittmatter, G., Sollner, W., [The validity of the Hornheide questionnaire for psychosocial support in skin tumor patients: a survey in an Austrian and German outpatient population with melanoma], Psychother Psychosom Med Psychol, 2001. 51(1): p. 25-33., http://www.ncbi.nlm.nih.gov/pubmed/11227322

827. Missiha, S. B., Solish, N., From, L., Characterizing anxiety in melanoma patients, J Cutan Med Surg, 2003. 7(6): p. 443-8., http://www.ncbi.nlm.nih.gov/pubmed/15926214

828. Brown, J. E., Brown, R. F., Miller, R. M., Dunn, S. M., King, M. T., Coates, A. S., et.al. Coping with metastatic melanoma: the last year of life, Psychooncology, 2000. 9(4): p. 283-92., http://www.ncbi.nlm.nih.gov/pubmed/10960926

829. Fawzy, F. I., Fawzy, N. W., Hyun, C. S., Elashoff, R., Guthrie, D., Fahey, J. L., et.al. Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later, Arch Gen Psychiatry, 1993. 50(9): p. 681-9., http://www.ncbi.nlm.nih.gov/pubmed/8357293

830. Hamama-Raz, Y., Solomon, Z., Schachter, J., Azizi, E., Objective and subjective stressors and the psychological adjustment of melanoma survivors, Psychooncology, 2007. 16(4): p. 287-94., http://www.ncbi.nlm.nih.gov/pubmed/16858669

831. Herschbach, P., Weis, J., Screeningverfahren in der Psychoonkologie - Testinstrumente zur Identifikation betreuungsbedürftiger KrebspatientenDeutsche Krebsgesellschaft, 2010., https://www.wpo-ev.de/wp-content/uploads/2023/07/Screening_broschuere.pdf

832. Cormier, J. N., Davidson, L., Xing, Y., Webster, K., Cella, D., Measuring quality of life in patients with melanoma: development of the FACT-melanoma subscale, J Support Oncol, 2005. 3(2): p. 139-45., http://www.ncbi.nlm.nih.gov/pubmed/15796446

833. Cormier, J. N., Askew, R. L., Assessment of patient-reported outcomes in patients with melanoma, Surg Oncol Clin N Am, 2011. 20(1): p. 201-13., http://www.ncbi.nlm.nih.gov/pubmed/21111967

834. Newton-Bishop, J. A., Nolan, C., Turner, F., McCabe, M., Boxer, C., Thomas, J. M., et.al. A quality-of-life study in high-risk (thickness > = or 2 mm) cutaneous melanoma patients in a randomized trial of 1-cm versus 3-cm surgical excision margins, J Investig Dermatol Symp Proc, 2004. 9(2): p. 152-9., http://www.ncbi.nlm.nih.gov/pubmed/15083783

835. Trask, P. C., Tellefsen, C., Espindle, D., Getter, C., Hsu, M. A., Psychometric validation of the cancer therapy satisfaction questionnaire, Value Health, 2008. 11(4): p. 669-79., http://www.ncbi.nlm.nih.gov/pubmed/18194397

836. Kirkwood, J. M., Bender, C., Agarwala, S., Tarhini, A., Shipe-Spotloe, J., Smelko, B., et.al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy, J Clin Oncol, 2002. 20(17): p. 3703-18., http://www.ncbi.nlm.nih.gov/pubmed/12202672

837. Brown, L. F., Kroenke, K., Cancer-related fatigue and its associations with depression and anxiety: a systematic review, Psychosomatics, 2009. 50(5): p. 440-7., http://www.ncbi.nlm.nih.gov/pubmed/19855028

838. Stone, P. C., Minton, O., Cancer-related fatigue, Eur J Cancer, 2008. 44(8): p. 1097-104., http://www.ncbi.nlm.nih.gov/pubmed/18381237

839. Hauschild, A., Gogas, H., Tarhini, A., Middleton, M. R., Testori, A., Dreno, B., et.al. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion, Cancer, 2008. 112(5): p. 982-94., http://www.ncbi.nlm.nih.gov/pubmed/18236459

840. Bender, C. M., Yasko, J. M., Kirkwood, J. M., Ryan, C., Dunbar-Jacob, J., Zullo, T., Cognitive function and quality of life in interferon therapy for melanoma, Clin Nurs Res, 2000. 9(3): p. 352-63., http://www.ncbi.nlm.nih.gov/pubmed/11276624

841. Chiarion-Sileni, V., Del Bianco, P., De Salvo, G. L., Lo Re, G., Romanini, A., Labianca, R., et.al. Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients, Eur J Cancer, 2003. 39(11): p. 1577-85., http://www.ncbi.nlm.nih.gov/pubmed/12855265

842. Noorda, E. M., van Kreij, R. H., Vrouenraets, B. C., Nieweg, O. E., Muller, M., Kroon, B. B., et.al. The health-related quality of life of long-term survivors of melanoma treated with isolated limb perfusion, Eur J Surg Oncol, 2007. 33(6): p. 776-82., http://www.ncbi.nlm.nih.gov/pubmed/17300914

843. Beutel, M. E., Blettner, M., Fischbeck, S., Loquay, C., Werner, A., Marian, H., [Psycho-oncological aspects of malignant melanoma. A systematic review from 1990-2008], Hautarzt, 2009. 60(9): p. 727-33., http://www.ncbi.nlm.nih.gov/pubmed/19701615

844. Cormier, J. N., Askew, R. L., Mungovan, K. S., Xing, Y., Ross, M. I., Armer, J. M., Lymphedema beyond breast cancerJohn Wiley and Sons Inc. (P.O.Box 18667, Newark NJ 07191-8667, United States), 2010. p. 5138-5149.

845. Faries, M. B., Thompson, J. F., Cochran, A., Elashoff, R., Glass, E. C., Mozzillo, N., et.al. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I), Ann Surg Oncol, 2010. 17(12): p. 3324-9., http://www.ncbi.nlm.nih.gov/pubmed/20614193

846. Bastiaannet, E., Beukema, J. C., Hoekstra, H. J., Radiation therapy following lymph node dissection in melanoma patients: treatment, outcome and complications, Cancer Treat Rev, 2005. 31(1): p. 18-26., http://www.ncbi.nlm.nih.gov/pubmed/15707701

847. Vrouenraets, B. C., Klaase, J. M., Nieweg, O. E., Kroon, B. B., Toxicity and morbidity of isolated limb perfusion, Semin Surg Oncol, 1998. 14(3): p. 224-31., http://www.ncbi.nlm.nih.gov/pubmed/9548605

848. Carmeli, E., Bartoletti, R., Retrospective trial of complete decongestive physical therapy for lower extremity secondary lymphedema in melanoma patients, Support Care Cancer, 2011. 19(1): p. 141-7., http://www.ncbi.nlm.nih.gov/pubmed/20066550

849. Becker, G., Hatami, I., Xander, C., Dworschak-Flach, B., Olschewski, M., Momm, F., et.al. Palliative cancer care: an epidemiologic study, J Clin Oncol, 2011. 29(6): p. 646-50., http://www.ncbi.nlm.nih.gov/pubmed/21263094

850. Gallais Serezal, I., Beaussant, Y., Rochigneux, P., Tournigand, C., Aubry, R., Lindelof, B., et.al. End-of-life care for hospitalized patients with metastatic melanoma in France: a nationwide, register-based study, Br J Dermatol, 2016. 175(3): p. 583-92.

851. Abdel-Rahman, O., Helbling, D., Schmidt, J., Petrausch, U., Giryes, A., Mehrabi, A., et.al. Treatment-associated Fatigue in Cancer Patients Treated with Immune Checkpoint Inhibitors; a Systematic Review and Meta-analysis, Clin Oncol (R Coll Radiol), 2016. 28(10): p. e127-38.

852. Long, G. V., Weber, J. S., Infante, J. R., Kim, K. B., Daud, A., Gonzalez, R., et.al. Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib, J Clin Oncol, 2016. 34(8): p. 871-8.

853. World Health Organization, Palliative Care, 2017. 2017:

854. Bundesärztekammer, Deutscher Hospiz- und PalliativVerband e.V., Deutsche Gesellschaft für Palliativmedizin e.V., Charta zur Betreuung schwerstkranker und sterbender Menschen in Deutschland, 2017. 2017:, www.charta-zur-betreuung-sterbender.de

855. Ferris, F. D., Bruera, E., Cherny, N., Cummings, C., Currow, D., Dudgeon, D., et.al. Palliative cancer care a decade later: accomplishments, the need, next steps -- from the American Society of Clinical Oncology, J Clin Oncol, 2009. 27(18): p. 3052-8., http://www.ncbi.nlm.nih.gov/pubmed/19451437

856. Levy, M., Smith, T., Alvarez-Perez, A., Back, A., Baker, J. N., Beck, A. C., et.al. Palliative Care Version 1.2016, J Natl Compr Canc Netw, 2016. 14(1): p. 82-113.

857. Peppercorn, J. M., Smith, T. J., Helft, P. R., Debono, D. J., Berry, S. R., Wollins, D. S., et.al. American society of clinical oncology statement: toward individualized care for patients with advanced cancer, J Clin Oncol, 2011. 29(6): p. 755-60., http://www.ncbi.nlm.nih.gov/pubmed/21263086

858. Vist, G. E., Bryant, D., Somerville, L., Birminghem, T., Oxman, A. D., Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate, Cochrane Database Syst Rev, 2008. (3)(3): p. MR000009., http://www.ncbi.nlm.nih.gov/pubmed/18677782

859. Vist, G. E., Hagen, K. B., Devereaux, P. J., Bryant, D., Kristoffersen, D. T., Oxman, A. D., Systematic review to determine whether participation in a trial influences outcome, BMJ, 2005. 330(7501): p. 1175., http://www.ncbi.nlm.nih.gov/pubmed/15905256

860. Kunz, R., Vist, G., Oxman, A. D., Randomisation to protect against selection bias in healthcare trials, Cochrane Database Syst Rev, 2007. (2)(2): p. MR000012., http://www.ncbi.nlm.nih.gov/pubmed/17443633

861. (ÄZQ), Ärztliches Zentrum für Qualität in der Medizin, E, Gramsch, JD, Hoppe, G, Jonitz, A, Köhler, al., Ollenschläger G et, Kompendium Q-M-A. Qualitätsmanagement in der ambulanten VersorgungDt. Ärzte-Verl., 2008.

862. Leitlinienprogramm Onkologie, Entwicklung von Leitlinien basierten Qualitätsindikatoren. Methodenpapier für das Leitlinienprogramm OnkologieLeitlinienprogramm Onkologie (Deutsche Krebsgesellschaft (DKG), Deutsche Krebshilfe (DKH), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)), 2017.

863. Deutsche Krebsgesellschaft, Jahresbericht der zertifizierten HautkrebszentrenDeutsche Krebsgesellschaft, 2017., https://www.krebsgesellschaft.de/jahresberichte.html?file=files/dkg/deutsche-krebsgesellschaft-/content/pdf/Zertifizierung/Jahresberichte%20mit%20DOI%20und%20ISBN/hz_jahresbericht-2017-A1_170627.pdf